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Abbreviations 
 
 %-inhib. percent inhibition value 
° degree 
1-HOBT 1-hydroxybenzotriazole 
Abz 2-aminobenzoyl 
ACE angiotensin-converting enzyme  
AIDS acquired immune deficiency syndrome  
ATLL adult T-cell leukemia  
BICINE N,N-bis(2-hydroxyethyl)glycine  
Boc tert-butyloxycarbonyl 
Boc2O di-tert-butyl dicarbonate 
C celsius 
CA/NC  capsid/nucleocapsid cleavage site 
cal calorie 
CHES 2-(cyclohexylamino)ethanesulfonic acid 
ClogP  calculated logarithm of the octanol-water partition coefficient 
CNS central nervous system 
conc. concentration 
Da dalton 
DABCYL  4-(4-dimethylaminophenylazo)benzoyl) 
DCM dichloromethane 
DIPEA ethyldiisopropylamine 
DMAP 4-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DpmINV des-3-pyridylmethyl-indinavir  
DTT 1,4-dithiothreitol 
E. coli Escherichia coli 
EDANS 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid 
EDCI N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 
EDTA ethylenediaminetetraacetate 
EI electron ionization  
EP endothiapepsin 
ESI electrospray ionization  
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EtOAc ethyl acetate 
EtOH ethanol 
FBDD fragment-based drug discovery  
FDA food and drug administration 
FPLC fast protein liquid chromatography  
FRET fluorescence resonance energy transfer;  
also named “Förster resonance energy transfer” 
h hour 
HA number of non-hydrogen atoms, (i.e. heavy atoms) 
HAID HTLV-1-associated infective dermatitis  
HAM HTLV-1-associated myelopathy  
H-bond hydrogen bond 
HCV hepatitis C virus  
HEPES 2-[4-(2-hydroxyethyl)-piperazin-1-yl]ethanesulfonic acid 
HIV-1 human immunodeficiency virus-1 
HPLC high performance liquid chromatography 
HTLV-1 human T-cell leukemia virus-1 
HTS high-throughput screening 
Hz hertz 
INV indinavir 
IPTG isopropyl-β-D-thiogalactopyranoside 
l liter 
LB medium lysogeny broth medium 
LE ligand efficiency 
M mol/l 
m/z mass-to-charge ratio 
MeOH methanol 
MES 2-(N-morpholino)ethanesulfonic acid 
min minute 
mp melting point 
NMR nuclear magnetic resonance 
OD600 optical density at 600 nm 
PCR polymerase chain reaction  
PDB protein data bank 
PEG polyethylene glycol 
PEI percentage efficiency index  
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pH negative decimal logarithm of the hydrogen ion activity 
PIPES 1,4-piperazinediethanesulfonic acid 
PIs protease inhibitors 
PR protease 
PyBOP benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate 
qHNMR quantitative 1H NMR  
QSAR quantitative structure-activity relationship 
R ideal gas constant 
RFU relative fluorescence unit 
rmsd root-mean-square deviation 
rpm rounds per minute 
RT room temperature 
SAR structure-activity relationship 
SBDD structure-based drug design 
SDS sodium dodecyl sulfate 
SDS page sodium dodecyl sulfate polyacrylamide gel electrophoresis 
T temperature [K] 
TBAI tetrabutylammonium iodide 
TEA triethylamine 
TFA trifluoroacetic acid 
TFE trifluoroethanol 
THF tetrahydrofuran 
TLC thin layer chromatography  
Tm melting temperature 
TMS tetramethylsilane 
Tris 2-amino-2-hydroxymethyl-propane-1,3-diol 
TSA thermal shift assay 
ΔG Gibbs free energy 
σ standard deviation 
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1. Introduction 
 
1.1 Drug Design and Structure-Based Drug Design  
In the interdisciplinary field of drug design that has continuously emerged over the last 
three decades, the rational development of ligands for a biological target with the 
overall long-term aim to develop a novel drug for the respective target is pursued. Two 
main concepts are followed in this respect: the ligand-based and the structure-based 
drug design.  
According to the statement of the Nobel Prize winner James Black that “The most 
fruitful basis for the discovery of a new drug is to start with an old drug”,1,2 the ligand-
based drug design utilizes previously identified molecules that bind to the target, and, 
subsequently, quantitative structure-activity relationships (QSAR) and pharmacophore 
models are derived and used for further lead optimization.3 
Structure-based drug design (SBDD) relies on the knowledge of the three-dimensional 
structure of the biological target, which provides the basis for optimization of a lead 
structure. The first examples which reflect the central paradigm of SBDD were 
described in the 1970s and since then SBDD has become an important concept in 
medicinal chemistry.4 Knowledge about the structure of the target is mainly obtained by 
X-ray crystallography or NMR spectroscopy, in addition, homology models might also 
be applied to derive initial hypotheses if the experimental approach to determine the 
target structure does not succeed within the anticipated time frame. In addition to the 
information about the structure of the protein, the identification of ligands as starting 
point for the SBDD process is essential. Ligands can be identified by computer-aided 
as well as experimental methods:5 computer-aided methods include the virtual 
screening, where large databases of compounds are screened in silico against the 
structural model of the target and various de novo design methods. Among the 
experimental methods, which comprise lead finding strategies such as high-throughput 
screening (HTS), combinatorial chemistry approaches and fragment-based discovery 
of ligands, the concept of privileged structures provides a further alternative option. 
This concept was first described in 1988 by Evans et al.6 Privileged structures in a 
broader definition are ligands or scaffolds that show a biological effect on more than 
one target protein, often on related proteins of the same gene family.7 Once such a 
privileged scaffold has been identified, the selectivity profile towards the desired target 
needs to be optimized e.g. by exploiting sterical and/or electrostatic differences in the 
binding pockets of the related enzymes. In an ideal case, close structural analogues of 
the identified scaffold are already available allowing not only the deduction of a 
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preliminary SAR but also of a preliminary selectivity profile. In most cases, the 
knowledge of previously investigated compound characteristics such as data regarding 
the bioavailability and other pharmacokinetic properties are beneficial for the further 
development. Examples of privileged scaffolds in approved drugs comprise for instance 
the indole moiety (e.g. sumatriptane, indometacin, etodolac, ondansetron), the 
benzimidazole ring system (e.g. thiabendazole, rabeprazole, clemizole), or the 
benzothiophene scaffold (e.g. raloxifene, zileuton).8,9      
To embark on an SDBB approach, after identification of a first ligand hit, the 
subsequent structure determination of the target protein in complex with the detected 
hit or lead molecule provides valuable information about key interactions of the small 
molecule to the protein. Based on this information, the further hit-to-lead- and lead 
optimization processes, which can be described as an iterative process of design, 
synthesis, affinity-, and structure determination of promising hits (Figure 1.1), is 
pursued. In the best case, after several cycles of optimization, a set of lead compounds 
with sufficient potency and various other suitable properties required for drug-likeliness, 
such as e.g. a low molecular weight, good solubility, cell permeability, metabolic 
stability, and compliance to the Lipinski rules (oral bioavailability) are obtained. 
 
 
 
 
 
  
 
 
 
 
 
Figure 1.1. Drug design cycle in structure-based drug design. 
 
The identification of these lead compounds for the respective target is the first step on 
the long way towards an approved drug. Further years of research and development 
are generally necessary to meet the requirements of toxicology and the ADME 
properties (Absorption, Distribution, Metabolism, Excretion), to start and pass the pre-
clinical testings as well as clinical trials which finally might end up in an approved drug. 
The time span from the drug development to the approved drug nowadays takes about 
3D Protein 
Structure 
Lead 
Optimization Design 
Synthesis 
Biological 
Evaluation 
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15 years.10 Between 2005 and 2013, on average 25 new molecular entities and 
therapeutic biologics were approved per year.11  
As straightforward as the described lead-optimization process seems to be in theory, it 
is far-off from being an established standard procedure as it bears a lot of challenges: 
the first step of the directed optimization of a lead structure is the design of novel 
inhibitors, which is mostly performed by in silico methods while making use of the 
determined 3D structure of the target to identify the most promising candidates for 
prioritizing medicinal chemistry activities. In docking studies ligands are fitted into the 
active site of the target protein and the predicted binding pose is scored and ranked 
based on the interactions of the ligand to the potential key interaction partners on the 
protein side.  
There are various limitations associated with this procedure: at the beginning, the 
correct binding pose of the inhibitor needs to be predicted. This might fail and also 
binding mode switches within the same inhibitor series might occur. A striking example 
for such a rather unexpected behavior is given in chapter 6 of this thesis. The correct 
prediction of a ligand`s binding pose can be aggravated as well by the presence or 
absence of the ubiquitously available water within and in the neighborhood of the 
binding pocket, as by any induced-fit adaptations occurring on the protein side upon 
ligand binding. Once a suitable placement of ligands within the expected binding site 
has been achieved, the subsequent affinity estimation (“scoring”) is a further challenge. 
In general, most scoring functions attempt to predict the binding affinity by evaluation of 
assumed polar and hydrophobic protein-ligand contacts. However, the strength of 
those interactions depends on various aspects. Knowledge on the protonation states of 
the ligand’s and the protein`s functional groups is an essential prerequisite to assess 
the H-bond network, but, however, relies in most cases on assumptions, as the 
experimental validation is rather resource-intensive. In addition, thermodynamic 
features such as enthalpy- or entropy-driven binding are mostly not considered by 
scoring functions. Desolvation of ligand and binding site are ultimate prerequisites to 
the binding process, however, difficult to simulate for a meaningful affinity ranking. 
Moreover, features such as buriedness of the interaction site, which influences the 
strength of H-bonds, or compensating effects such as enthalpy-entropy compensation 
are challenging to assess in absence of experimental methods.12–14   
Hence, the “holy grail of structure-based drug design” to identify potent and specific 
ligands only by means of computational methods and structural information of the 
protein target of interest by reasonably predicting binding affinities has not yet been 
achieved.15   
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As a further prerequisite, also the synthesis of the in silico-identified ligands should be 
feasible, while still possessing sufficient options for structural variation.  
The biological evaluation and especially the impact for the clinical success is uncertain 
due to the complexity of a whole number of various interdependent parameters. As 
recently collected evidence demonstrates, the determination of the affinity of a ligand to 
the target does not represent the solely relevant parameter describing the interaction 
between target and ligand. The transferability towards the biological system is often 
insecure, as aspects like the residence time of the ligand to the target protein seem to 
play an important role in the clinical performance.16 Hence, the prediction of in vivo 
effects of a drug candidate is quite difficult.13 Also the target selectivity is poorly 
predictable, but represents an important aspect for toxicology studies and side effects. 
These aspects explain why drug discovery, despite a continuously increasing 
knowledge base, is a highly challenging as well as cost- and time-demanding 
endeavor.  
 
1.2 Aspartic Proteases 
1.2.1 Aspartic Proteases – an Overview 
In general, proteases are enzymes, which cleave proteins by hydrolysis of peptide 
bonds. Depending on the mechanism of catalysis, they can be divided into seven major 
classes:17 the aspartic-, cysteine, glutamic-, metallo-, asparagine-, serine-, and 
threonine-proteases. In addition, some peptidases of unknown catalytic type and one 
class of mixed peptidases are notated in the Merops database.17 
The focus of this work lays on aspartic proteases, the history of which is nicely 
reflected in a publication from Szesci et al.:18 
“The aspartic proteases (EC 3.4.24) were the first type of enzymes known to 
mankind, the first protease type described, the second protein to be crystallized and 
subjected to numerous early investigations by the pioneers of modern enzymology 
and protein chemistry.”18 
Aspartic proteases possess two catalytic aspartates in the active site and usually 
require an acidic pH-value for efficient catalysis. They can be divided into endogenous 
and exogenous proteinases: endogenous aspartic proteases occur in the human 
organism, like the gastric proteinases pepsin and gastricsin, renin, which is involved in 
the regulation of blood pressure, or cathepsin D. Exogenous proteinases are found in 
bacteria, fungi, yeasts and viruses.19 Therefore, aspartic PR are involved in physiolog-
ical as well as pathophysiological processes.  
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Eukaryotic aspartic proteases are produced as catalytically inactive precursor proteins, 
so-called zymogenes, and are converted to their proteolytically active counterparts 
depending on their physiological role. This mechanism allows to regulate the location of 
action of the proteases and therefore inter alia protects the producing cells and the 
surrounding environment against damages. To auto-inhibit their catalytic activity, 
zymogenes contain an N-terminal extension (prosegment), while the mode of inhibition 
differs among the aspartic protease zymogenes: in gastric zymogenes, the substrate 
binding pocket is blocked by the prosegment, which is therefore inaccessible to 
substrates. In the case of proplasmepsin II, the zymogene of the malaria target 
plasmepsin II, the prosegment severely distorts the active site and therefore prevents 
the formation of a functional active site. The activation of zymogenes might occur by 
auto-activation at acidic pH, like for example for the gastric zymogene pepsinogene, or 
through assisted catalysis of other proteases, like for example in the case of prorenin.20  
According to the Merops database, proteases are further subdivided into clans and 
families. A clan contains proteases which show the same evolutionary origin. Proteins 
of one clan are divided into different protein families; proteins of the same family 
typically exhibit similarity in their amino acid sequence and their tertiary protein 
structure. Currently, the aspartic family is classified into six different clans, with clan AA 
being the biggest one, which itself contains eight different protein families. Among them 
the aspartic protease families A1 (pepsin family) and A2 (retropepsin family) bearing 
183 identifiers (9381 sequences) and 51 identifiers (1150 sequences), respectively, are 
of utmost importance.17 [status: 23.04.2015] 
 
1.2.2 Catalytic Mechanism of Peptide Cleavage 
The proposed mechanism of the cleavage of the peptide bond in the active site is 
shown in Figure 1.2.21 Herein, the lytic water molecule, which is located close to the 
two catalytic aspartates, plays a key role. Before the onset of the cleavage reaction, 
one of the two aspartates is deprotonated and acts as H-bond acceptor to the water 
molecule, while the other aspartate remains protonated, thus destabilizing the C=O 
bond of the peptide bond by forming an H-bond to the carbonyl-oxygen. The now 
polarized nucleophilic water molecule then attacks the electrophilic carbonyl function of 
the peptide bond resulting in a geminal diol as tetrahedral intermediate, which in the 
following decomposes under reconstruction of the more stable carbon-oxygen-double 
bond rendering the respective carboxylic acid and amine. 
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Figure 1.2. Schematic representation of the catalytic mechanism of aspartic proteases. The lytic water 
molecule is shown in blue. 
 
1.2.3 Aspartic Proteases in Drug Design  
Although in comparison to other peptidase families the group of aspartic proteases is a 
small group of enzymes, it is involved in several physiological and pathophysiological 
processes. Hence, its members represent attractive targets for inhibitor development. 
Famous examples of aspartic proteases show their significance in human diseases: 
they are inter alia involved in the regulation of the blood pressure (renin), in cancer-
related processes (cathepsin D), in neurological diseases like Alzheimer’s (β-
secretase), in mycosis processes (SAP proteins), in malaria (plasmepsins) or in 
infectious diseases like HIV infections (AIDS).22   
One common strategy for protease inhibition is to mimic the structure of the natural 
substrate and to prohibit its cleavage by blocking the active site of the enzyme with so-
called transition-state analogs. In 1949, Pauling already stated that the interaction of an 
enzyme with its substrate is the strongest at the transition state.23,24  In the mid-1970s 
this concept was applied to the aspartic proteases by the analysis of the activity of 
pepstatin.25 It turned out that pepstatin is a potent inhibitor for a number of enzymes of 
the aspartic protease family. Pepstatin (Figure 1.3) represents a hexa-peptide and was 
originally isolated from actinomyces. The statine moiety as non-proteinogenic amino 
acid with the leucine side chain in P1 position and the hydroxyethylene moiety in 
direction to the C-terminus mimics the scissile peptide bond and enables pepstatin to 
function as transition-state analogs. The two catalytic aspartates are addressed by its 
central hydroxyl group.  
 
Figure 1.3. Chemical structure of pepstatin. 
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Besides the statin motif, other isosters of the transition-state, which are shown in 
Figure 1.4, have successfully been exploited.26,27 For the first attempt to develop 
inhibitors for a respective target protein, the modification of natural substrates often 
leads to potent inhibitors. Nevertheless, as straightforward as it may sound, highly 
potent inhibitors of a target protein do not necessarily fulfil the requirements of an 
approved drug, but nevertheless, provide the indispensable basis for further studies.  
 
Figure 1.4. Examples of transition-state isosters of aspartic protease inhibitors. 
 
The main challenge is therefore the development of so-called drug-like molecules. To 
estimate if the developed ligand might be orally bioavailable, the Lipinski “Rule of five”28  
might give a first indication. In many cases peptides show a high potency to the target 
of interest, but their most striking disadvantages are their poor bioavailability, metabolic 
instability, and poor drug-likeness. Therefore, research activities mostly aspire the 
development of inhibitors with a low peptidic character, namely peptidomimetic or non-
peptidic molecules.  
Currently approved aspartic protease inhibitors comprise renin- as well as HIV-1 
protease inhibitors. The first approved HIV-1 PR inhibitor saquinavir (Figure 1.5) 
represents a transition-state isoster: the central scaffold is the hydroxyethylamine 
moiety which replaces the substrate cleaving site Phe-Pro of the protease/reverse 
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transcriptase autocleavage site.29 In addition, the peptidominetic inhibitors indinavir, 
nelfinavir, (fos)amprenavir, and darunavir are also based on the hydroxyethylamine 
motif. Aliskiren, the first renin inhibitor, was approved in 2006 and is a non-peptidic 
inhibitor. Its development was inspired by the peptide analog of angiotensinogen, the 
natural substrate of renin, and eventually led via peptitomimetic compounds to the non-
peptide-like compounds, with aliskiren as the approved representative.30     
 
Figure 1.5. Chemical structures of saquinavir (HIV-1 PR inhibitor) and aliskiren (renin inhibitor). The 
hydroxyethylamine motif of saquinavir is colored blue. 
Besides the above mentioned significance in drug design, nearly everybody is 
somewhat linked to the history of an aspartic protease in one’s everyday life: the 
trademark “Pepsi Cola®” originally derived from the aspartic protease pepsin. Caleb 
Bradham, a pharmacist, renamed his drink, which was supposed to be more than a 
refreshment but should also support the digestion (like pepsin), in 1898 to the 
nowadays well-known “Pepsi-Cola”.31 
 
1.2.4 Structural Features of Aspartic Proteases  
In 1972, the first amino acid sequence of an aspartic protease was determined by Tang 
et al. from porcine pepsin.32 The first three-dimensional structures of aspartic proteases 
with a nowadays moderate crystallographic resolution around 3 Å were reported in 
1977 and comprise the three fungal enzymes rhizopuspepsin, endothiapepsin and 
penicillopepsin, which all belong to the pepsin family A1.23,33,34   
The structure of the pepsin-like proteases consists of two lobes, the N- and C-terminal 
one, with the substrate binding pocket in between the two lobes, where the two 
catalytic aspartates are located in a centric manner  (Figure 1.6a). At the top of the 
active site a hairpin-like beta structure, the so called “flap”, is present being a 
characteristic of most aspartic proteases. The first retroviral protease 3D structures 
(family A2) were determined from the rous sarcoma virus (RSV)35,36 and from the HIV 
PR37 in 1989. 
The retroviral proteases exhibit similar characteristics (Figure 1.6b), while they consist 
of two identical monomers which form a homodimer as functional proteolytic unit. The 
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active site is located between both monomers and above the dimer interface and 
covered by the flap. Each monomer contributes one of the catalytic aspartates and one 
flap.  
 
Figure 1.6. a) X-ray structure of endothiapepsin as representative of the pepsin family (A1), PDB entry: 
1OEW. The protein consists of one amino acid chain, shown in blue. b) X-ray structure of HIV-1 PR, PDB 
entry: 1SDT, as member of the retroviral family (A2). The HIV-1 PR functions as a homodimer; each 
monomer is colored differently (light and dark green). Proteins are shown as cartoon, the catalytic 
aspartates in stick representation. 
 
The similarity between pepsin-like (A1) and retroviral (A2) aspartic proteases cannot be 
dismissed: the functional proteolytic units are similar in size and in the arrangement of 
the active site, while the amino acid chain of proteases of the pepsin-like family are in 
general larger than those of the retroviral proteases.38  
The main difference between the structures of the pepsin-like (A1) and retroviral (A2) 
aspartic proteases is reflected in the symmetrical arrangement of the amino acid chain 
or rather of the two monomers in case of the A2 family, which, however, does not cast 
doubt on their overall similarity. The pepsin-like proteases consist of one amino acid 
chain, but their C- and the N-terminal lobes show high homology in their secondary and 
tertiary structure.23,39 On the contrary, the retroviral proteases bear not only two similar 
lobes, they instead feature two identical monomers which function as a homodimer.  
The catalytic aspartates in the active site are in all aspartic proteases embedded in a 
conserved Asp-Thr/Ser-Gly sequence. This sequence is located within a loop and 
stabilized by a rigid hydrogen network, often called “fireman’s grip”, stabilizing the 
active site (Figure 1.7). Therefore the fireman’s grip is important for the conformation of 
the active site and in case of the retroviral proteases additionally for the dimerization 
and dimer stability.36,40 Between the two catalytic aspartates, a water molecule can be 
located, forming H-bonds to the carboxylate groups of the aspartates, acting as the lytic 
water molecule which is involved in the cleavage of the peptide bond, however this 
water molecule can be displaced by binding of certain inhibitors. 
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Figure 1.7. Stabilizing, rigid H-bond network (fireman’s grip) of the conserved Asp-Thr-Gly sequence of 
aspartic proteases. a) Endothiapepsin (PDB entry: 1OEW). The amino acids of the N- and C-terminal lobe 
are colored light blue and blue, respectively. b) HIV-1 PR (PDB entry: 1SDT). The amino acids of each 
monomer are colored differently (light green and green). 
 
Due to the proximity to the active site and the associated flexibility the flap, another 
characteristic feature of aspartic proteases,23 plays an important role in substrate 
recognition and ligand specificity. During binding of substrates or inhibitors, the flap 
mostly changes the orientation and forms interactions to the ligand, and is therefore 
crucial in binding events to aspartic proteases. Most inhibitors address the closed flap 
conformation. Interestingly, in case of the HIV-1 PR it was shown that novel inhibitors 
can also target the protein in the open flap conformation,41 which represents a different 
binding mode in comparison to all approved HIV-1 PR inhibitors which might thus be 
beneficial for the avoidance of drug resistance. Figure 1.8 shows the open and closed 
flap-conformation of the HIV-1 protease. 
 
 
Figure 1.8. HIV-1 PR with open (a) and closed (b) flap conformation. PDB entries: (a) 2PC0; (b) 1SDT. 
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1.3 HTLV-1 and its Virus-Encoded Protease 
1.3.1 Virus, Infections, Epidemiology and Related Diseases 
The Human T-cell lymphotropic virus type 1 (HTLV-1) was the first human retrovirus 
isolated in the early 1980s.42 The discovery of HTLV-1 by Robert Gallo and coworkers 
confirmed the existence of human retroviruses, which had been discussed 
controversially until then. The technological developments leading to the discovery of 
HTLV turned out to be a milestone for the discovery of further retrovirus like the human 
immunodeficiency virus (HIV) and its identification as causative agent of AIDS.42 
Worldwide approximately 10-20 million people are currently infected with HTLV-1.43,44 
Areas with high prevalence include Japan, Africa, the Caribbean islands, South 
America, and Iran.45 In Europe and North America, the majority of HTLV-1 infected 
humans are immigrants or drug-addicted persons mainly dependent on intravenously 
applied drugs.46  
The virus predominantly infects CD4+ T-cells. The transmission of HTLV-1 
predominantly occurs via cell-cell contacts. The virus is mainly transmitted via breast-
feeding, through contaminated blood products as well as by sexual contacts. As typical 
for a retrovirus, HTLV-1 persists in the host cell in form of a provirus: the viral DNA is 
inserted in the human DNA of the host cell and thus causing a lifelong infection. The 
diseases which are associated with HTLV-1 infections are quite divers: they comprise 
cancer-developing processes like the adult T-cell leukemia (ATLL) as well as 
neurological (HTLV-1-associated myelopathy (HAM)) and dermatological (HTLV-1-
associated infective dermatitis (HAID)) diseases.44,47 Due to the low incidence of these 
diseases within the whole population, these three types of disorder are classified as 
orphan diseases (< 5 out of 10,000 people).48 Currently, no causative treatment options 
to cure these HTLV-1 associated diseases are available. 
Even though most people remain free of symptoms after an infection with HTLV-1, still 
about 10 % of the infected people develop one of the typical fatal diseases among 
which 1-5 % acquire the adult T-cell leukemia, which represents an aggressive form of 
leukemia with a very poor life-time prognosis. About 0.3-4 % of all infected people 
suffer from the chronical inflammatory and neurodegenerative disorder of the medulla 
(HAM). Other HTLV-1-associated manifestations of the infection include HAID, uveitis, 
polymyositis, and arthropathy.44 Until now, it has not been understood, why only a 
minor part of the infected people develop one of the related diseases, while others 
have an unaffected life. 
The carcinogenic potential of HTLV-1 may origin from the oncogenic protein named 
tax. In addition to the virus-encoded structural and other non-structural proteins, the 
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genome of HTLV-1 encodes the tax gene product. The nuclear protein tax promotes 
the transcription of its own proviral genome, but also that of human genes, like for 
example anti-apoptotic genes and cytokines. It influences several signaling pathways 
like the NF-κB signal pathway and inter alia represses the transcription of genes that 
play an important role in the activation of apoptosis as well as in DNA repair. Tax also 
directly interacts with proteins that are involved in tumor suppression and DNA repair. 
As a consequence, genetic damages are not repaired, apoptosis of damaged cells 
does not occur and mutations may be accumulated in infected T-cells. In total, these 
negative effects of the tax protein promote the development of ATLL.44  
Patients with ATLL have a low life expectation, the median survival in dependence of 
the subtype is shown in Table 1.1. 
 
Table 1.1. Subtypes of ATLL, prevalence, and survival time.46 
subtype ratio median survival 
acute 55 % 6 months 
lymphomatous 20 % 10 months 
chronic 20 % 2 years 
smouldering 5 % - 
 
 
The HTLV-1-associated myelopathy (HAM) leads to neurological dysfunctions in 
infected people, resulting from an inflammation of the spinal cord. Infected T-cells 
infiltrate the CNS. Most likely, the immunological response against HTLV-1 antigens 
leading to an enhanced production of inflammatory cytokines results in lesions in the 
spinal cord, in this context axons as well as myelin sheaths were affected. However, 
the complete mechanism how HTLV-1 causes HAM is not yet fully understood today.49 
 
1.3.2 HTLV-1 Protease – an Overview 
Like other retrovirus, HTLV-1 encodes a protease which is essential for the replication 
of the virus.50 The HTLV-1 protease was identified and isolated in the late 1980s.50,51 
Structurally, the HTLV-1 PR comprises the typical fold as observed for other proteases 
of the retroviral family (A2), and functions as a homodimer with each monomer 
consisting of 125 amino acids.  
As successful drug discovery approaches have shown in the past, attacking the 
retroviral protease, which is essential for the replication of the virus, provides a 
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promising concept to combat viral infections. As a prominent example of this strategy, 
hitherto ten HIV-1 protease inhibitors have been approved and successfully used in the 
treatment of the acquired immune deficiency syndrome (AIDS). Therefore, and in 
addition to its essential role in the maturation of the virus, the HTLV-1 PR represents 
an attractive target for the development of HTLV-1 PR inhibitors that could overcome 
the still existing lack of a curative treatment against HTLV-1 infections.50 
For directed development of novel HTLV-1 PR inhibitors by structure-based drug 
design, knowledge about the structure of the protease is an indispensable requirement. 
In view of this fact that the virus and the protease have been known for a long time, the 
first X-ray structure of the HTLV-1 PR was determined rather late. Its elucidation was 
reported in 2005,52 five years later additional six HTLV-1 crystal structures were 
published.53 All these seven structures were determined in complex with peptidic 
inhibitors, which means, up to now, to the best of our knowledge, no structure in 
absence of a bound ligand has been determined. Furthermore, all these structures 
were not determined with the full-length protein, but rather with a construct C-terminally 
truncated by about nine amino acids, consisting of 116 amino acids per monomer. The 
role of the C-terminal residues is still being discussed controversially in the literature 
and described in more detail in chapter 2 of this thesis. 
The HTLV-1 protease shows a high sequence similarity to other protease structures of 
the retroviral family. As therapeutic target of the retroviral aspartic PR family A2, 
particularly the HIV-1 PR is subject of successful and present research approaches. 
The overall protein fold of the HIV-1 and HTLV-1 PR is very similar (Figure 1.9), their 
overall sequence identity is about 28 %, their ligand binding regions are even more 
conserved (45 %), but it is well known, that they differ remarkably from each other in 
their substrate specificity as well as in their inhibition profile.54 The approved HIV-1 PR 
inhibitors show strongly reduced affinity against the HTLV-1 PR,54,55 and to the best of 
our knowledge, no highly potent (≤ sub-µM) non-peptidic HTLV-1 PR inhibitors have 
been described so far. Considering the current state of the research regarding the 
discovery of HTLV-1 PR inhibitors, the development of novel protease inhibitors is 
strongly necessary in order to enhance the chance of identifying treatment options for 
HTLV-1 infections in the future.  
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Figure 1.9. The overall structure of the HTLV-1 PR (PDB entry: 3LIX) and the HIV-1 PR (PDB entry: 
1SDT) is very similar. 
 
1.4 Endothiapepsin as Model System for Members of the A1 Family 
Endothiapepsin (EP), the aspartic protease of Endothia parasitica belongs to the 
aspartic protease family A1. In the daily industrial business, EP is typically used as 
fungal rennet in cheese production.56 In drug discovery, EP is commonly used as 
model enzyme and has successfully been exploited as surrogate in the structure-based 
drug design of renin as well as β-secretase inhibitors.57,58 Major advantages of using 
endothiapepsin as model enzyme include its commercial availability, its biochemical 
stability, and the well-established crystallization conditions to name just a few. 
Therefore, EP is also well suited for the establishment of other biochemical and 
biophysical methods to characterize small molecules further regarding their inhibitory 
activity. 
 
1.5 Aims of the Thesis 
The strategy of protease inhibition and identification of suitable lead structures has 
been successfully established for quite some time.59 Examples comprise among others 
the angiotensin-converting enzyme (ACE), the Hepatitis C virus (HCV) NS3/4A 
protease, and the HIV-1 protease. Ten HIV-1 protease inhibitors are still being used or 
have been used as approved drugs to date.59–61  
Within this thesis, the two aspartic proteases human T-cell leukemia virus type 1 
protease (HTLV-1 PR) and endothiapepsin (EP) are investigated in detail, particularly 
with focus on the identification and synthesis of small-molecule-type, nonpeptidic 
protease inhibitors as well as the kinetic and structural characterization of these in 
complex with the respective protease. 
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1.5.1 HTLV-1 Protease 
The initial aims of this project focused on the generation of the target-related laboratory 
platform, particularly the establishment of suitable and robust protocols for protein 
expression, purification and refolding in the in-house laboratory in order to provide 
continuous access to the required target proteins. In addition, a reliable assay protocol, 
which enables the detection of the protease activity and its inhibition by various test 
compounds had to be established (chapter 2).  
The overall purpose of the first project of this thesis was the identification of novel, non-
peptidic small molecules for HTLV-1 protease inhibition.  
For the validation of the kinetic assay as well as for the establishment of a suitable 
crystallization protocol, the commercially available HIV-1 protease inhibitor indinavir 
was initially selected. According to the literature, indinavir possesses, in contrast to 
several other approved HIV-1 PR inhibitors that were shown to be inactive against 
HTLV-1 PR, a Ki-value against the latter of 3.5 µM,55 and therefore represents an easily 
accessible inhibitor with moderate affinity against the HTLV-1 protease. Hence, it 
turned out to be a well-suited inhibitor for the validation of the in-house assay 
establishment.  
Interestingly, despite more than 10 years of structural research on HTLV-1 PR, prior to 
this thesis, only crystal structure complexes with peptide-type inhibitors had been 
described thus neglecting non-peptide-type ligands despite their increased relevance 
for structure-guided lead discovery in the recent past. Hence, the first central aim of 
this thesis as detailed in chapter 3 was the generation of a crystal structure complex of 
HTLV-1 PR with bound indinavir in order to get insights into its binding mode, to 
investigate the structural basis of the different binding affinities with respect to HIV-1 
and HTLV-1 PR, and finally to suggest appropriate structure-derived modifications for 
the next chemical candidates with improved properties.  
Chapter 4 and 5 of this thesis focuses on the generation of novel chemical starting 
points for HTLV-1 PR lead discovery activities by means of the privileged scaffold 
approach, i.e. to exploit knowledge on inhibitor scaffolds already available for other 
representatives of the same enzyme family, and to generate novel chemical matter by 
characterizing their binding properties towards the particular target of interest. For this 
purpose, the aspartic protease inhibitor library synthesized in our research group over 
the last years, should be evaluated to identify suitable scaffolds with HTLV-1 PR 
inhibitory activity. Identified hits were ought to be investigated regarding their inhibitory 
properties and in structural terms with respect to their binding modes to the HTLV-1 PR 
by X-ray crystallography. The results of these studies were supposed to be interpreted 
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with respect to the deduction of an initial SAR from the library subset with appropriate 
inhibitory activity, and in terms of deviating binding features between their original 
target and HTLV-1 PR. 
 
1.5.2 Endothiapepsin 
The general aim of the second project (chapter 6) was the detailed investigation of the 
binding modes of 2-amino-thiophene ligands in the active site of endothiapepsin.  
In the preliminary work of Dr. Ruben Bartholomäus, Amir Shahim und Dr. Helene 
Köster, Gewald reaction-based 2-amino-thiophene inhibitors of endothiapepsin were 
synthesized and characterized in terms of affinity measurements and X-ray structure 
determination.62,63  
The crystal structures of three inhibitors in complex with EP were successfully 
determined by Dr. Helene Köster.62 Most interestingly, each of these inhibitors exhibits 
a different binding mode (Figure 1.10): the orientation of the inhibitors in the active site 
as well as the mode of addressing the catalytic aspartates significantly differs among 
the three inhibitors. For the further investigation and interpretation of these unexpected 
findings, the synthesis of a novel series of 2-amino-thiophene ligands should be 
performed, as well as their kinetic characterization and crystallization. 
 
 
Figure 1.10. a.) Chemical structures of the Gewald reaction-based inhibitors RB49, RB91 and SH40, as 
well as %-inhibition data at 100 µM inhibitor concentration. b.) The X-ray structures of the inhibitors in 
complex with endothiapepsin exhibit different binding modes. Interactions of the inhibitors to the catalytic 
aspartates are shown, as well as the 2Fo-Fc electron densities for the ligands (blue mesh, 1σ). 
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In addition, within a cooperation project with the research group of Prof. Klebe 
(Philipps-Universität Marburg) regarding different methods for fragment screening, the 
in-house fragment library should be screened against endothiapepsin utilizing the 
thermal shift assay (TSA) (chapter 7). This TSA was supposed to contribute to the 
overall aim of comparing and analyzing the hit-overlap with hit lists of other fragment 
screening methods, such as a fluorescence-based assay, fragment screening by X-ray 
crystallography, or STD-NMR experiments. For this purpose, an appropriate robust 
experimental TSA setup had to be established for this protein, followed by the 
screening of the fragment library64 of 364 existing fragments to identify stabilizing 
fragment-type binders.  
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2. In-House Establishment of a HTLV-1 Protease Technology 
Platform: Protein Production, TSA, Fluorescence-Based 
Assay, and Crystallographic Setup  
  
2.1  HTLV-1 Protease Constructs 
As described in more detail in chapter 1.3 of this thesis, the HTLV-1 PR is an aspartic 
protease which functions as a homodimer, each monomer consisting of 125 residues. 
A comprehensive literature search revealed that, mainly two different protease 
constructs were used to characterize the HTLV-1 PR as well as to investigate the 
substrate and inhibition profile: for X-ray structure determinations of the HTLV-1 PR, a 
construct truncated by nine amino acids (HTLV-1 PR 1-116) was used, while for 
biochemical assays the full-length PR (HTLV-1 PR 1-125) as well as the HTLV-1 PR 
1-116 were applied.1–4 In order to identify small molecules which show inhibitory activity 
against the HTLV-1 PR as well as to get a deeper insight into their mode of action by 
determining the X-ray structures in complex with the protease, both constructs are of 
considerable interest. 
Noteworthy, for all seven X-ray structures of the HTLV-1 PR available in the PDB,5,6 the 
shorter HTLV-1 PR 1-116 construct was used.1,2 However, there is an ongoing debate 
regarding the activity of the shortened constructs (truncated by 9 or 10 amino acids): 
the results vary from exhibiting similar activity in comparison to the full-length protein to 
reports describing the truncated ones to be inactive.1,7–9 Overall, the importance of the 
C-terminal residues of the HTLV-1 PR is still not fully understood. Besides the HTLV-1 
protease also the protease of the bovine leukemia virus (BLV) belonging likewise to the 
class of the deltaretroviruses possesses such a C-terminal extension, which is not 
present in most of the other retroviral proteases.7  
Kádas et al.7 performed purposeful experiments to prove the importance of the C-
terminus of the HTLV-1 PR especially with respect to the stability of the enzyme dimer.  
Besides kinetic parameters they performed inter alia gel filtration experiments and 
determined Kd-values to investigate the dimer stability and rationalized their results by 
building a molecular model of the full-length protease based on the X-ray structure of 
the shortened construct followed by manual addition of the missing C-terminal residue 
and appropriate in silico energy minimization. According to Kádas et al.,7 the C-terminal 
residues seem to play a critical role in dimerization as the shorter protease constructs 
have a significantly lower dimer stability. Also the aggregation tendency of the protease 
seems to be dependent on the C-terminal residues: the full-length protein shows a 
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higher aggregation tendency than the shortened constructs. The X-ray structure of the 
HTLV-1 PR 1-116 reveals that a hydrophobic surface is present close to the terminal β-
sheets. The proposed molecular model of the full-length protein suggests that the C-
terminal residues might form new strands for the terminal β-sheet and interacts with 
this hydrophobic surface thus rationalizing the observation of the contribution of the C-
terminus towards the dimer stability and the aggregation tendency. In addition, it is 
reported that the C-terminus is also critical for the infectivity of the HTLV-1 virions, as 
the by about ten amino acids truncated C-terminal PR abolished the infectivity. Hence, 
the dimerization interface may also provide an additional target site of the HTLV-1 
protease.7  
Considering the state of research and the aims of this thesis, the protein expression, 
purification, and refolding for the two most commonly used HTLV-1 PR constructs 
should be established in the in-house laboratory: the shortened HTLV-1 PR 1-116 
especially for crystallization experiments and the full-length protein mainly for kinetic 
measurements.  
Besides the variability of the length of the HTLV-1 PR constructs used in various 
experiments, the applied ones also vary to some degree in their amino acid sequence. 
These mutations have mainly been introduced to prevent autoproteolysis. Mostly, as 
also in our case the single mutant L40I was used. Louis et al.10 mapped the site of 
autoproteolytic cleavage and described the stabilization against autoproteolysis caused 
by the L40I mutant. This mutant was shown to exhibit nearly identical kinetic 
parameters in comparison to the wild type protease. 
 
2.2 Expression, Purification and Refolding of the HTLV-1 Proteases 
Dr. Alexander Wlodawer, National Cancer Institute, Frederick, Maryland, USA, kindly 
provided the plasmid encoding the HTLV-1 PR 1-116 harboring the mutations L40I and 
Y114N for our studies. First, the asparagine was re-mutated to tyrosine by site-directed 
mutagenesis to obtain the favored plasmid only containing the L40I mutation. 
The plasmid encoding the full-length protein was ordered from Life 
Technologies/GeneArt (Germany). 
 
2.2.1 Site-Directed Mutagenesis of the HTLV-1 PR 1-116 Plasmid by PCR 
The polymerase chain reaction (PCR) is one of the most important methods in 
molecular biology. The PCR technique was invented and developed by Kary Mullis in 
the 1980s and awarded with the Nobel Prize in Chemistry in 1993.11 The PCR is e.g. 
used in the diagnostics of diseases, in forensic analysis, and as an important technique 
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in molecular biology research, for example for DNA cloning.12  
The PCR is a three-step reaction: first the double-stranded DNA is denatured resulting 
in two single strands (95 - 98°C). In the second step, the temperature is decreased 
(≈50 - 60°C) allowing the primer to anneal to the DNA. In the third step, typically 
performed at 72°C, the applied thermo-stable polymerase finally creates the new DNA 
strand complementary to the DNA template strand. These three steps were repeated 
(about 25-35 cycles) resulting in the exponential amplification of the DNA.12 
Within this thesis, the PCR technique was used for the site-directed mutagenesis of the 
HTLV-1 PR 1-116 (L40I, Y114N) construct: for the identification of the following 
optimized PCR conditions, different ratios of the components of the PCR solution as 
well as different hybridization temperatures were tested. 
Finally, the following composition of the PCR solution and parameters of the PCR 
program were used: 
10 µl 5x HiFi-buffer (BioCat) 
1 µl PRECISOR high-fidelity DNA Polymerase, 250 U (BioCat) 
5 µl plasmid (encoding HTLV-1 PR 1-116, L40I, Y114N) 
1 µl primer 1 (20 nM) 
1 µl primer 2 (20 nM) 
1 µl dNTP-Mix (each 25 mM) 
31 µl water (sterile) 
 
The PCR was performed in a Thermocycler PCR Mini Cycler (MJ Research). Steps 2-4 
were repeated 30 times (30 PCR cycles). 
step time temperature  
1 60s 98°C  
2 30s 98°C denaturation 
3 30s 63°C hybridisation 
4 7min 72°C extension 
5 ∞ 4°C  
Before transforming the new plasmid into E. coli cells, first a DpnI digestion must be 
performed to remove the starting plasmid and the PCR product has to be purified. The 
DpnI digestion was performed by incubating 30 µL of the PCR product solution and 
3 µL DpnI (10 U/µL, Fermentas) for 2 h at 37°C. For purification of the PCR product a 
purification kit (peQLab) was used.  
After the plasmid minipreparation, the new plasmid (L40I) was sequenced (Eurofins, 
Germany) to confirm the mutation. 
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2.2.2 Expression System 
The full-length protease (HTLV-1 PR 1-125) as well as the truncated protease (HTLV-1 
PR 1-116) were expressed in the E. coli strain Rosetta 2 (DE3).  
First, the respective plasmids, both bearing the L40I mutation, were transformed via 
heat shock into the Rosetta 2 (DE3) competent cells according to a standard protocol 
and a glycerol stock was prepared and stored at -80°C. 
 
2.2.3 Inclusion Bodies 
According to the literature, the HTLV-1 protease is expressed as inclusion bodies in E. 
coli. Inclusion bodies often result from overexpression of recombinant proteins through 
aggregation of the expressed and un- or partially folded protein. For the recovery of 
active protein from inclusion bodies, they firstly need to be extracted from the E. coli 
cells, followed by the solubilization of the aggregated protein, typically using strong 
denaturants, such as for example highly concentrated urea or guanidine hydrochloride, 
thiocyanate salts or detergents causing denaturation. Finally, the protein usually has to 
be refolded, for example by dilution or by chromatography. In this step the denaturing 
agent is removed to enable the refolding of the protein. Finding suitable refolding 
conditions is often quite challenging, due to aggregation and misfolding of the protein. 
Therefore it seems in general to be easier to work with soluble proteins instead of 
insoluble inclusion bodies. Process parameters that might influence the production of 
soluble protein are e.g. the media composition, the expression temperature, the 
production rate, and the availability of chaperones. To address the problem of protein 
insolubility, also special E. coli cell lines are available, providing a further approach to 
increase the yield of soluble protein, like e.g. the ArcticExpress cells.13 However, 
working with inclusion bodies might also have some advantages: soluble impurities can 
easily be separated by washing steps and centrifugation. Usually the expression level 
is higher than in soluble systems, the protein product is protected from proteolytic 
degradation, and in case of target proteins with toxic properties towards the used 
expression organism, the cells are usually protected against their toxicity.14,15 
 
2.2.4 Protein Expression 
The protein expression protocol is based on the literature procedure from Li et al.1 The 
pre-culture was prepared in 10 ml LB medium containing the antibiotics ampicillin 
(100 mg/l) and chloramphenicol (20 mg/l) at 37°C and 220 rpm shaking overnight. For 
the main culture two pre-cultures (20 ml) were transferred into 1.6 l LB medium 
containing the same antibiotics as in the pre-culture and shaken at 37°C until an OD600 
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of about 0.7 was observed (≈ 3.5 h). The protein expression was induced by addition of 
isopropyl-β-D-thiogalactopyranosid (IPTG) (1 mM). The temperature was decreased 
from 37°C to 14°C to enable a slower protein production, after ca. 15 hours the cells 
were harvested by centrifugation (5500 rpm, 15 min, 4°C). The cells were resuspended 
in 70 ml buffer A (Table 2.1) and for cell disruption this solution was first incubated with 
lysozyme (1 h) followed by sonication on ice (10 times for 90 seconds). For removal of 
nucleic acids, the solution was incubated for 1 h at 4°C with Benzonase® Nuclease 
(1.5 µl). After that a washing step of the inclusion bodies was performed: first, urea was 
added to the inclusion body solution to finally obtain an urea concentration of 0.5 M, 
while the solution was again stirred for 1 h at 4°C. Second, the solution was centrifuged 
(20000 rpm, 30 min, 4°C) and the obtained inclusion bodies were washed three times 
with buffer B. For solubilization of the inclusion bodies, the pellet was resuspended in 
buffer C, containing 8 M urea as strong denatured, and stirred at 4°C for 15 h.  
 
2.2.5 Protein Purification 
The purification was performed according to the procedure from Li et al.1 and 
comprises two purification steps by fast protein liquid chromatography (FPLC). First, 
the inclusion body solution (supernatant) was passed through a Q Sepharose (anion 
exchange column) equilibrated with buffer D. Before loading the eluate onto an SP 
Sepharose (cation exchange columns) equilibrated with buffer E, the pH of the eluate 
was adjusted to 3.0. The bound protein was eluted with buffer E containing 0.3 M NaCl.  
 
2.2.6 Refolding 
The refolding of both protease constructs was performed via dialysis; however, a 
different refolding protocol was used for each protein. 
The refolding of the HTLV-1 PR 1-116 was performed according to the publication from 
Li et al.1 using the sodium acetate buffer F. The protein was stored at -80°C until use.   
The refolding of the full-length protease (HTLV-1 PR 1-125) was performed as 
published9 and comprised three different refolding steps: first, the protein was dialyzed 
against buffer G for 15-24 h, followed by buffer H for 12-24 h, and, finally, against 
buffer I for 24 h. The HTLV-1 PR 1-125 was stored at -20°C until use. 
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Table 2.1. Used buffers for HTLV-1 PR expression, purification and refolding. 
buffer buffer composition buffer buffer composition 
A 
 
10 mM Tris, pH 7.5 
5 mM EDTA 
F 15 mM sodium acetate, pH 3.0 
5 % PEG 300 
5 mM DTT 
B 
 
0.5 M urea 
10 mM Tris, pH 7.5 
5 mM EDTA 
G 25 mM formic acid, pH 2.8 
C 
 
8 M urea 
10 mM Tris, pH 7.5 
5 mM EDTA 
10 mM DTT 
H 50 mM sodium acetate, pH 5.0 
1 mM EDTA 
1 mM DTT 
D 
 
6 M urea 
10 mM Tris, pH 7.5 
5 mM EDTA 
5 mM DTT 
I 20 mM PIPES, pH 7.0 
150 mM sodium chloride 
10 % glycerol 
1 mM EDTA 
2 mM DTT 
0.5 % Nonidet P-40 
E 
 
6 M urea 
20 mM sodium acetate, pH 3.0 
5 mM EDTA 
5 mM DTT 
  
 
 
2.2.7 Conclusion and Outlook 
Within this thesis a robust protocol for the expression, purification, and refolding of 
HTLV-1 PR was successfully established in our laboratory which provides continuous 
access to both HTLV-1 protease constructs. As the SDS gels (Figure 2.1 and 2.2) 
indicate the expression of both proteins worked well. Via the inclusion body washing 
steps most of the protein impurities were removed; only two weak protein bands 
between 35 and 40 kDa were present before the purification via Q and SP Sepharose. 
After the purification by the Q and SP Sepharose hardly any impurities were detectable 
(Figure 2.1 and 2.2).  
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Figure 2.1. SDS gels of the HTLV-1 PR 1-116. 
 
 
 
Figure 2.2. SDS gel of the HTLV-1 PR 1-125. 
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2.3 Thermal Shift Assay  
Thermal shift assay (TSA) measurements are in general easy to perform and suitable 
as screening method to identify novel inhibitor scaffolds as well as stabilizing buffer 
conditions (e.g. required to proceed into crystallization trials), while neither substrate 
nor knowledge about the protein function or even enzymatic activity is needed. 
Therefore, this assay was chosen for the identification of novel inhibitor scaffolds which 
could serve as starting points for the discovery of HTLV-1 PR inhibitors. Crystallization 
of these should, in the following step, provide valuable insights into the binding mode of 
these novel inhibitor scaffolds in complex with the protease and thus facilitate the 
further structure-based optimization of the initial screening hits. The principle and 
general application of the TSA is described in detail in chapter 7.1.  
Within this thesis, the development of a suitable TSA assay protocol was envisaged for 
the truncated as well as for the full-length protein constructs (HTLV-1 PR 1-116 and 
HTLV-1 PR 1-125, respectively). 
 
2.3.1 HTLV-1 PR 1-116 
The first measurements were performed in an assay buffer published for the truncated 
construct (buffer 1, Table 2.2) using different protein concentrations and protein 
batches which had been stored at different conditions as well as pepstatin as tool 
inhibitor. In addition, the buffer was used without DTT (buffer 2) and the heating 
temperature was expanded from the classical range of 20 - 80°C to 5 - 100°C. 
Unfortunately, no evaluable melting curves were obtained under these various 
conditions.  
To investigate the feasibility of the TSA setup in general, the assay was performed with 
endothiapepsin as well as with the related HIV-1 protease as model systems.  
 
Figure 2.3. TSA curves of the HIV-1 PR without inhibitor (blue) and with pepstatin (63 µM) (green). The 
curves possess the shape of typical TSA curves and a clear shift of the melting temperature due to protein 
stabilization through pepstatin as inhibitor is observed. 
 
42                                       2. In-House Establishment of a HTLV-1 Protease Technology Platform 
 
	  
In both cases the typical TSA curves were obtained (Figure 2.3) indicating that the 
assay setup itself in principle was functional.  
Attempts to optimize the assay setup for HTLV-1 PR included measurements in 
different buffers (Table 2.2) having been used in the literature for HTLV-1 PR in 
different assay systems as well as in water. Besides the refolded protein, also protein 
before the refolding step as well as protein which had been denatured through heating 
after the refolding was used for TSA experiments. In Figure 2.4, TSA curves from the 
HTLV-1 PR as well as from the related HIV-1 PR are shown, for comparison each one 
with denatured protein as well. In case of the HTLV-1 PR no difference between the 
denatured and refolded protein as well as the protein before the refolding step can be 
seen, while in case of the HIV-1 PR a typical curve was obtained for the active 
protease whereas a curve similar to that of the HTLV-1 PR was observed for the 
denatured protein. 
Noteworthy, the solvent exchange of buffer for water yielded different melting curves 
(Figure 2.5). However, this curve progression was only observed with protein before 
refolding, and could not be interpreted in a meaningful way while the curves recorded 
from protein batches after the refolding step resembled the curves obtained for the 
denatured protein (Figure 2.4). Also a pH-screen (pH-values from 4.0 to 9.5 (pH-
screen I) did not result in any improvement of the curves. 
 
 
Figure 2.4. TSA curves of the HIV-1 PR (left) and HTLV-1 PR (right) of refolded protein (blue) and 
denatured protein (red), in the case of the HTLV-1 PR also protein before the refolding step is shown 
(purple). 
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Figure 2.5. HTLV-1 PR before the refolding measured in water as “assay buffer”. 
 
After the first successful crystallization trials of the refolded protein using the truncated 
construct, once again some additional tests were performed to find suitable buffer 
conditions for the TSA measurements utilizing the following screening conditions: 
 
• A pH-screen (pH-screen II) probing the pH-range from 4.5 - 9.5 with in total 23 
different buffers, combined with different sodium chloride concentrations 
(without NaCl, 100 mM NaCl and 500 mM NaCl), was performed on the basis of 
the publication from Ericsson et al.16  
• A PACT Screen (Quiagen), originally composed to test the effect of anions, 
cations, and pH-values on crystallization, was performed based on a published 
protocol.17 
 
However, also these attempts did not yield typical TSA curves. Thus, the establishment 
of a TSA protocol for the HTLV-1 1-116 protease construct was discontinued as this 
construct is obviously not suited for this biophysical assay. 
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Table 2.2. Different buffers used in the TSA of the HTLV-1 PR 1-116. 
buffer (annotation) buffer composition buffer (annotation) buffer composition 
buffer 1 
(HTLV-1 1-116 
assay)1 
0.5 M NaCl 
50 mM Na-acetate, pH 5.5 
5 mM DTT 
buffer 6 
(crystallization)1 
0.1 M Na-acetate, pH 5.2 
17 % PEG 8000 
10 % PEG 300 
10 mM DTT 
buffer 2 
(buffer 1 without 
DTT) 
0.5 M NaCl 
50 mM Na-acetate, pH 5.5 
 
buffer 7 
(HTLV-1 PR 
assay)3 
0.4 M citric acid, pH 5.3 
2.1 mM NaCl 
10.4 mM EDTA 
12.5 % gylcerol 
2.1 mM DTT 
buffer 3 
(HTLV-1 PR 
refolding)3 
20 mM PIPES, pH 7.0 
1 mM EDTA 
150 mM NaCl 
10 % glycerol 
2 mM DTT 
buffer 8 
(HIV-1 PR assay) 
100 mM MES, pH 5.5 
300 mM KCl 
5 mM EDTA 
buffer 4 
(HTLV-1 PR 1-116 
refolding)2 
15 mM Na-acetate, pH 3.0  
5 % PEG 300 
5 mM DTT  
buffer 9 
(endothiapepsin 
assay) 
0.1 M Na-acetate, pH 4.6 
0.01 % Tween20 
buffer 5 
(HTLV-1 PR 1-116 
SP Sepharose)1 
20 mM Na-acetate, pH 3.0 
6 M urea 
5 mM EDTA 
5 mM DTT 
0.3 M NaCl 
water 
 
 
 
2.3.2 HTLV-1 PR 1-125 
TSA measurements for the full-length protein were performed in numerous different 
buffers (Table 2.3), and in presence of a variety of inhibitors as tool compounds 
(pepstatin, NK102, NK192, NK232, (see appendix)) using different protein 
concentrations. Also attempts were made using other protein buffers (buffer exchange 
after refolding of the full-length protein immediately before the TSA measurements into 
water or sodium acetate buffer (50 mM, pH 5.0, containing 1 mM EDTA)).  
Unfortunately, none of these tested conditions resulted in evaluable TSA curves, which 
led to the termination of the establishment efforts towards a TSA setup for the full-
length protease as well. Similarly to other target proteins, not all biophysical methods 
are necessarily suitable to study particular proteins of interest, hence, the investigation 
of ligand binding towards HTLV-1 PR was pursued using other methods.   
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Table 2.3. Different buffers used in the TSA of the HTLV-1 PR 1-125. 
buffer (annotation) buffer composition 
  buffer 8 
(HIV-1 PR assay) 
see Table 2.2. 
buffer 9 
(endothiapepsin assay) 
see Table 2.2. 
buffer 10 
(HTLV-1 PR 1-125 refolding buffer 2)7  
50 mM Na-acetate, pH 5.0 
100 mM NaCl 
buffer 11 
(HTLV-1 PR 1-125 refolding buffer 3)9  
20 mM PIPES, pH 7.0 
150 mM NaCl 
10 % glycerol 
1 mM EDTA 
2 mM DTT 
0.5 % Nonidet P-40 
buffer 12 
(HTLV-1 PR 1-125 fluorescence assay)18 
250 mM potassium hydrogen phosphate, pH 5.6 
5 % glycerol 
1 mM EDTA  
5 mM DTT 
500 mM NaCl 
 
 
2.3.3 Conclusion and Outlook 
Unfortunately, all attempts to establish the thermal shift assay for the HTLV-1 protease 
did not succeed after testing many various conditions for both protease constructs (full-
length protein and HTLV-1 PR 1-116). As subsequently the full-length protein showed 
activity in the fluorescence-based assay and the shortened construct could 
successfully be used for crystallization of the protease, hence confirming reasonably 
folded protein preparations for both constructs, these negative TSA results are, 
retrospectively, rather surprising. One possible explanation could be that the refolding 
rate is too low and that the non-properly folded amounts of protein thus disturbs the 
detection of the unfolding process. Additionally, the used fluorescence dye (SPYRO 
Orange) might not be compatible with the protein. The usage of other fluorescence 
dyes, like for example 1.8-ANS (1-anilino-8-naphthalene sulfonate), bis-ANS, nile red 
or dapoxyl sulfonic acid (see chapter 7.2) could perhaps enable TSA measurements. 
However, it is also described in literature that the terminal β-sheets of the HTLV-1 PR 
are comparatively hydrophobic and exposed to the solvent, while in the HIV-1 PR for 
example theses residues are hydrophilic and might interact with the solvent.7 Thus, 
maybe the resulting and also experimentally proven high aggregation tendency of the 
HTLV-1 PR as well as the surface characteristics might also impede TSA 
measurements in the folded form. 
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2.3.4 Experimental Section 
General TSA Protocol 
TSA measurements were performed using the iCycler IQ5 Real Time Detection System 
(Bio-Rad). For the assay 96-well plates (MultiplateTM Low-Profile 96-well unskirted PCR 
Plates, BioRad) were used. Unless specified otherwise, the total volume of the well 
solution was 40 µL and the plate was heated from 20°C to 80°C with a heating rate of 
0.5°C/min. SYPRO Orange (protein gel stain 5000x concentration in DMSO, Invitrogen) 
was used as fluorescence dye. 
 
Detailed TSA Procedures 
pH-Screen I 
12 different buffer solutions (see below) covering pH-values from 4.0 - 9.5 were used. 
2 µl of each buffer solution (1 M) were added to 38 µl of the water-protein-SYPRO 
Orange-mixture (800 µl water, 1.7 µl SYPRO Orange, 22 µl HTLV-1 PR 1-116 before 
refolding (10 mg/ml). For comparison, the screen was also performed with the protein 
being denatured by heating.   
 
1 1 M sodium acetate, pH 4.0 7 1 M HEPES, pH 7.0 
2 1 M sodium acetate, pH 4.5 8 1 M HEPES, pH 7.5 
3 1 M sodium acetate, pH 5.0 9 1 M Tris, pH 8.0 
4 1 M MES, pH 5.5 10 1 M Tris, pH 8.5 
5 1 M MES, pH 6.0 11 1 M CHES, pH 9.0 
6 1 M MES, pH 6.5 12 1 M CHES, pH 9.5 
 
pH-Screen II (Ericsson) 
The pH-screen was similarly performed as described in the publication by Ericsson et 
al.16 In total, 23 different buffer conditions were tested (see below). The well solution 
consisted of 19 µl water-SYPRO Orange solution (water with 0.2 % SYPRO Orange), 
19 µl twofold buffer solution (200 mM), and 1.5 µl protein solution (HTLV-1 PR 1-116, 
10 mg/ml).  
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1 Sodium acetate, pH 4.5 13 Potassium phosphate, pH 7.0 
2 Sodium citrate, pH 4.7 14 HEPES, pH 7.0 
3 Sodium acetate, pH 5.0 15 Ammonium acetate, pH 7.3 
4 Potassium phosphate, pH 5.0 16 Sodium phosphate, pH 7.5 
5 Sodium phosphate, pH 5.5 17 Tris, pH 7.5 
6 Sodium citrate, pH 5.5 18 Imidazole, pH 8.0 
7 MES, pH 5.8 19 HEPES, pH 8.0 
8 Potassium phosphate, pH 6.0 20 Tris, pH 8.0 
9 MES, pH 6.2 21 BICINE, pH 8.0 
10 Sodium phosphate, pH 6.5 22 Tris, pH 8.0 
11 Sodium cacodylate, pH 6.5 23 BICINE, pH 9.0 
12 MES, pH 6.5   
 
PACT buffer screen 
The PACT buffer TSA screen was performed according to a published protocol:17 to a 
TBS (Tris-buffered saline) buffer pH 7.5, 35 µl HTLV-1 PR 1-116 (10 mg/ml) as well as 
2 µl SYPRO Orange were added to a final volume of 2 ml. 19 µl of this mixture were 
pipetted in each well of the 96-well plate, followed by the addition of 19 µl of the 
respective PACT screen solution (Quiagen). This procedure was also repeated using 
the sodium acetate buffer pH 5.5 (final concentration: 50 mM) as protein solution, 
based on buffer 1, instead of the TBS buffer. 
 
2.4 Fluorescence-Based Assay 
2.4.1 Assay Establishment and Validation 
For the establishment of a fluorescence-based assay aiming to further characterize 
inhibitors affinity-wise, different substrates were tested, all based on the fluorescence 
resonance energy transfer (FRET), which is also referred to as Förster resonance 
energy transfer. 
FRET describes the emission-light-free energy transfer of a fluorophore (donor) to a 
quencher molecule (acceptor). Therefore, the emission spectrum of the donor must 
overlap with the absorption spectrum of the acceptor. For this purpose so-called FRET-
substrates have a harmonized fluorophore- and quencher molecule in close proximity 
(each at one site of the scissile bond). The excitation of the fluorophore does not result 
in a significant fluorescence signal if the fluorophore and quencher molecule are in 
close proximity. Caused by the catalytic activity of the enzyme, the cleavage of the 
substrate induces a separation of the fluorophore from the quencher molecule and 
results thereby in an increase in fluorescence. Under some conditions the fluorescence 
 
48                                       2. In-House Establishment of a HTLV-1 Protease Technology Platform 
 
	  
can also be quenched by the quencher group of neighboring cleavage products or 
substrate molecules, which results in a lower fluorescence signal not reflecting the 
whole amount of the cleaved substrate (inner filter effect). The magnitude of the inner 
filter effect is dependent on the substrate concentration, the wavelength range, and the 
path length, and therefore might vary in dependence of the instrumental 
configuration.19    
Within this thesis, in total three different substrates were tested using the full-length 
protein: the HIV-1 PR substrate (substrate A, purchased from Bachem), and two 
substrates derived from the natural HTLV-1 CA/NC cleavage site, possessing the 
Abz/p-nitro-Phe (substrate B) or the EDANS/DABCYL (substrate C)18 as 
fluorophore/quencher pair. Substrate B and C were kindly synthesized by Dr. Kornelia 
Hardes (AK Steinmetzer, Philipps-Universität Marburg), substrate C was also 
reordered from Bachem (Germany). ↓ denotes the cleavage site. 
 
Substrate A Abz-Thr-Ile-Nle-p-nitro-Phe-Gln-Arg-NH2  
HTLV-1 CA/NC  
cleavage site 
 
Lys-Thr-Lys-Val-Leu↓Val-Val-Gln-Pro-Lys 
Substrate B Abz-Lys-Thr-Lys-Val-Leu↓Val-Val-Gln-Pro-Lys-p-nitro-Phe-NH2 
Substrate C18 Arg-Glu-(EDANS)-Thr-Lys-Val-Leu↓Val-Val-Gnl-Pro-Lys(DABCYL)-Arg-NH2 
 
As expected, the full-length HTLV-1 PR did not cleave the HIV-1 PR substrate 
(substrate A), which underlines the known differences in the substrate specificity of 
both related proteases. Substrate B, an anthraniloyl-substrate derived from the natural 
HTLV-1 cleavage site, is cleaved by the protease, but the slopes of the curves are 
relatively low. However, with the EDANS/DABCYL HTLV-1 substrate (substrate C) the 
obtained results enabled the determination of Km-values and kinetic inhibitor 
characterization. 
In addition to the full-length protein, also measurements with the shortened construct 
(HTLV-1 PR 1-116) were performed using substrate C. These measurements revealed 
that the shortened protease construct possesses to some extent catalytic activity, 
however, higher protein concentrations are required (ca. factor 20) to obtain 
comparable slopes of the recorded curve in comparison to the full-length protein. 
Therefore, the full-length protein was subsequently used for kinetic measurements and 
affinity determinations via the fluorescence-based assay. 
For validation of the Ki-value determination via the fluorescence-based assay, the 
HIV-1 PR inhibitor indinavir was used as reference ligand. A Ki-value against HTLV-1 
PR of 3.48 µM was reported in literature,18 which is in good agreement with the Ki-
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value determined in our laboratory (2.5 ± 0.7 µM, average of in total 7 measurements 
(chapter 4 and 5)). The following assay setup was used for affinity determination of 
HTLV-1 PR inhibitors which is based on the protocol from Bagossi et al.:18 
The fluorescence-based assay was performed in 96-well plates using a Tecan Safire II 
plate reader. Each well contained a reaction mixture consisting of 186 µL assay buffer, 
2 µL substrate C (500 µM/300 µM (concentration is specified in the corresponding 
chapter of this thesis)), 2 µL DMSO/inhibitor. Immediately before the measurement, 
10 µL HTLV-1 PR 1-125 (≈ 24 µg/ml, diluted with the protein buffer (buffer I, Table 2.1)) 
were added to start the substrate cleavage. The assay buffer consisted of 250 mM 
potassium hydrogen phosphate, pH 5.6, 5 % glycerol, 1 mM EDTA, 5 mM DTT and 
500 mM sodium chloride. The increase of fluorescence was detected at 490 nm after 
excitation at 340 nm. IC50-values as well as percent inhibition values were determined 
at a substrate concentration of 5 µM, for Km-determination 12 different substrate 
concentrations were used (50 µM - 24 nM). From the increase in fluorescence, the 
IC50-values were calculated with the program GraFit 4.09 (Erithacus Software). The 
corresponding Ki-values were calculated by means of the Cheng-Prusoff-equation20 
using the determined Km-value (Lineweaver-Burk) and the substrate concentration.  
 
2.4.2 Conclusion 
Within this thesis, a fluorescence-based assay procedure could be successfully 
established enabling the affinity estimation by means of either percent inhibition values 
or Ki-value determination of small molecule inhibitors to the HTLV-1 PR. Testing 
different substrates, the EDANS/DABCYL substrate (substrate C) was found to be the 
most suitable one. The assay was validated for the full-length protein using indinavir as 
reference. Also the shortened protease construct HTLV-1 PR 1-116 exhibited catalytic 
activity in our hands, however, due to the enhanced activity of the full-length construct, 
the latter was chosen for the enzymatic assay and inhibitor characterization. 
 
2.5 Crystallization 
Within this thesis, elucidation of the binding modes of small molecule inhibitors to the 
HTLV-1 PR was of great interest. To achieve this, extensive efforts were undertaken 
focusing on the crystallization of the shortened construct HTLV-1 PR 1-116 that in the 
past had already been successfully used for crystallization; however, also attempts with 
the catalytically more active HTLV-1 PR 1-125 were performed.  
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2.5.1 HTLV-1 PR 1-116 
As it was expected that the C-terminal residues, which are truncated in this protease 
construct, are essential for the dimerization, the focus was laid on cocrystallization 
experiments in order to induce a stabilizing effect by the ligand towards the 
dimerization hence compensating for the loss of the C-terminal residues relevant for 
dimer formation.   
 
Initial Crystallization Screen 
As the identification of successful crystallization conditions for a protein does not follow 
any predictable rules to identify promising starting conditions and succeeds often by 
serendipity, we started the crystallization project with a robot screening at the Core 
Facility Structural Biology, Philipps-Universität Marburg: crystallization attempts were 
performed with two inhibitors, namely with pepstatin, a well-known and unselective 
aspartic protease inhibitor, and with the in-house developed HIV-1 PR inhibitor NK101 
(Figure 2.7, appendix). In total, 1248 conditions were screened in 96-well plates by the 
sitting-drop method.  
Fortunately, this initial screen yielded promising crystals in presence of NK101 as 
inhibitor in the protein solution at five different conditions, for pepstatin two conditions 
afforded crystal-like rods (Table 2.4). The crunch test, a first easily accessible indicator 
for protein crystals, was used to qualify the obtained crystals before the initiation of 
initial diffractions experiments. Measurements of the obtained crystals at the 
synchrotron (Bessy II, Berlin, Germany) confirmed that the crystals were indeed protein 
crystals, and for some HTLV-1 PR-NK101 crystals initial datasets with resolutions of 
3.5 - 4 Å could be collected. Therefore, the identified conditions provided the basis for 
further optimization. 
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Table 2.4. Crystallization hits from the initial screen (HTLV-1 PR 1-116). 
crystal photo inhibitor screen (Quiagen) condition 
 
 
NK101 
 
AmSO4 
Suite 
 
0.2 M potassium sodium tartrate 
2.2 M ammonium sulfate 
 
 
 
NK101 
 
AmSO4 
Suite 
 
0.1 M tri-sodium citrate, pH 4.0 
1.6 M ammonium sulfate 
 
 
 
NK101 
 
Cryos Suite 
 
0.16 M magnesium acetate 
0.08 M sodium cacodylate, pH 6.5 
20 % glycerol 
16 % polyethylene glycol 8,000 
 
 
 
NK101 
 
JCSG Core 
Suite III 
 
0.1 M MES, pH 6.0 
2.4 M ammonium sulfate 
 
 
 
NK101 
 
JCSG Core 
Suite III 
 
0.1 M tri-sodium citrate, pH 5.0 
1 M lithium chloride 
 
 
 
pepstatin 
 
JCSG Core 
Suite II 
 
0.1 M tri-sodium citrate, pH 5.0 
2.4 M ammonium sulfate 
 
 
 
pepstatin 
 
JCSG Core 
Suite II 
 
0.07 M Na-acetate, pH 4.6 
0.14 M calcium chloride 
30 % glycerol 
14 % 2-propanol 
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Reproduction and Optimization  
Attempts to reproduce these hits manually did not succeed which prompted us to 
reproduce these initial conditions at the same screening facility again. Indeed, crystal 
growth for drops containing NK101 was again observed, however, at different 
conditions (Table 2.5) 
 
Table 2.5. Crystallization screens and successful conditions used for the second robot 
screen for the HTLV-1 PR 1-116. 
screen 
(Quiagen) condition 
AmSO4 Suite 0.2 M ammonium nitrate 
2.2 M ammonium sulfate 
AmSO4 Suite 0.2 M potassium iodide 
2.2 M ammonium sulfate 
AmSO4 Suite 0.1 M Tris, pH 8.5 
1.5 M ammonium sulfate 
15 % (v/v) glycerol 
JCSG Core Suite II 0.14 M calcium chloride 
0.07 M sodium acetate, pH 4.6 
30 % (v/v) glycerol 
14 % (v/v) 2-propanol 
 
The comparison of conditions which yielded crystals of the HTLV-1 PR showed that 
most conditions contain ammonium sulfate (1.6 - 2.4 mM) as precipitant.  
Further attempts to reproduce the screening hits by varying the pH-value, PEG, 
glycerol, and salt concentration of the hit conditions, using sitting as well as hanging 
drops, with and without seeding, or trying to crystallize HTLV-1 PR in presence of other 
inhibitors did not succeed. All these attempts were performed with a drop volume of 2 
or 4 µl, containing reservoir/protein-inhibitor solution at a ratio of 1:1.  
Further crystallization attempts comprised the variation of the ratio of reservoir solution 
to protein-inhibitor solution, again using grids around the found conditions varying the 
pH, the precipitant concentrations as well as the crystallization temperature (291K as 
well as 277K). Surprisingly, crystals appeared in some drops only containing the 
protein-inhibitor solution in absence of the reservoir solution. The thereby obtained 
crystals of HTLV-1 PR in complex with NK101 finally resulted in an X-ray structure with 
a resolution of 3.15 Å (chapter 5). The following crystallization conditions were 
successful for HTLV-1 PR-NK101 crystals, which grew in hanging drops at 291K, using 
1 ml reservoir solution (0.1 M Tris, pH 7.5, 1.5 M ammonium sulfate, 20 % glycerol) 
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and a drop volume of 1 µl, containing 5 mM inhibitor.  
Using a grid screen around the successfully determined ammonium sulfate conditions 
varying the ammonium sulfate as well as the glycerol concentration, and pH-values, a 
set of 21 additional HTLV-1 PR inhibitors were tried to crystallize by cocrystallization 
(Table 2.6). 
 
Table 2.6. Protease inhibitors used for crystallization trials of the HTLV-1 PR 1-116 
using ammonium sulfate crystallization conditions. 
inhibitor class inhibitors 
aspartic protease inhibitors pepstatin, saquinavir,  
ritonavir, des-3-pyridylmethyl-
indinavir 
C2-symmetric 3,4-disubstituted pyrrolidines*: 
 
AB69, AB83, AB84, AB91,  
AB101, AB111 
 
pyrrolidine-based bicyclic inhibitors:** 
 
NK102, NK192, NK232, NK237, 
NK251, NK252, NK253, 
NK343 (one carbonyl group) 
other 3,4 disubstituted pyrrolinde-based  
HIV-1 PR inhibitors:** 
NK88, NK200 
 
*) inhibitors were developed and synthesized as HIV-1 PR inhibitors by Dr. Andreas Blum. 
**) inhibitors were developed and synthesized as HIV-1 PR inhibitors by Dr. Nina Klee. 
 
Via these trials, X-ray structures of the pyrrolidine-based C2-symmetric inhibitors AB83 
and AB84 in complex with the HTLV-1 PR were obtained providing important insights 
into the SAR of this inhibitor series, which are discussed in detail in chapter 4.  
Additionally, a screen in 96-well plate format was performed using AmSO4 Suite, Cryos 
Suite, PACT Suite, and JCSG Core Suite III purchased from Quiagen in presence of 
the inhibitors indinavir and NK253. Crystals were obtained for both inhibitors: the 
protein crystals obtained in the drops containing NK253, however, did not result in an 
evaluable diffraction pattern at the synchrotron (Bessy II, Berlin, Germany), while for 
the HTLV-1 PR-indinavir crystals an X-ray structure with a resolution of 2.4 Å was 
obtained. The results are discussed in detail in chapter 3. 
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2.5.2 HTLV-1 PR 1-125 
The effort of crystallizing the full-length protein was started using conditions which 
yielded crystals for the truncated protease construct including the successful 
ammonium sulfate conditions (0.1 M Tris, pH 7.5, 1.5 M ammonium sulfate, 20 % 
glycerol) containing only protein-inhibitor solution in the crystallization drop with 
indinavir, NK101, NK253 as inhibitors, and in absence of any inhibitor. As these 
attempts did not yield crystals for the full-length construct, again a screen at the Core 
Facility Structural Biology, was performed; for this screen a total of 1248 conditions 
(Table 2.7) with indinavir and NK253 were tested. Crystals which grew in this screening 
were evaluated by the crunch test, staining trials and at the synchrotron (Bessy II, 
Berlin, Germany), but did turn out not to consist of protein.  
 
Table 2.7. Applied crystallization screens for the HTLV-1 PR 1-125. 
screen (Quiagen) crystallization temperature 
AmSO4 Suite 277K and 291K 
Anions Suite 291K 
Classics Suite 291K 
Cryos Suite 291K 
JCSG Core Suite I 277K and 291K 
JCSG Core Suite II 277K and 291K 
JCSG Core Suite III 277K and 291K 
JCSG Core Suite IV 277K and 291K 
 
2.5.3 Conclusion and Outlook 
In conclusion, four novel X-ray structures of the HTLV-1 protease 1-116, being the first 
HTLV-1 PR structures with non-peptidic inhibitors (chapters 3, 4, and 5), could 
successfully be obtained. The HTLV-1 PR-indinavir complex was obtained directly from 
one screening hit, while the optimization of crystallization conditions found in the initial 
screening of the HTLV-1 PR resulted in X-ray structures in complex with NK101, AB83, 
and AB84. To the best of our knowledge, these results provided the first X-ray 
structure-supported SAR interpretation of small molecule HTLV-1 PR inhibitors 
described so far. 
Unfortunately, despite various crystallization efforts for the full-length protein, no protein 
crystals were obtained within the screens performed during this thesis. In further 
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crystallization trials, variation of the crystallization parameters such as usage of 
different protein buffers or different ratio of protein- and reservoir solution in the 
crystallization drop could be beneficial. Additionally, the usage of another protein 
construct, e.g. the expression of the homodimer as a single-chain construct, while 
connecting both monomers by a linker, or, furthermore, the usage of inhibitors with 
other scaffolds or higher affinity could eventually be successful. As described at the 
beginning of this chapter, the full-length protein has a high aggregation tendency, 
which might explain the difficulties observed during the crystallization process. 
 
2.6 Appendix 
 
 
Figure 2.6. HIV-1 PR inhibitors used for HTLV-1 PR crystallization trials synthesized by Dr. Andreas Blum, 
AK Diederich, Philipps-Universität Marburg. 
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Figure 2.7. HIV-1 PR inhibitors used for HTLV-1 PR crystallization trials synthesized by Dr. Nina Klee, AK 
Diederich, Philipps-Universität Marburg. 
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3. Structural Basis for HTLV-1 Protease Inhibition by the HIV-1 
Protease Inhibitor Indinavir*	  
	  
3.1 Introductory Remarks 
The following chapter has been published in the Journal of Medicinal Chemistry: 
Kuhnert, M., Steuber, H., Diederich, W. E., J. Med. Chem. 2014, 57(14), 6266-72. 
The respective text is taken from the original publication, figures of the supporting 
information are implemented in the main text. The author of this thesis performed all 
experiments including the protein expression and purification, the kinetic assay, 
crystallization, synchrotron data collection and docking studies, the interpretation of the 
structure- and affinity data as well as drafting of the manuscript. This project was 
carried out in cooperation with Dr. Holger Steuber (LOEWE-Zentrum für Synthetische 
Mikrobiologie SYNMIKRO, Philipps-Universität Marburg), who refined the X-ray 
structure. 
 
 
 
 
* Reproduced with permission from J. Med. Chem. 2014, 57, 6266–6272. Copyright 2014 American 
Chemical Society. 
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3.2 Abstract 
HTLV-1 protease (HTLV-1 PR) is an aspartic protease which represents a promising 
drug target for the discovery of novel anti-HTLV-1 drugs. The X-ray structure of HTLV-1 
PR in complex with the well-known and approved HIV-1 PR inhibitor Indinavir was 
determined at 2.40 Å resolution. In this contribution, we describe the first crystal 
structure in complex with a nonpeptidic inhibitor that accounts for rationalizing the 
rather moderate affinity of Indinavir against HTLV-1 PR and provides the basis for 
further structure-guided optimization strategies. 
 
3.3 Introduction 
Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus involved in several cancer-
developing processes, neurological and dermatological diseases such as the adult T-
cell leukemia (ATL), tropical spastic myelopathy (HAM), and HTLV-1-associated 
infective dermatitis (HAID).1,2 Approximately 10−20 million people of the world’s 
population are infected with the virus.3 Because all currently available treatment options 
(cytotoxic chemotherapy, interferons, zidovudine) show only limited therapeutic 
efficiency,1,4 the development of novel treatment alternatives is still of utmost 
importance. As the successful drug discovery programs against the human 
immunodeficiency virus-1 (HIV-1) protease as well as the hepatitis C virus NS3-4A 
protease have impressively shown, attacking the viral protease being essential for the 
maturation of the virus provides a promising therapeutic concept.5,6 Thus, the 
development of new HTLV-1 PR inhibitors could overcome the still existing lack of a 
curative treatment against HTLV-1 infections.  
The HTLV-1 PR is an aspartic protease and functions as a homodimer, each chain 
consisting of 125 residues.1,7,8 The protease is closely related to the well-known HIV-1 
PR, the latter representing a highly validated and exploited drug target. The strategy of 
developing protease inhibitors to attack the HIvirus has now been successfully pursued 
for almost 30 years, leading to hitherto 10 HIV protease inhibitors that are in clinical 
use.5,9 While the overall sequence identity between both proteases is about 28 %, their 
binding regions are even more conserved (45 %).10 Even though both proteases are 
very similar in their overall protein fold, they, however, substantially differ in their 
substrate specificity as well as inhibition profile.10 Considerable differences were also 
observed with respect to the effect of known protease inhibitors: some of the highly 
potent HIV protease inhibitors, namely Saquinavir, Ritonavir, Nelfinavir, and 
Amprenavir, did not show any relevant affinity against the HTLV-1 protease, thus 
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disqualifying them for further lead discovery campaigns (Ki > 20 µM).10,11 Interestingly, 
only the likewise approved HIV protease inhibitor Indinavir was able to inhibit the 
protease at low micromolar concentration (Ki = 3.5 µM).11 Albeit its affinity against 
HTLV-1 PR is still strongly reduced in comparison to HIV-1 PR (Ki = 540 pM),12 this 
moderate activity suggests Indinavir as putative starting point for the development of 
design hypotheses toward the first nonpeptidic HTLV-1 PR lead candidate. To pursue 
this approach on a rational basis, knowledge of the interaction geometry is 
indispensable, especially as the strong affinity deviation challenges a conserved 
binding mode of Indinavir toward both proteases. To answer this question and thereby 
provide the basis for lead design hypotheses, we determined the crystal structure of 
the clinically used, peptidomimetic HIV-1 PR inhibitor Indinavir in complex with HTLV-1 
PR. In addition, founding on the results of this study, the influence of the pyridyl moiety 
of the inhibitor was investigated in more detail. 
 
3.4 Results and Discussion 
3.4.1 Structure Determination and Binding Mode of Indinavir to HTLV-1 PR 
The X-ray structure of HTLV-1 PR in complex with the HIV-PR inhibitor Indinavir was 
determined at 2.40 Å resolution in the hexagonal space group P6322 (Table 3.3, 
appendix), presenting a well-defined density for the inhibitor structure (Figure 3.1, left). 
The obtained crystal structure unambiguously confirms Indinavir with its clearly defined 
stereochemistry bound in the substrate binding pocket of HTLV-1 PR. As expected, the 
two catalytic aspartates Asp32 and Asp32' are directly addressed by the ligand’s 
central hydroxyl group. As the core of the inhibitor resides in the S1/S1' pockets, the 
four side chain substituents of Indinavir are located in the S2/S2' and S1-S3/S1-S3' 
subpockets, respectively (Figure 3.1, right).  
 
Figure 3.1. Left: the omit Fo-Fc electron density map contoured at 2.5σ (blue) for Indinavir (green) is well 
defined. HTLV-1 protease is shown as cartoon in wheat. Right: chemical structure of Indinavir and 
schematic representation of the binding mode. 
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While the polar piperazinyl and pyridyl moiety point into the hydrophilic S1 and S1-S3 
pockets, respectively, the rather hydrophobic S2 and S2' pockets are addressed by the 
tert-butyl and indanol substituents of Indinavir. Its benzyl group occupies the likewise 
hydrophobic surrounding of the S1'-S3' subpocket. The H-bond inventory established by 
Indinavir is shown in Figure 3.2.  
 
Figure 3.2. Observed hydrogen bonds between Indinavir (green) and active-site HTLV-1 PR residues 
(wheat). Distances are in Å, ligand and amino acids are displayed in stick representation, color-coded by 
atom types. 
 
Except for the two nitrogen atoms of the piperazine moiety, all other ligand heteroatoms 
form H-bonds to the protease, either directly or water-mediated. For both protease 
monomers of the asymmetric unit, the flaps exhibit significant mobility, as indicated by 
elevated B-factors and a less well-defined electron density compared to the remaining 
protease. The interactions to the flap region are formed between two Indinavir carbonyl 
atoms and the Ala59 amide nitrogen via a water molecule, also known as “flap” water. 
The two tryptophanes 98 and 98' enable edge-to-face π−π interactions between the 
protein and the benzyl and pyridyl moiety of the inhibitor, which are oriented at a 
distance of 3.5 Å to Trp98' and 3.4 Å to Trp98, respectively. Even though the pyridyl-
nitrogen of Indinavir is in distance to form a weak direct polar contact to Arg10 (3.4 Å), 
the geometry for such an interaction is rather unfavorable, while the presence of an 
interstitial water molecule mediates a polar contact between the ligand nitrogen and 
Arg10. 
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3.4.2 Comparison with Currently Known HTLV-1 PR X-Ray Structures 
To date, seven HTLV-1 PR crystal structures with six different substrate analogues or 
peptide-like inhibitors have been published.1,7 The first one represents a cocrystallized 
statine-based inhibitor, whereas all other ligands are so-called KNI-inhibitors, which 
share a hydroxyl-phenyl-butane-amide moiety at a similar position (Figure 3.3).  
 
	  
	  
	  
	  
	  
	  
	  
	  
 
Figure 3.3. Chemical structures of the statine- and KNI-inhibitors, of which crystal structures with the 
HTLV-1 PR exist.1,7 
 
Comparable to Indinavir, all these inhibitors address the two catalytic aspartates 32 
and 32' by their central hydroxyl functionality. 
Because the statine-based inhibitor (Ac-Ala-Pro-Gln-Val-Sta-Val-Met-His-Pro) is 
considerably larger than all published KNI-inhibitors, it occupies significantly more 
space in the binding pocket, even reaching into the S5/S5' pocket. On the contrary, the 
smaller KNI-inhibitors only occupy the S3-S2' pocket (Figure 3.4).	  	  
	  
	  
Figure 3.4. Occupancy of the HTLV-1 PR binding pocket. Superposition of the statine-based inhibitor 
(magenta), which occupies the S5-S5' pocket, with KNI-10673 (cyan) and Indinavir (green), which are 
smaller and occupy the S3-S2' and S1-S3-S1'-S3' pocket, respectively. 
Inhibitor R1 R2 
KNI-10562 (pdb: 3LIN) 
  
KNI-10673 (pdb: 3LIQ) H  
KNI-10681 (pdb: 3LIT) H 
 
KNI-10683 (pdb:3LIV) H 
 
statine inhibitor (pdb: 2B7F, 3LIY) KNI-10729 (pdb: 3LIX) 
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In comparison, the occupancy of the subpockets by the KNI-inhibitors as well as 
Indinavir is quite similar, except for the important fact that Indinavir addresses the 
S3/S3' pockets only partially. Interestingly, all inhibitors, including Indinavir, have a tert-
butyl or iso-propyl moiety in common, either of which reside in the S2 pocket. Indinavir’s 
larger 3-pyridylmethyl-piperazinyl moiety reaches into the S1-S3 pocket, whereas for all 
other KNI-inhibitors, only the S1 pocket is occupied by the smaller benzyl group. The 
S1' pocket is addressed by the benzyl substituent of Indinavir instead of the KNI’s 
dimethylthiazolidine residue, whereas the S2' pocket hosts an indanol ring in place of 
the hydrophobic alkyl substituent of the KNI-inhibitors.  
The flap region of the protease, namely Ala59 and Ala59', is typically addressed via a 
water molecule in all structures, which seems to be conserved at this position. The B-
factors of the flap water molecules in the published X-ray structures range from 14 to 
37 Å2,13 a similar value of 42 Å2 is observed in our Indinavir complex. Considerable 
differences between these structures regarding the protein mainly concern the 
tryptophanes 98 and 98' that both exhibit pronounced mobility with respect to the 
orientation of the aromatic ring (Figure. 3.5a). In comparison to the larger statine-based 
inhibitor, the Trp98 and 98' in the HTLV-1-PR−Indinavir complex are flipped away 
around their χ2 angle by about 100° and 160°, respectively, for the two monomers. 	  
 
Figure 3.5. (a) Different conformations of Trp98/98' observed in the HTLV-1 PR (wheat: Indinavir 
structure, cyan: KNI-10673 (PDB: 3LIQ), magenta: statine inhibitor (PDB: 3LIY)) with the correspondent 
PR inhibitors (green: Indinavir). The tryptophanes show an inhibitor-dependent flexibility to avoid clashes 
with the inhibitors thus enabling π-π-interactions. (b) and (c) π-π-interactions of KNI-10673 and Indinavir 
to Trp98'/98, respectively. Distances are in Å. Ligands and amino acids are displayed in stick 
representation, color-coded by atom types. 
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Even though this tryptophan conformation observed in our complex resembles those 
found in most of the structures of the KNI-inhibitors (KNI-10673, KNI-10683, KNI-
10562, KNI-10681), a slight adaptation by ~40° is still observed for the indole moiety of 
Trp98. Several reasons might rationalize this conformational change, two of which are 
discussed in the following. The first one concerns the avoidance of clashes with the 
protein. Indinavir’s pyridyl and benzyl moiety, located in the S1-S3/S1'-S3' pockets, as 
well as the thiazolidine and benzyl residue of the KNI-inhibitors would result in clashes 
with the Trp98/Trp98', if these amino acids were to reside at the same position as 
observed in the statine-inhibitor complex structure. Thus, the observed adaptations are 
strongly required for inhibitor binding of KNI-type inhibitors as well as for Indinavir. 
Another important fact speaks for a changed conformation: the tryptophanes are turned 
in a way that π-π interactions are established. Edge-to-face stacking is observed 
between Indinavir’s benzyl and pyridyl group and Trp98' and Trp98, respectively, and 
likewise between the benzyl moiety of the KNI-inhibitors and Trp98 (Figure 3.5b,c).  
 
3.4.3 Comparison of Indinavir Binding to HTLV-1 PR and HIV-1 PR  
After superposition of both retroviral proteases bound to Indinavir, the overall 
orientation of the inhibitor structure in the binding pocket is almost identical in both 
proteases. Regarding the inhibitor, the only pronounced difference is the relocation of 
the pyridyl ring (Figure 3.6). 	  
 
Figure 3.6. (a) Different conformations of Indinavir`s pyridyl ring in HTLV-1 PR, PDB: 3WSJ (green) and 
HIV-1 PR, PDB: 1SDT (purple). (b) Amino acids in the binding pocket which interact with Indinavir in 
HTLV-1 PR (yellow) und HIV-1 PR (purple), color-coded by atom types. Water molecules which are 
involved in interactions are shown as spheres. 
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Proteinwise, the overall location as well as orientation of most amino acids in the 
binding pocket of HIV-1 PR interacting with the inhibitor resembles very much that of 
HTLV-1 PR. The first slight structural alteration can be observed in the flap region: 
while in the case of HIV-1 PR, Ile50/50' are found there, in the HTLV-1 PR, the less 
space-demanding amino acids Ala59/59' are located at nearly the same position. A 
major difference can be determined in the so-called 80s loop, where in the HTLV-1 PR 
Trp98/98' are present, whereas in the HIV-1 PR, the smaller amino acids Val82/82' 
appear at this location. Nearly identical positions are observed for Asp32 and Asp25, 
Gly34 and Gly27, Asp36 and Asp29, as well as Arg10 and Arg8 in both the HTLV-1 PR 
and HIV-1 PR, respectively. In addition, slight differences are also observed concerning 
the water molecule pattern that directly mediates interactions between the protein and 
the inhibitor. While in the HIV-1 PR, four water molecules (including the flap water) are 
involved in H-bond interactions, in the HTLV-1 PR three of them mediate similar 
contacts. Interestingly, the arrangement of H-bond interactions between Indinavir and 
the protein are also very similar for both proteins (Figure 3.2 and Figure 3.7).  
 
 
Figure 3.7. Hydrogen bond network of Indinavir bound to HIV-1 PR (PDB: 1SDT), color-coded by atom 
types. Involved water molecules are shown as spheres, distances are in Å. 
 
The H-bonds between the N4 atom of Indinavir and Gly34/27' are nearly identical in 
both proteases, as are those to the catalytic aspartates, where only little differences 
regarding the geometry of the H-bonds are observed. In both proteases, the hydroxyl 
group of the indanol moiety forms an H-bond to Asp36/29'. Significant differences can 
be observed in the flap region concerning the interactions between the protein and the 
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pyridyl as well as the piperazine moiety of Indinavir: in the HIV-1 PR, both carbonyl 
atoms of Indinavir form H-bonds to the flap water, which at the same time addresses 
both Ile50/50' amide nitrogens of the flap. In contrast, the flap water of the HTLV-1 PR 
forms just one H-bond to one of the alanines, namely Ala59. In the HIV-1 PR, one of 
the nitrogens of the piperazine ring (N1) forms, mediated via a water molecule, an H-
bond to the carbonyl oxygen of Gly27 and a charge-reinforced H-bond to the Arg8' side 
chain nitrogen. On the contrary, in the HTLV-1 PR complex, both piperazine nitrogens 
do not contribute to polar interactions, and the shift of this scaffold by about 1 Å toward 
the bottom compared to the HIV-1 PR complex prevents the insertion of a similar water 
molecule. The orientation of the pyridyl group of Indinavir is the most pronounced 
difference between the binding modes toward the respective targets. In the HTLV-1 
PR, the pyridyl moiety forms a water-mediated H-bond of moderate strength to Arg10. 
Furthermore, a π−π interaction to Trp98 is observed that cannot be established in 
HIV-1 PR due to the absence of the Trp moiety. At a first glance, this pyridyl moiety 
might be detrimental to binding affinity, as in the HTLV-1 PR-bound conformation, it 
requires a rearrangement of Trp98 in HTLV-1 PR, thereby possibly reducing the affinity 
gain of the additionally established π−π interaction.  
To investigate the above-mentioned influence of Indinavir’s pyridyl substituent in more 
detail, we determined percentage inhibition values for Indinavir as well as for des-3-
pyridylmethyl-Indinavir (DpmINV) (Figure 3.8) at 80, 40, and 8 µM in a fluorescence-
based assay (Table 3.1). The percentage efficiency index (PEI) was calculated from 
the percentage inhibition values and the molecular weight.14 In fact, the affinity of the 
des-pyridylmethyl-derivative is significantly reduced compared to Indinavir possessing 
the pyridyl moiety, which is also reflected in the higher PEI values for the latter one. 
Even though the pyridyl ring does not establish pronounced polar interactions, its 
presence in Indinavir obviously significantly contributes to the ligand affinity, although 
slight protein adaptations are required to enable Indinavir binding. 
 
	   	  
Figure 3.8. Chemical structure of des-3-pyridylmethyl-Indinavir (DpmINV). 
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Table 3.1. Percent inhibition values (%-inhib) for Indinavir (INV) and DpmINV at 80 µM, 
40 µM, and 8 µM and the correspondent PEI values. 
[inhibitor] 80 µM 40 µM 8 µM 
INV 
%-inhib 95.4 ± 0.8 91.2 ± 1.1 71.8 ± 3.7 
PEI 1.55 1.49 1.17 
DpmINV 
%-inhib 60.8 ± 3.9 45.1 ± 5.2 16.8 ± 3.0	  
PEI 1.16 0.86 0.32 
 
 
3.5 Implications for Further Lead Design 
3.5.1 Structural Origin for Affinity Deviation 
As the affinity of Indinavir against the proteases HIV-1 PR and HTLV-1 PR deviates 
strongly by about 4 orders of magnitude (Ki: 3.5 µM for HTLV-1 PR vs 540 pM for 
HIV-1 PR),11,12 one naturally would assume significant differences in the interaction 
mode toward the two targets. Thus, the detection of those and the determination of the 
actual binding mode of Indinavir is a prerequisite for the development of novel design 
hypotheses toward improved leads. Surprisingly, as our contribution on the crystal 
structure determination of the HTLV-1 PR-Indinavir complex elucidates, the interaction 
patterns in both proteases at a first glance seem rather conserved. The most 
pronounced difference regarding the inhibitor concerns the orientation of its pyridyl 
moiety, thus enabling additional π-π stacking interactions to Trp98 in case of the 
HTLV-1 PR. The main difference proteinwise are the amino acids being involved in van 
der Waals interactions to the inhibitor in the S1−S3 pocket, in which Trp98/98' in the 
HTLV-1 PR is exchanged by the smaller Val82/82' in the HIV-1 PR. The required side 
chain relocation for Indinavir binding of the Trp moiety indeed leads to additional 
interactions, albeit this still appears to be entropically unfavorable. As the comparison 
between the crystal structures in complex with the statine-type ligand, the KNI-
inhibitors, and Indinavir clearly demonstrates, Trp98/98' is able to adopt multiple 
conformations. Assuming that these persist as well in a ligand-free state, inhibitor 
binding will be associated with an entropic penalty. On the contrary, binding to HIV-1 
PR should not be affected by this issue because of the less mobile Val residue and 
hence lower entropic costs.  
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As described above, our crystal structure provides insights into the changed inventory 
of affinity-relevant polar contacts (interaction to flap water in HTLV-1 PR only via one 
instead of two H-bonds in HIV-1 PR; loss of one H-bond of the piperazine moiety). In 
addition, the HTLV-1 PR-Indinavir complex enables for the first time a structure-guided 
interpretation of previously determined mutagenesis data, particularly as it provides 
experimental evidence of the exact positioning of the inhibitor in the HTLV-1 PR 
binding site. Interestingly, in HIV-1 PR, the mutation V82F, among others, was found to 
contribute to drug resistance during the treatment with Indinavir.12,15,16 This mutation 
leads to a reduced susceptibility toward Indinavir and other PIs. Particularly, for 
Indinavir, the HIV-1 PR V82F mutant shows a reduced inhibitory activity by 2 orders of 
magnitude.17 These results suggest that the incorporation of even larger aromatic 
moieties at this position such as Trp98 in HTLV-1 PR most likely would act even more 
detrimental on the binding affinity and thus helps to rationalize the loss in inhibitory 
potency by about 2 orders of magnitude. Unfortunately, the experimental validation of 
this mutational effect suffers from a strongly reduced catalytic activity of the HTLV-1 PR 
W98V mutant.10  
Former studies of substrate and inhibitor specificity of HTLV-1 and HIV-1 PR suggest 
that the flap region, which differs between both proteases, also plays an important role 
in substrate specificity as well as for inhibitor susceptibility. This has been unambig-
uously demonstrated by HTLV-1 PR mutants (e.g., for the HTLV-1 PR triple mutant 
V56I, L57G, A59I), which particularly increase the affinity against HIV-PR inhibitors by 
about 1 order of magnitude.10 This is presumably caused by the establishment of 
additional van der Waals contacts to the inhibitor facilitated by the exchange of the 
smaller Ala/Val side chain against the bulkier Ile, which consequently leads to more 
shape-defined subpockets. Even though it has to be stated that the above-mentioned 
mutational results do not necessarily cooperate in an additive manner,18 deviations in 
the 80s loop (Trp98) and in the flap region (Val56, Leu57, Ala59) account for 2 and 1 
orders of magnitude of the affinity deviation, respectively. The influence of these 
residues contributing essential van der Waals contacts to the inhibitor on the binding 
affinity seems to be more pronounced than the effect of the slightly changed network of 
polar interactions. This view is also supported by scoring the two Indinavir structures in 
complex with HIV-1 and HTLV-1 PRs with the scoring tool DSX.19 Here, nonpolar 
atoms of Indinavir show a significantly more favorable contribution to binding in HIV-1 
PR compared to HTLV-1 PR (Figure 3.9) and overall a significantly better scoring value 
(−245 for HIV-1 PR−Indinavir versus −172 units for HTLV-1 PR-Indinavir). In particular, 
the tert-butyl and the benzyl moieties of Indinavir allow a more efficient van der Waals 
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contact inventory to HIV-1 PR compared to HTLV-1 PR. The structural basis for this 
deviation consists in a larger S2 pocket harboring the tert-butyl substituent (in HTLV-1 
PR extended in particular by the Val56/Ala59 deviation to HIV-1PR Ile47/Ile50) and a 
larger S3' pocket harboring the benzyl moiety (caused by a reorganized conformation of 
the 80s loop in which the space occupied by Val82 in HIV-1 PR is unoccupied in HTLV-
1 PR due to the flipped Trp98 conformer). Caused by the Val56/Ile47 and Met37/Asp30 
deviation in HTLV-1 PR vs HIV-1 PR, respectively, also the inhibitor’s indanol moiety 
more favorably contributes to the overall binding affinity, as these replacements result 
in a narrower and more polar S2' pocket in the HIV-1 PR (Figure 3.9). 
 
Figure 3.9. Visualization of favorable (blue spheres) interactions with DSX19 for Indinavir in complex with 
HTLV-1 PR (PDB: 3WSJ, left) in green and HIV-PR (PDB: 1SDT, right) in purple.    
 
3.5.2 Binding Properties of Further HIV-1 PR Inhibitors 
We have selected Indinavir for our study as this HIV-1 PR inhibitor exhibited, among a 
set of experimentally tested marketed drugs, solely sufficient potency.11 The cocrystal 
structure of HTLV-1 PR-Indinavir determined in this study raises the question whether 
this novel protein conformer helps to rationalize the lower potencies of other HIV-1 PR 
inhibitors. We have chosen Saquinavir, Ritonavir, Nelfinavir, and Amprenavir as 
representative examples to compare their binding geometries to HIV-1 PR with putative 
binding modes to HTLV-1 PR. For this purpose, two approaches were followed: first, 
we superimposed the corresponding HIV-1 PR-ligand complexes20 with the novel 
HTLV-1 PR conformer and searched for suitable or detrimental features toward binding 
affinity. This analysis reveals for all four ligands significantly unfavorable interactions 
and close contacts (Figure 3.10), thus suggesting poor affinity for these inhibitors.  
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Figure 3.10. Clashes of the HIV-1 PR inhibitors Saquinavir, Amprenavir, Ritonavir, and Nelfinavir after 
superposition with the HTLV-1 PR (PDB: 3WSJ) are schematically shown with red curves.20 
 
Second, as this approach would disqualify also Indinavir as inhibitor to HTLV-1 PR,1 we 
next accounted for compensating adaptations in ligand geometry by docking the four 
ligands into the novel HTLV-1 PR conformer and compared the resulting DSX scores 
with those of the corresponding HIV-1 PR complexes (Table 3.2).  
 
Table 3.2. Calculated dsx_csd scores19 for the HIV-1 PR inhibitors Saquinavir, 
Nelfinavir, Ritonavir, and Amprenavir for the corresponding HIV-1 PR X-ray structures20  
and the best scored docking solution in HTLV-1 PR (PDB: 3WSJ). 
 
 dsx_csd scores 
Inhibitor HIV-1 PR X-ray 
HTLV-1 PR 
docking in 3WSJ 
Saquinavir -215.362 -96.119 
Nelfinavir -207.444 -120.946 
Ritonavir -205.813 -135.306 
Amprenavir -236.789 -92.382 
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Here, all four ligands showed a significantly reduced (mostly about halved) score in 
HTLV-1 PR compared to HIV-1 PR, while the redocked Indinavir (rmsd 1.0 Å) virtually 
retains its original scoring value. In accordance with previous experimental data, these 
results rationalize that Indinavir is able to maintain moderate inhibitory potency to 
HTLV-1 PR after inducing some conformational changes while other HIV-1 PR drugs 
are not able to compensate for detrimental binding features in HTLV-1 PR. 
 
3.5.3  Design Hypotheses for Next-Generation Indinavir Derivatives 
In absence of any knowledge of Indinavir’s binding geometry, rational design of 
potentially improved derivatives was challenging, and the strong affinity deviation 
aggravated those efforts even more, as the reduced affinity might easily have 
originated from a changed binding mode. The structural insights into the first 
nonpeptidic HTLV-1 PR inhibitor complex now enable the development of design 
hypotheses for further affinity improvement. The observed strong deviation in affinity of 
Indinavir toward the two analyzed retroviral proteases possessing an almost conserved 
polar contact inventory suggests that introduction of more suitable van der Waals 
contacts shall provide a key element for affinity improvement. The comparison of the 
visualized atom-by-atom scores reveals the indanol, the tert-butyl, and the benzyl 
moiety as promising sites for chemical variation toward larger substituents, as these 
moieties contribute less favorably to the van der Waals contact inventory in HTLV-1 PR 
compared to HIV-1 PR. First approaches for the design of next-generation Indinavir 
derivatives derived from our HTLV-1 structure are shown in Figure 3.11. The benzyl 
moiety for example could be replaced by larger aromatic residues (e.g., naphthyl 
derivatives) because of the bigger S3' pocket of the HTLV-1 PR compared to the HIV-1 
PR due to the absence of Val82 and different conformations of the 80s loop. Likewise 
the S2 pocket is larger than in the HIV-1 PR, so that the exchange of the tert-butyl 
residue for other branched aliphatic side chain moieties might increase van der Waals 
contacts. We have already shown that the elimination of the pyridyl ring results in a 
significant decrease in affinity. On the basis of unoccupied space in the S3 pocket, a 
more space-demanding residue thus should increase the affinity. In addition, the larger 
S2' pocket suggests to explore the influence of halogen or methyl substitution at the 
indane moiety. 
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Figure 3.11. Design hypotheses for next-generation Indinavir derivatives. Wheat: HTLV-1 PR (PDB: 
3WSJ) shown as surface [excluding the amino acids of the flap: 55-67/55'-67', 95-96, 95'-96']; green: 
Indinavir bound to the HTLV-1 PR shown in stick representation. 
 
3.6 Conclusions 
In this contribution, we present the first crystal structure of HTLV-1 PR in complex with 
Indinavir, an approved, nonpeptidic HIV-protease inhibitor in clinical use. Even though 
the binding modes of Indinavir in HTLV-1 and HIV-1 protease seem to be quite similar 
at a first glance, the affinity of this inhibitor against the HIV-1 PR is about 4 orders of 
magnitude higher than that toward HTLV-1 PR, which suggests more significant 
deviations with respect to the interaction network. While some conformational 
adaptations are required in HTLV-1 PR to enable Indinavir binding, which, however, 
might be penalized by unfavorable entropic costs, it has to be challenged whether 
these differences alone might sufficiently explain the affinity difference between the 
contended proteases. Nevertheless, the comparison of our crystal structure with the 
HIV-1 PR−Indinavir complex supports the interpretation of previous mutagenesis data 
accounting for contributions of a 2 and a 1 order of magnitude drop in affinity when 
considered in isolated mutant enzymes. In addition, we could show by visualization of 
scoring contributions that the tert-butyl, the indanol, and the benzyl moieties contribute 
less favorable contacts to HTLV-1 PR compared to HIV-1 PR, suggesting these 
moieties as candidates for variation. The strong deviation in affinity combined with an 
almost conserved inventory of polar interactions confirms a well-known paradigm that 
the establishment of suitable van der Waals interactions is of major importance, and 
their (e.g., mutational) modification shall significantly affect ligand affinity.18  
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In summary, among the broad structural variety of HIV-1 PR inhibitors that have been 
launched to the market, only Indinavir exhibits moderate affinity against HTLV-1 PR at 
low micromolar concentrations in biochemical assays. Albeit this residual affinity was 
sufficient for our successful crystallization studies, it, notwithstanding, has to be taken 
into account that different enzymes of different viruses are being compared here. 
Although the proteins show a similar fold, their sequence identity of 28 % overall and 
46 % for the binding pocket also accounts for differences concerning protein dynamics 
as well as entropic and desolvation properties. In consequence, single amino acid 
variations not directly involved in inhibitor binding might additionally be important for 
inhibitor susceptibility. Nevertheless, the above presented novel HTLV-PR-Indinavir 
complex represents the first nonpeptidic inhibitor bound to this virus-obligatory enzyme 
and therefore now enables development of design hypotheses for a prospective 
rational drug design process toward the first nonpeptidic HTLV-1 PR lead.  
 
3.7 Experimental Section 
3.7.1 Protein Expression and Purification 
For crystallization, a nine amino acids-truncated construct of the HTLV-1 PR (HTLV 
1-116), which has also been utilized for all seven published HTLV-1 PR X-ray 
structures,1,7 was used. The protease assay was performed with the full-length protein 
(HTLV 1-125). Both protein constructs harbor the mutation L40I to prevent 
autoproteolysis.21 
The plasmid encoding the truncated protease as L40I and Y114N mutant was kindly 
provided by Dr. Alexander Wlodawer (NCI, Frederick/USA). To receive a plasmid only 
containing the L40I protease, Y114 was remutated to N by site-directed mutagenesis. 
The PCR product was sequenced (Eurofins, Germany) to confirm the mutation. The 
plasmid encoding the full-length protein was ordered from Life Technologies/GeneArt 
(Germany). The received plasmids were transformed into Rosetta 2 (DE3) cells. 
Cultures in LB-Media were induced with 1 mM IPTG (OD ≈ 0.6) for about 14 h (14 °C), 
cells were pelleted and resuspended in 10 mM Tris and 5 mM EDTA solution at pH 7.5. 
Cell disruption was performed with lysozyme and by sonification, the obtained inclusion 
bodies were washed with solutions of 0.5 M urea, 10 mM Tris and 5 mM EDTA.1 The 
protein purification was performed as previously described,7 however, using DTT 
instead of 2-mercaptoethanol.  
The refolding conditions diverge for both protein constructs. The HTLV 1-116 protein 
was refolded via dialysis in one refolding step against a sodium acetate puffer as 
published1,7 and stored at -80°C. The full-length protein (HTLV 1-125) was dialyzed in 
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three different buffers consecutively as described before:22 25 mM formic acid at pH 2.8 
for 15 h, 50 mM sodium acetate at pH 5.0, 1 mM DTT and 1 mM EDTA for 12 h, and 
finally against a PIPES buffer at pH 7.0 consisting of 20 mM PIPES, 150 mM NaCl, 
10 % Glycerol, 1 mM EDTA, 2 mM DTT, and 0.5 % Nonidet P-40 for 24 h. The protein 
was stored at -20°C. 
 
3.7.2 Indinavir and Des-3-pyridylmethyl-Indinavir 
The HIV-1 protease inhibitor Indinavir was purchased from Sigma Aldrich (Germany) 
as its sulfate salt with a purity of 98 % determined by HPLC. Des-3-pyridylmethyl-
Indinavir was ordered from Toronto Research Chemicals Inc (TRC). The purity was 
determined by combustion analysis and quantitative 1H NMR (qHNMR)23 and accounts 
for 80 %. Elemental combustion analyses were performed on a vario MICRO cube 
(Elementar Analysensysteme GmbH, Hanau, Germany). The qHNMR was recorded on 
a Jeol ECX-400 spectrometer. 
 
3.7.3 Protease Assay 
Percentage inhibition values for Indinavir and des-3-pyridylmethyl-Indinavir were 
determined via a fluorescence assay. The assay buffer (250 mM potassium hydrogen 
phosphate, 5 % glycerol, 1 mM EDTA, 5 mM DTT, 500 mM NaCl, pH 5.6) and 
fluorescence substrate (RE(Edans)TKVLVVQPK(Dabsyl)R) were used as published,11 
however, the protocol was modified: each well contained a reaction mixture consisting 
of 186 µL assay buffer, 2 µL substrate (500 µM), 2 µL DMSO/inhibitor (8 mM/ 4 mM/ 
0.8 mM). For des-3-pyridylmethyl-Indinavir 10 mM / 5 mM/ 1 mM stock solutions were 
used which corresponds to 8 mM/ 4 mM/ 0.8 mM inhibitor concentration taking the 
inhibitor’s purity of about 80 % into account. The reaction was started with 10 µL 
protease HTLV 1-125 (≈ 24 µg/ml) per well. The increase of fluorescence was detected 
at 490 nm after excitation at 340 nm using a Tecan Safire II plate reader. Percent 
inhibition values and blanks were measured at least in triplicate at room temperature. 
 
3.7.4 Crystallization 
Crystals of the HTLV-1-PR-Indinavir complex were obtained from a HTLV-1 PR (1-116) 
solution at a concentration of 10 mg/ml in presence of 5 mM Indinavir sulfate using 
10 % PEG 3000, 0.2 M lithium sulfate, and 0.1 M imidazole, pH 8.0 as reservoir 
solution. Crystals appeared after several days of incubation at 291 K.  
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3.7.5 Data Collection, Structure Determination and Refinement 
Crystals of the HTLV-1-PR-Indinavir complex were harvested from mother liquor and 
frozen without cryoprotectant in liquid nitrogen. Data were collected at 100K at the 
Bessy II (Helmholtz-Zentrum Berlin, Germany), Beamline 14.1.24 Data processing and 
scaling was performed using the program XDS25 as implemented into the graphical 
user interface XDSAPP.26 The coordinates of HTLV-1 PR as deposited under PDB 
access code 3LIX7 were used as search model after removal of ligand and water 
molecules. Molecular replacement was carried out via Phaser27 as implemented in 
Phenix.28 Refinement was performed under repeated cycles of manual model building 
using Coot29 and crystallographic refinement with the program phenix.refine. The final 
model was validated using PROCHECK.30 Data collection and refinement statistics are 
shown in Table 3.3 (appendix). 
 
3.7.6 Docking of HIV-1 PR Inhibitors 
The docking of Amprenavir, Saquinavir, Ritonavir, and Nelfinavir in the HTLV-1 PR-
Indinavir complex (PDB: 3WSJ) was performed with FlexX31 (version 2.0.2.), after 
minimization of the ligand with MOE32 (version 2012.10). In each case, the top-ranked 
solution was scored with DSX19 using csd potentials and visualized with the DSX-
visualization tool.  
 
3.7.7 Figure Preparation 
Figure 3.1, 3.2, 3.4, 3.5, 3.6, 3.7, 3.9, and 3.11 were prepared with PyMol.33 
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3.8 Appendix 
Table 3.3. Data collection and refinement statistics. 
 
Data Collection and Refinement Statistics (PDB entry 3WSJ) 
Data collection and Processing 
No. of crystals used      1 
Wavelength [Å]       0.91841 
Space group       P 63 2 2 
Unit cell parameters  
a, b, c [Å]      77.3; 77.3; 159.3 
α, β, γ [°]      90 ; 90 ; 120 
Matthews coefficient [Å³/Da]     2.66 
Solvent content [%]      53.8 
Diffraction data 
Resolution range [Å]      42.0 – 2.40 (2.55-2.40)* 
Unique reflections      11 561 (1 813) 
R(I)sym [%]       11.7 (64.8) 
Completeness [%]      99.3 (100.0) 
Redundancy       12.5 (10.6) 
I/σ(I)        20.4 (3.8) 
Refinement 
Resolution range [Å]      41.6 – 2.40 
Reflections used in refinement (work/free)   10 740 / 807  
Final R values for all reflections (work/free) [%]   20.5 / 25.6 
Protein residues      232 
Inhibitor atoms       45 
Water molecules      68 
RMSDs 
Bonds [Å]       0.003 
Angles [°]       0.704 
Ramachandran plot 
Residues in most favoured regions [%]    89.9 
Residues in additional allowed regions [%]   10.1 
Residues in generously allowed regions [%]    - 
Mean B factors [Å2] 
Protein        47.9 
Inhibitor       46.4 
Water        43.3 
 
* Numbers in parentheses characterize the highest resolution shell. 
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4. Privileged Structures Meet Human T-Cell Leukemia Virus-1 
(HTLV-1): C2-Symmetric 3,4-Disubstituted Pyrrolidines as 
Non-Peptidic HTLV-1 Protease Inhibitors* 
 
4.1 Introductory Remarks 
The following text is accepted for publication in the Journal of Medicinal Chemistry: 
Kuhnert, M., Blum, A., Steuber, H., Diederich, W. E., J. Med. Chem. 2015, in press. 
The respective text is taken from the original manuscript, figures of the supporting 
information are implemented in the main text. The author of this thesis performed the 
expression and purification of the HTLV-1 protease, the kinetic assay, crystallization, 
synchrotron data collection, the interpretation of the structure- and affinity data as well 
as drafting of the manuscript. The set of evaluated inhibitors was synthesized by Dr. 
Andreas Blum within a structure-guided design project of HIV-1 protease inhibitors. The 
project of this chapter was carried out in cooperation with Dr. Holger Steuber (LOEWE-
Zentrum für Synthetische Mikrobiologie SYNMIKRO, Philipps-Universität Marburg), 
who refined the HTLV-1 PR X-ray structures.  
 
 
 
 
 
 
 
* Reproduced with permission from J. Med. Chem., in press. Unpublished work copyright 2015 American 
Chemical Society. 
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4.2 Abstract 
A series of 3,4-disubstituted pyrrolidines originally designed to inhibit the closely related 
HIV-1 protease was evaluated as privileged structure against HTLV-1 protease 
(HTLV-1 PR). The most potent inhibitor of this series exhibits two-digit nanomolar 
affinity and represents, to the best of our knowledge, the most potent non-peptidic 
inhibitor of HTLV-1 PR described so far. The X-ray structures of two representatives 
bound to HTLV-1 PR were determined and the structural basis of their affinity is 
discussed. 
	  
4.3 Introduction 
Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus being 
isolated in the early 1980s.1,2 Infections with HTLV-1 are associated with neurological 
and dermatological diseases as well as cancer-related processes.3,4 Worldwide, 
approximately 10-20 million people are currently infected with HTLV-1.5 Although the 
virus has been known for quite a long time, so far no causative means to attack the 
virus are known. All currently available treatment options to cure such an infection or 
rather the related diseases show only limited therapeutic efficacy.3,6 One promising 
target to combat this therapeutic lack is the virus-encoded protease, an approach 
which in case of the related human immunodeficiency virus type 1 protease (HIV-1 PR) 
has led to a number of approved protease inhibitors within the last decades. The HTLV-
1 protease (HTLV-1 PR), an aspartic protease which is essential for the maturation of 
the virus, represents a homodimer with each subunit consisting of 125 residues.2 The 
protease is closely related to the thoroughly studied HIV-1 PR, which belongs to the A2 
family of aspartic proteases.7 Both proteins show a very similar fold and share a 
sequence identity within the binding region of about 45% (overall 28%).8 However, it is 
well known that their substrate specificity as well as their inhibition profile differs 
remarkably from each other.8 As a consequence, approved HIV-1 PR inhibitors show 
only a strongly reduced affinity against the HTLV-1 PR, thus hampering their clinical 
use. Hence, rational design as well as synthesis strategies directed towards the 
discovery of novel HTLV-1 PR inhibitors are strongly required to overcome the lack of 
treatment options in the future. We have recently described the complex of the HIV-1 
PR inhibitor indinavir as the first peptidomimetic inhibitor bound to HTLV-1 PR,9 which 
should facilitate the further structure-based optimization of this and related 
peptidomimetic inhibitors. By in-silico screening of about 140,000 compounds from the 
National Cancer Institute Developmental Therapeutics Program, thirteen structurally 
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diverse non-peptidic inhibitors of HTLV-1 PR with affinities ranging from two-digit to 
0.8 µM were identified.10 However, to the best of our knowledge, no structural data for 
any of these screening hits are available so far, which complicates the further 
optimization of these inhibitors.  
In this contribution, we therefore embarked on a privileged structure approach11,12 to 
identify novel HTLV-1 PR inhibitors and screened an in-house library of non-peptidic 
aspartic protease inhibitors that had originally been designed to target either members 
of the pepsin-like (A1) or the viral aspartic protease family (A2).7,13–17 As common 
feature in all these inhibitors the two aspartates of the catalytic dyad are addressed via 
a most likely protonated amino functionality. Through decoration of this key element 
with appropriate side chains, selectivity towards particular family members could be 
achieved in previous studies.13,14 The screening finally led to the identification of a 
novel series of HTLV-1 PR inhibitors based on a 3,4-disubstituted pyrrolidine core 
motif. X-ray structures for two representatives bound to the target protein were 
determined to elucidate their binding mode and to provide the structural basis for 
meaningful SAR interpretations. 
 
4.4 Results and Discussion 
4.4.1 Biological Evaluation 
The initial screening of a diverse subset of our in-house aspartic PR inhibitor library 
against HTLV-1 PR in a fluorescence-based assay at 100 µM inhibitor concentration 
revealed that, except for 3,4-substituted pyrrolidine derivatives, most of the compounds 
displayed only weak inhibitory activity (data not shown). Interestingly, some 
representatives of a series of C2-symmetric 3,4-bis-N-alkylsulfonamido-pyrrolidines 
which had initially been developed as potent inhibitors against wildtype and Ile84Val 
mutant of HIV-1 PR13,18 showed promising inhibitory activity against the HTLV-1 PR.  
Based on these initial single-concentration screening results, Ki-values were 
determined for a congeneric series of ten compounds (Table 4.1).  
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Table 4.1. Ki-values of 1-10 towards HTLV-1 PR as well as HIV-1 PR. 
 
 R1 R2 HTLV Ki  [µM] 
HIV 
Ki [µM]* 
1   
172.5 ± 16.3 12.3 
2 
  
17.8 ± 7.7 74.7 
3 
  
11.6 ± 1.9 1.57 
4 
  
2.0 ± 0.4 2.15 
5 
  
>200a 0.39 
6 
  
>250a 0.80 
7 
  
2.6 ± 0.1 0.67 
8 
  
2.4 ± 0.2 0.77 
9 
  
7.9 ± 1.7 1.72 
10 
  
0.015 ± 0.0004 0.27 
* Ki-values taken from reference13 
a Ki-value could not be determined accurately, due to inhibitor precipitation at high concentrations. 
 
As observed by crystal structure analysis of HIV-1 and HTLV-1 PR-inhibitor complexes 
(see below), the R1 substituents reside within the S1/S1’ pockets, while the R2 moieties 
populate the S2/S2’ pockets. Six compounds of the selected library are altered in their 
P1/P1’ substituent (R1) while sharing a phenyl ring in P2/P2’ position (R2), whereas the 
remaining four compounds differ in the decoration of the P2/P2’ position and are 
equipped with a benzyl moiety as invariant P1/P1’ substituents. As expected, despite  
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Figure 4.1. Superposition of the S1 and S2 pocket, as well as Arg10/Arg8, Asp36/29 and the catalytic dyad 
of HTLV-1 PR (green, PDB code: 4YDF) and HIV-1 PR (grey, PDB code: 2PWC) shows the similarity in 
the active site. Differences are indicated with red frames, amino acids are shown in stick representation, 
color coded by atom type.   
some similarity in between the active sites of the HIV-1 and HTLV-1 PR (Figure 4.1), 
the inhibition profile against both proteases differs for the presented inhibitor series.  
Within the first subset of inhibitors (1-6) being varied only in P1/P1’ position, a steady 
increase in affinity from the allyl-substituted derivative (1) via sterically more 
demanding allylic substituents (2 and 3) to the benzyl-substituted derivative (4) can be 
observed, the latter representing the most potent derivative of this subset with an 
affinity of 2.0 µM. However, the introduction of hydrophobic residues in para-position of 
the benzyl moiety such as an iodo (5) or a CF3 substituent (6) clearly reduces the 
affinity. 
In the second subset of inhibitors, the P2/P2’ position is altered: compounds 7 and 8 are 
decorated with a phenyl ring bearing hydrophobic ortho substituents; in 9 and 10, the 
phenyl ring is substituted in para-position with a nitro or amino group, respectively. 
Neither the ortho-methyl (7) nor the ortho-chloro (8) substituent in P2/P2’ position has 
any significant influence on the affinity against the HTLV-1 PR in comparison to the 
unsubstituted derivative 4 (2.6 and 2.4 µM, respectively, versus 2.0 µM). While the 
introduction of a para-nitro residue in P2/P2’ position (9) decreases the affinity by a 
factor of 4, the presence of a para-amino moiety (10) results in a remarkable increase 
in affinity by about two orders of magnitude (2 µM versus 15 nM). Consequently, 10 not 
only represents the most potent compound within this inhibitor series, but, moreover, to 
the best of our knowledge, the most potent non-peptidic inhibitor of HTLV-1 PR 
described to date. 
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4.4.2 Binding Mode Analysis 
Since knowledge of the binding mode of an inhibitor in the active site of a target protein 
is on the one hand a prerequisite for structure-based drug design and on the other 
hand facilitates the deduction of a meaningful SAR, we embarked on cocrystallization 
experiments and successfully determined the X-ray structures of 9 and 10 in complex 
with HTLV-1 protease at a resolution of 2.8 Å and 3.25 Å, respectively (Table 4.2, 
appendix). In both complex structures, the observed difference density allows an 
unambiguous placement of the ligand molecules (Figure 4.2a). However, the better 
resolved HTLV-1 PR-9 complex offers a more comprehensive picture, since in the 
HTLV-1 PR-10 complex the hairpin-like loops of the flap region are disordered. 
 
Figure 4.2. a) The 2Fo−Fc electron density maps for 9 (green) and 10 (orange) bound to the HTLV-1 PR 
contoured at 1.3σ (blue mesh) are well-defined. b) Superposition of 9 (green) and 10 (orange) bound to 
the HTLV-1 PR. c) The flap water19 (red spheres) is replaced by the ligand`s sulfonyl-oxygens, here 
exemplarily shown for 9 (green, surface representation). Ligands are shown in stick representation, color-
coded by atom types. 
At first glance, the crystal structure analysis shows a quite similar binding mode for 
both inhibitors (Figure 4.2b): the two aspartates of the catalytic dyad are addressed by 
the endocyclic amine, the R1 substituents reside in the S1/S1’, while the R2 moieties 
populate the S2/S2’ pockets. Interestingly, 9 and 10 both adopt a slightly unsymmetrical 
binding mode within the active site.  
However, a more detailed look into the structures yet reveals slight differences in the 
binding poses: although, in both structures the presumably protonated pyrrolidine 
nitrogen addresses the two catalytic aspartates 32/32’, the position of the central 
pyrrolidine ring of 10 seems to be slightly shifted towards the catalytic aspartates 
(Figures 4.2b, 4.3, 4.4). However, these slight deviations might to some degree be 
attributed to the coordinate uncertainties at the given resolutions.  
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The interactions of 9 to the HTLV-1 PR are shown in Figure 4.3: either sulfonyl group of 
9 forms direct hydrogen bonds to the backbone NH of Ala59 and Ala59’ (3.1 and 3.4 Å, 
respectively), which are located in the flap region, while the flap water, which mediates 
the interaction to the flap region throughout all previously published HTLV-1 PR X-ray 
structures, is in this case released upon inhibitor binding (Figure 4.3). 
 
Figure 4.3. Binding mode of 9 to HTLV-1 PR. Amino acids and 9 are shown in stick representation, color-
coded by atom type, distances are in Å. Hydrogen bonds are shown as black dashes. Unfavorable polar 
contacts in the S2/S2’ pocket are shown as red dashes.  
 
A superposition of our novel X-ray complexes with those previously determined clearly 
shows that the original position of the flap water is occupied by either of the bound 
inhibitors (Figure 4.2c), hence excluding the possible presumption that the flap water 
might not be observed in our complexes due to the deviating crystallographic 
resolutions of the compared crystal structures. The P1/P1’ benzyl moieties occupy the 
S1/S1’ pockets mainly formed by Leu30/30’, Asp32/32’, Gly34’/34, Ile100/100’, 
Ala59’/59, and Trp98/98’, and the P2/P2’ substituents reach into the S2/S2’ pockets, 
where Asp36/36’, Met37’/37, Val39’/39, Leu91’/91, and Ile100’/100 are involved in key 
interactions. The P1/P1’ benzyl moieties form π-π stacking interactions to Trp98/98’ via 
distances of 3.6 and 3.5 Å, respectively and also intramolecular π-π edge-to-face 
stacking interactions to the aromatic residues in P2/P2’ position. In the S1’ pocket the 
phenyl ring forms an additional cation-π interaction to Arg10’. In the S2/S2’ pockets the 
nitro groups form an H-bond to the backbone amides of Met37’/Met37 (2.9 and 2.6 Å, 
respectively, Figure 4.3). 
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Figure 4.4. Binding mode of 10 bound to the HTLV-1 PR. Amino acids and 10 are shown in stick 
representation, color-coded by atom type, distances are in Å.  
	  
Besides the slightly shifted position of the pyrrolidine core structure of 10 in the active 
site in comparison to 9, the interactions of 10 in the S1/S1’ pocket are overall similar to 
that described for 9: both phenyl rings establish π-π interactions to the tryptophanes 
98/98’ as well as cation-π interactions to Arg10/10’ (Figure 4.4).  
However, in the S1 pocket this interaction is with a distance of 4.7 Å rather weak. A 
major difference between the two HTLV-1 structures can be observed on the protein 
side: the tryptophanes 98/98’ in the S1/S1’ pocket show, especially in the S1’ pocket, 
distinct flexibility in their conformation (Figure 4.5). A pronounced flexibility of Trp98/98’ 
and seemingly adaptation through inhibitor binding was also observed in the past.9 In 
the S2/S2’ pocket, each amino group of 10 forms one charge-assisted H-bond to 
Asp36’/36 (2.8 and 2.9 Å, respectively) and weak polar contacts to the backbone 
amides of Met37’/Met37 (3.8 and 4.0 Å, respectively, Figure 4.4). 
The flap region in the HTLV-1 PR complex of 10 is, probably due to a reduced internal 
order of the crystal accompanied by only moderate resolution, not defined and was 
therefore omitted from the structural model. Hence, we could not observe the 
interaction of 10 to the flap at the molecular level, however, the high structural similarity 
suggests similar interactions as observed in the HTLV-1 PR complex with 9.  
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Figure 4.5. Superposition of 9 (green) and 10 (orange) bound to the HTLV-1 PR, their pyrrolidine-cores 
are slightly shifted. Tryptophanes 98/98’ show distinct flexibility in their conformation, especially in the S1’ 
pocket (Trp98’).  
 
4.4.3 Comparison of Binding Modes and SAR Between HTLV-1 PR and HIV-1 PR 
Overall, the described binding mode in the HTLV-1 PR is quite similar to that observed 
for this ligand series in the HIV-1 PR, except for the interaction to the flap region.13 Due 
to the unsymmetrical binding mode observed in the HIV-1 PR complexes as well, in the 
latter only one of the sulfonamide moieties is involved in the interaction to the flap 
region (Ile50/50’). 9 and 10 also adopt a slightly unsymmetrical binding mode within the 
active site of the HTLV-1 PR, yet the deviation from C2-symmetry is not as pronounced 
as already observed in the HIV-1 PR complexes.  
Assuming a similar binding mode for the inhibitors of this lead series in HTLV-1 PR, the 
SAR follows a coherent picture: with increasing steric demand of the R1 substituent, the 
available space in the S1/S1’ pockets is filled more properly, thus an aromatic ring 
system is favored over allylic substituents. Moreover, the phenyl ring is able to form 
π-π interactions to Trp98/98’ and cation-π interactions to Arg10/10’ more efficiently 
compared to the allylic substituents. The comparison of the inhibition data determined 
for 1, 2, 3, and 4 against HTLV-1 PR and HIV-1 PR suggests that the introduction of an 
aromatic moiety is more beneficial in case of HTLV-1 PR, as the establishment of a π-π 
stacking to Trp98/98` is due to the absence of an appropriate stacking partner in case 
of HIV-1 PR not relevant for the latter. 4, which bears an unsubstituted benzyl moiety in 
P1/P1’ position, possesses nearly the same affinity towards HTLV-1 PR (2.0 µM) and 
HIV-1 PR (2.15 µM). 
The elongation of the P1/P1’ substituents in para-position with hydrophobic moieties (5: 
iodo and 6: CF3) yet has an opposing effect: in the HTLV-1 PR this structural 
modification leads to a dramatic drop in affinity by about two orders of magnitude, 
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whereas the affinity against HIV-1 PR is increased about 3-fold. This deviating behavior 
is challenging to explain, however, in case of HTLV-1 PR it might be related to 
deviating dynamic properties of Arg10/10’. To accommodate these larger P1/P1’ 
substituents, a flip of Arg10/10’ would be required. 
In the S2/S2’ pockets the effect of the substitution pattern of the phenyl rings on the 
affinity deviates again between HTLV-1 PR and HIV-1 PR: in case of HIV-1 PR the 
introduction of hydrophobic residues in ortho-position (7: methyl, 8: chloro) results in an 
increase of affinity by a factor of 3. In case of HTLV-1 PR, however, to accommodate 
these substituents, presumably a slight change of the rotational state of the Ile100/100’ 
side chains is required, which might explain the observation that these substituents 
exert only a marginal influence on the potency.  
Introduction of polar substituents in para-position of the benzene moiety (9: NO2, 10: 
NH2) addressing the S2/S2’ pockets has the strongest impact on the affinity amongst the 
derivatives tested in our set: in 9 the affinity towards HTLV-1 PR is decreased about 4-
fold, whereas that towards HIV-1 PR is nearly unaffected. The introduction of a para-
amino group (10) increases the affinity in both PR: in case of HIV-1 PR by about one 
order, and in case of HTLV-1 PR even more significantly by about two orders of 
magnitude. 
In general, the nitro group is a weak H-Bond acceptor. For 9 an H-bond to the 
backbone NH of Met37 and Met37’, respectively, is formed. However, especially in the 
S2’ pocket the interacting oxygen atom of the nitro group comes in close contact (2.6 Å) 
to the backbone carbonyl group of Met37 (Figure 4.3). In the S2 pocket the distance of 
this unfavorable contact amounts to 3.5 Å. In addition, an adverse contact of the nitro 
group to the carbonyl oxygen of the side chain of Asp36’/36 is observed (3.8 Å and 4.0 
Å, respectively). These unfavorable repulsive interactions rationalize well the loss in 
affinity compared to the unsubstituted derivative 4 (7.9 vs 2.0 µM). 
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Figure 4.6. a) Asp36/36’ turned towards 10 (HTLV-1 PR, orange), whereas in the structure of 9 (HTLV-1 
PR, green) the aspartates form an internal salt bridge to Arg10/Arg10’. b.) H-Bond network of 10 (yellow) in 
the HIV-1 PR (grey). Amino acids and ligands are shown in stick representation, involved water molecules 
as spheres, distances in Å. 
 
On the contrary, the para-amino group in 10 is capable of acting as H-bond donor, and 
two charge-assisted H-bonds to Asp36’/36 via distances of 2.8 and 2.9 Å, respectively, 
are established (Figure 4.4). The contacts of the amino to the carbonyl groups of 
Met37’/37 are, in contrast to the nitro derivative, in this case not detrimental towards 
binding. However, with distances of 3.8 and 4.0 Å, respectively, these contacts are not 
expected to have a major impact on the binding affinity. Noteworthy, to enable the 
charge-assisted interactions, Asp36’/36 turn towards the ligand’s amino groups, thus 
disrupting the internal salt bridges towards Arg10/10’ observed in the complex with 9 
(Figure 4.6a). Most likely, the deviating interaction pattern of the amino and nitro 
groups of 9 and 10 account for their different inhibitory activity towards HTLV-1 PR. In 
comparison to 4, 10 is able to establish favorable polar contacts in the S2/S2’ pockets of 
the protein. As the formation of a charge-assisted H-bond is accompanied by a gain in 
binding enthalpy of 5-30 kJ/mol per H-bond,20–22 the increase in affinity by about two 
orders of magnitude (2.0 µM vs 15 nM) can likely be attributed to the establishment of 
two charge-assisted H-bonds in the S2/S2’ pockets.  
Interestingly, the introduction of an amino function in para-position is beneficial for 
binding to both proteases, however, as described, this substituent effect is much more 
pronounced for HTLV-1 PR. Fortunately, for a direct comparison X-ray structures of 10 
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in complex with both proteases are available. While in the HIV-1 PR 10 exhibits an 
unsymmetrical binding mode13 which results in a different interaction pattern of the 
ligand’s amino groups in the S2 and S2’ pocket, in the HTLV-1 PR the interactions of the 
amines are similar (Figure 4.4 and 4.6b). The structural comparison provides an 
explanation for the observed distinct difference in affinity of 10 against the two 
proteases: whereas in HTLV-1 PR two charge-assisted H-bonds, one in the S2 and one 
in the S2’ pocket, are established, in HIV-1 PR such a direct charge-assisted H-bond is 
only formed in the S2’ pocket.  
As noted before, in our study we detect remarkable changes in affinity caused solely by 
the variation of the substituents interacting to the S2/S2’ pockets. That minor structural 
alterations can result in distinctive shifts in affinity is also well-described in literature: as 
in our case, these are mostly related to an unfavorable switch regarding the 
electrostatic contact inventory such as the replacement of an H-bond acceptor by a 
donor functionality or vice versa. An example is represented by a series of phosphorus-
containing thermolysin inhibitors:23 the exchange of a phosphonamide to a 
phosphonate reduces the affinity by about three orders of magnitude. Besides the lack 
of one H-bond, in this example also two H-bond acceptors face each other resulting in 
an unfavorable repulsion of the ligand oxygen and a carbonyl oxygen on the protein 
side. Another example is described for a series of hydroxypyrroline-based thrombin 
inhibitors,24 where the exchange of an amide (N(R2)-CO-CH3) for an amine residue 
(N(R2)-CH2-CH3) has a dramatic effect on the affinity, likely due to the loss of an H-
bond and the change of the electronic properties thus resulting in an affinity decrease 
by four orders of magnitude.25 
	  
4.5 Conclusion	  
Despite various definitions, the fundamental idea of the “privileged structure” concept 
suggests to identify inhibitor scaffolds for a target of interest by utilizing knowledge on 
attractive scaffolds that are clearly established within a particular target class instead of 
performing (ultra-)high-throughput screenings of large chemical libraries. In this 
contribution, we applied this concept to HTLV-1 PR and identified C2-symmetric 
pyrrolidine-based 3,4-bis-N-alkylsulfonamides making this compound class a novel, 
non-peptidic scaffold for HTLV-1 protease inhibition. A series of ten inhibitors exerted 
affinities from the submillimolar down to two-digit nanomolar range against HTLV-1 
protease, which, in combination with the successful crystal structure determination, 
lays the foundation for further structure-guided design of HTLV-1 protease inhibitors 
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based on the presented pyrrolidine scaffold. Undoubtedly, our proof-of-concept study 
only monitors the evolving SAR by means of a strictly limited set of ten compounds 
selected to explore the suitability of the pyrrolidine scaffold for HTLV-1 PR inhibition in 
general, accompanied by structure analysis. Hence, a broader collective set of 
compounds should certainly allow to study and interpret substituent effects in much 
more detail than reliably possible with our set. For this purpose, the two crystal 
structures determined in our study provide some guidance for further lead optimization: 
first, an appropriate substitution of the so far non-decorated P1/P1’ benzyl moiety shall 
be attempted. Here, addressing the Gly34/34’ carbonyl group and the side chain of 
Arg10/10’ by appropriate functional groups such as e.g. meta-carboxamide or para-
methoxy/carboxylate are options to be pursued. For P2/P2’, Asp36/36’ and Met37/37’ 
may be addressed more efficiently by e.g. a para-carboxamide substituent. In addition, 
even combinatorial approaches have been considered for this purpose at this stage, 
once a suitable “privileged structure” core motif has been identified.11 Nevertheless, 
among the tested compounds 10 bearing a para-amino-substituted phenyl moiety as 
P2/P2’ substituent exhibits a Ki-value of 15 nM and thus represents not only the most 
potent compound of this inhibitor series, but, moreover, to the best of our knowledge, 
the most potent non-peptidic inhibitor of HTLV-1 PR described so far. 
 
4.6 Experimental Section	  
4.6.1 Protein Expression and Purification 
The protein expression, purification, and refolding was performed as previously 
described.9,26 For the protease assay the full-length protein (HTLV 1-125) was used, 
while the crystallization was performed with a nine amino acids-truncated construct of 
the protease (HTLV 1-116), which has been used for all eight HTLV-1 PR X-ray 
structures published to date. To prevent autoproteolysis, both constructs harbor the 
stabilizing mutation L40I.  
 
4.6.2 Kinetic Assay 
The fluorescence-based assay was in general performed as previously published.9  
IC50-values were determined at a substrate concentration of 5 µM, for Km-determination 
12 different substrate concentrations were used (50 µM- 24 nM). From the increase in 
fluorescence the IC50-values were calculated with the program GraFit 4.09 (Erithacus 
Software). The corresponding Ki-values were calculated by means of the Cheng-
Prusoff-equation27 under inclusion of the determined Km-value and substrate 
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concentration. Each Km- and Ki-values were determined at least in duplicate.  
The assay was validated using indinavir as reference inhibitor: using our settings we 
achieve a Ki-value of 3.1 ± 0.6 µM, which is in acceptable agreement as found in the 
literature (3.48 µM).26 In addition, we have confirmed exemplarily that our inhibitor 
series (10) does not act as fluorescence quencher in the relevant wavelength range. 
 
4.6.3 Crystallization of HTLV-1 Protease Inhibitor Complexes 
Crystals of the HTLV-1 protease inhibitor complexes were obtained by cocrystallization 
from a HTLV-1 PR (1-116) solution at a concentration of 10 mg/ml in presence of 5 mM 
inhibitor using 1.0-1.3 M ammonium sulfate, 20 % glycerol (v/v), 0.1 M Tris, pH 7.0 as 
reservoir solution. Crystals appeared after several days of incubation at 291K.  
 
4.6.4 Data Collection and Refinement 
Crystals of the HTLV-1-PR-Inhibitor complexes were harvested from mother liquor and 
frozen without cryoprotectant in liquid nitrogen. Data were collected at 100K at the 
Bessy II (Helmholtz-Zentrum Berlin, Germany), Beamline 14.1.28 Data processing and 
scaling was performed using the program XDS29 as implemented into the graphical 
user interface XDSAPP.30 The coordinates of HTLV-1 PR as deposited under PDB 
access code 3LIX31 were used as search model after removal of ligand and water 
molecules. Molecular replacement was carried out via Phaser32 as implemented in 
Phenix.33 Refinement was performed under repeated cycles of manual model building 
using Coot34 and crystallographic refinement with the program phenix.refine. The final 
model was validated using PROCHECK.35 Data collection and refinement statistics are 
shown in Table 4.2 (appendix). 
 
4.6.5 Synthesis  
The synthesis and analytical data of compound 1-10 are described in Blum et al.13 All 
test compounds (1-10) were at least 95 % pure, determined by combustion analysis. 
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4.7     Appendix 
Table 4.2.  Data collection and refinement statistics. 
Data Collection and Refinement Statistics  
Complex/PDB entry    9/4YDF    10/4YDG 
Data collection and Processing 
No. of crystals used    1    1 
Wavelength [Å]     0.91841    0.91841 
Space group     P 63 2 2    P 63 2 2 
Unit cell parameters  
a, b, c [Å]    77.4; 77.4; 160.1   77.6; 77.6; 160.2 
Matthews coefficient [Å³/Da]   2.55    2.56 
Solvent content [%]    51.7    52.0 
Diffraction data 
Resolution range [Å]    50.0 – 2.80    50.0 – 3.25 
      (3.05-2.80)*   (3.5-3.25) 
Unique reflections    7 097 (1 573)   4 746 (907) 
CC(1/2)       99.8 (91.5)   98.8 (83.1) 
Completeness [%]    94.6 (96.1)   96.3 (97.4) 
Redundancy     9.9 (10.3)   14.3 (14.9) 
I/σ(I)      15.5 (3.7)   8.6 (3.2) 
Refinement  
Resolution range [Å]    38.7 – 2.80   41.9 – 3.25 
Reflections used in refinement (work/free)  6 735 / 355   4 499 / 238  
Final R values for all reflections (work/free) [%] 24.2 / 29.7   27.9 / 31.7 
Protein residues     232    219 
Inhibitor atoms     45    41 
Water molecules     4    0 
RMSDs 
Bonds [Å]     0.006    0.003 
Angles [°]     1.3    0.7 
Ramachandran plot 
Residues in most favoured regions [%]  89.4    88.8 
Residues in additional allowed regions [%]  10.1    10.7 
Residues in generously allowed regions [%]    0.5        - 
Residues in disallowed regions [%]     -      0.5 
Mean B factors [Å2] 
Protein      25.9    47.4 
Inhibitor      35.4    42.4 
Water      9.9       -  
 
* Numbers in parentheses characterize the highest resolution shell 
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5. Pyrrolidine-Based Bicyclic Compounds as HTLV-1 Protease 
Inhibitors 
 
5.1     Introduction 
The initial screening of a diverse subset of our in-house aspartic protease inhibitor 
library yielded besides the C2-symmetric 3,4-bis-N-alkylsulfonamido-pyrrolidines 
(chapter 4) also pyrrolidine-based bicyclic inhibitors, which showed promising affinity 
against the HTLV-1 protease at 100 µM inhibitor concentration. The series of this 
compound class was originally designed and synthesized as HIV-1 PR inhibitors by Dr. 
Nina Klee.1 In total, ten bicyclic inhibitors (Table 5.1) were investigated in more detail 
regarding their inhibitory profile and binding mode to the HTLV-1 protease. 
 
5.2     Affinity Data  
The Ki-values of the bicyclic inhibitor series determined via a FRET assay are given in 
Table 5.1. Five of these ten inhibitors, in the following named two-armed inhibitors, are 
C2-symmetric being equipped with differently substituted benzyl moieties (NK101, 
NK102, NK191, NK192, NK237). Three other compounds (NK251, NK252, and NK253) 
are further substituted at the benzylic position in order to address additional specificity 
pockets of the enzyme and are in the following referred to as three-armed and four-
armed inhibitors, respectively. Common to all of the latter ones is a benzyhydryl moiety. 
NK343 and NK232 are both decorated with two benzhydryl substituents, however, in 
case of NK343 one carbonyl group of the bridging ring system was replaced by a 
methylene moiety resulting in a glycine-like bridging.  
The Ki-values for this inhibitor series range from three- up to one-digit micromolar, with 
NK232 representing the most potent inhibitor of this series with a Ki-value of 1.4 µM. 
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Table 5.1. Affinity data as well as ligand efficiency (LE) for a series of pyrrolidine-based 
bicyclic inhibitors against the HTLV-1 PR. 
 
 chemical structure 
%-inhibition 
values at 100 µM 
[%] 
Ki-values 
[µM] LE [kcal/mol]
2,3 
NK102 
 
25.9 ± 9.3 215.6 ± 83.5 0.20 
NK191 
 
50.8 ± 21 45.6 ± 0.9 0.22 
NK237 
 
83.0 ± 0.9 9.0 ± 0.5 0.26 
NK192 
 
83.4 ± 0.4 
 
5.0 ± 1.0 
 
0.27 
NK101 
 
66.7 ± 0.5 29.7 ± 4.4 0.23 
NK251 
 
71.1 ± 3.1 15.0 ± 1.8 0.21 
NK252 
 
81.2 ± 1.8 10.5 ± 3.3 0.21 
NK253 
 
91.7 ± 2.1 3.7 ± 0.7 0.22 
NK232 
 
89.2 ± 0.4 1.4 ± 0.4 0.22 
NK343 
 
64.8 ± 1.0 20.7 ± 1.8 0.18 
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5.3     SAR Interpretation and Binding Mode Analysis 
Considering at first only the inhibitors bearing unsubstituted benzyl- or benzhydryl-
moieties, it becomes evident that the affinity increases with the size of the molecule: 
the two-armed benzyl-substituted compound NK102 possesses the lowest affinity (Ki-
value ≈ 215 µM), the analogous three-armed derivative NK251 shows an increase by 
one order of magnitude, and the four-armed compound NK232 bearing two benzhydryl-
moieties exhibits improved affinity by two orders of magnitude in comparison to NK102 
and represents with a Ki-value of 1.4 µM the most potent compound of this ligand 
series. However, the ligand efficiency, which describes the gained binding energy per 
heavy atom of a ligand,3 and therefore indirectly considers the contribution of the size 
of the molecule towards the affinity, is similar for these three compounds (NK102, 
NK251 and NK232) (Table 5.1). NK343, deviating from NK232 only in the bridging of 
the 3,4-diamine-pyrrolidine scaffold (carbonyl versus methylene), exhibits in 
comparison to NK232 a significantly reduced affinity by one order of magnitude (20.7 
vs 1.4 µM) and exhibits the worst ligand efficiency of this inhibitor series against the 
HTLV-1 PR (0.18 kcal/mol). 
Within the symmetric two-armed inhibitors, an affinity difference by a factor of about 40 
is observed in dependence on the substitution pattern of the benzyl moiety. The affinity 
increases from the unsubstituted benzyl moiety (NK102) via the meta-fluoro- (NK191) 
and meta-hydroxyl- (NK101) substituted compounds to the meta-chloro (NK237) and 
meta-bromo (NK192) derivatives, the latter two showing a Ki-value in the one-digit µM 
range (9.0 and 5.0 µM, respectively). Interestingly, despite the slightly lower affinity, but 
considering the reduced number of heavy atoms in comparison to NK232, NK192 and 
NK237 exhibit the best ligand efficiency within this inhibitor series (0.27 kcal/mol and 
0.26 kcal/mol, respectively). 
A direct comparison of NK252 and NK251 reveals that the introduction of a hydroxyl 
substituent in meta-position of the benzyl moiety does not significantly affect the 
affinity. The removal of one carbonyl group (NK343) impairs the affinity by one order of 
magnitude. 
Overall, the SAR seems to be consistent, however, for a more comprehensive 
understanding further structural investigations of the binding mode have been applied 
to complement this SAR interpretation.  
The X-ray structure of NK101 in complex with the HTLV-1 protease was successfully 
determined at a resolution of 3.15 Å. The observed difference density allows an 
unambiguous placement of NK101 in the active site (Figure 5.1a). Unfortunately, 
despite extensive efforts (chapter 2), no diffracting crystals of HTLV-1 PR in complex 
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with other bicyclic inhibitors could be obtained. The X-ray structure of NK101 in 
complex with HTLV-1 PR was refined by Dr. Holger Steuber, Philipps-Universität 
Marburg. 
The binding mode of NK101 in the HTLV-1 PR is shown in Figure 5.1b. The pyrrolidine 
nitrogen addresses the two catalytic aspartates, while the meta-hydroxyl-substituted 
benzyl moieties reside in the S2 and S2’ pockets. Two H-bonds are formed between the 
NH groups of Ala59 and Ala59’ located in the flap region and the two carbonyl oxygens 
of the inhibitor. However, as the hairpin loops of the flap region are not well defined, the 
interactions need to be interpreted with care. As also observed for the C2-symmetric 
3,4-bis-N-alkylsulfonamido-pyrrolidines (chapter 4), the flap water is replaced by the 
inhibitor. The hydroxyl substituents of the benzyl moiety occupying the S2/S2’ pockets 
form H-bonds to Asp36’/36 at a distance of 2.9 and 3.2 Å, respectively.  
 
Figure 5.1. a) 2Fo−Fc electron density map for NK101 bound to the HTLV-1 PR contoured at 1.0σ (blue 
mesh). b) Binding mode of NK101 in the active site of the HTLV-1 PR.  
 
Compared to the unsubstituted analogue (NK102), the introduction of halogen atoms in 
meta-position of the benzyl substituent yields equal- or more potent derivatives with 
increasing size of the halogen. As no stacking partner for the aromatic moieties is 
located in adequate proximity, this effect is probably not mediated by the electronic 
properties of the latter, but rather dependent on the halogen substituents themselves: 
with increasing size they might contribute more efficiently to van der Waals contacts 
within the S2/S2’ pockets and their increasing polarizability (e.g. by Asp36/36’) might 
create a reinforcing electrostatic contribution growing with larger atom radius.  
In contrast to the C2-symmetric 3,4-bis-N-alkylsulfonamido-pyrrolidines (chapter 4), the 
bicyclic inhibitors are significantly less potent. However, the most active compound of 
the bicyclic inhibitors being equipped with two benzhydryl substituents (NK232) was not 
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specifically optimized to form directed interactions to the protein. NK232 exhibits, 
similar to the benzyl/phenyl-substituted 4-armed 3,4-bis-N-alkylsulfonamido-pyrrolidine 
AB69 (compound 4, chapter 4), a Ki-value in the one digit µM range (1.4 and 2.0 µM, 
respectively). As the molecular weight or, more precisely, the number of heavy atoms, 
is only slightly lower for NK232, the ligand efficiency of the two compounds is 
comparable (0.20 vs 0.22 kcal/mol). Thus, the pyrrolidine-based bicyclic inhibitors 
represent as well a promising scaffold for HTLV-1 PR inhibition and provide a suitable 
basis for lead optimization by introduction of tailor-made substituents.  
The superposition of  AB83 and AB84 (9 and 10, respectively, chapter 4) as 
representatives of the C2-symmetric 3,4-bis-N-alkylsulfonamido-pyrrolidines and the 
bicyclic pyrrolidine-based inhibitor NK101, all bound to the HTLV-1 PR (Figure 5.2) 
reveals that all three inhibitors occupy the S2/S2’ pocket with the substituted phenyl or 
benzyl moiety. 
The affinity gain most likely originates from the introduction of one or two additional 
aromatic “arms”, as these most probably address the so far unoccupied S1/S1’ pockets 
hence giving rise to an affinity improvement. 
 
Figure 5.2. Superposition of AB83 (green), AB84 (orange), and NK101 (yellow) bound to the HTLV-1 PR.  
 
Even though the bicyclic scaffold is more rigid, which in general is associated with a 
reduced conformational entropy loss upon binding, the inhibition data obtained for the 
two scaffolds do not support a clear affinity improvement for the more constrained 
scaffold in our case. 
 
 
 
 
 
 
5. Pyrrolidine-Based Bicyclic Compounds as HTLV-1 Protease Inhibitors 103 
 
	  
5.4      Comparison to the HIV-1 Protease 
The comparison of the inhibition profile of the pyrrolidine-based bicyclic inhibitors 
against the HTLV-1 PR and the HIV-1 PR (Table 5.2) reveals that these inhibitors are 
in general more potent against the HIV-1 PR than the HTLV-1 PR, which is not too 
surprising as these inhibitors were originally designed as HIV-1 PR inhibitors by 
structure-based drug design.1 A closer look reveals that the two-armed inhibitors only 
show a slightly enhanced inhibitory effect up to a factor of 6 against the HIV-1 PR 
whereas within the three- and four-armed inhibitors the difference in affinity is more 
pronounced. While the general tendency of the inhibition profile within each particular 
target is similar, the inhibitors are by factors between 20 - 200 more potent against the 
HIV-1 PR than the HTLV-1 PR. 
 
Table 5.2. Ki-values of a series of pyrrolidine-based bicyclic compounds against the 
HTLV-1 and HIV-1 protease. 
 chemical structure 
Ki-values 
[µM] 
HTLV-1 PR 
Ki-values 
[µM]  
HIV-1 PR* 
Ki(HTLV)/Ki(HIV) 
NK102 
 
215.6 ± 
83.5 35  6 
NK191 
 
45.6 ± 0.9 21  2 
NK237 
 
9.0 ± 0.5 23  0.4 
NK192 
 
 
5.0 ± 1.0 
 
7.3  0.7 
NK101 
 
29.7 ± 4.4 6.4  5 
NK251 
 
15.0 ± 1.8 0.9  17 
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NK252 
 
10.5 ± 3.3 0.21  50 
NK253 
 
3.7 ± 0.7 0.024  154 
NK232 
 
1.4 ± 0.4 0.007  200 
NK343 
 
20.7 ± 1.8 0.160 129 
* Ki-values taken from reference.1 
 
The superposition of the X-ray structures of NK101 in complex with the HIV-1 PR and 
HTLV-1 PR shows that this inhibitor occupies virtually the identical space within both 
proteases (Figure 5.3). Besides various water-mediated interactions in the HIV-1 PR-
NK101 complex, the ligand’s two hydroxyl groups both form an H-bond to the NH 
backbone of Asp29’/29 and Asp30’/30 in the S2/S2’ pockets, respectively. 
Due to the moderate resolution of the HTLV-1 PR-NK101 complex, no information on 
interacting or mediating water molecules could be deduced. Hence, a more detailed 
comparison of the binding modes of NK101 bound to HTLV-1 PR and HIV-1 PR, 
respectively, appeared rather speculative and was therefore omitted in this respect.  
 
Figure 5.3. Superposition of NK101 bound to the HIV-1 PR (purple, PDB code: 3QN8) and HTLV-1 PR 
(yellow), as well as interactions of the meta-hydroxyl moiety in the S2 and S2’ pocket.  
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5.5      Conclusion and Outlook 
The pyrrolidine-based bicyclic core structure represents an additional promising small 
molecule scaffold for HTLV-1 protease inhibition. Herein, the unsubstituted benzhydryl-
substituted inhibitor NK232 is the most potent compound of the investigated series with 
a Ki-value of 1.4 µM and therefore represents a well-suited starting point of further 
structure-based inhibitor design for this enzyme. The further decoration of the 
benzhydryl-moieties with appropriate substituents might enable the formation of 
additional directed interactions to the protein thus potentially enhancing the inhibitory 
effect of these newly designed ligands.  
As the para-phenyl substituents of AB83 and AB84 (9 and 10, chapter 4) and the meta-
benzyl substituent of NK101 all occupy nearly the same position in the active site 
(Figure 5.2), especially the introduction of meta-amino substituents at the benzyl or 
rather benzhydryl moieties of the pyrrolidine-based bicyclic compounds could be 
beneficial, since the introduction of an amino functionality resulted in a significant 
increase in affinity by two orders of magnitude in case of the C2-symmetric 3,4-bis-N-
alkylsulfonamido-pyrrolidines (chapter 4). 
 
5.6      Experimental Section 
The experimental procedure for the protein expression and purification, FRET assay as 
well as crystallization was in general performed as described in chapter 4. Little 
modifications regarding the substrate concentration in the fluorescence-based assay as 
well as the crystallization conditions were included:  
For IC50-determination of the pyrrolidine-based bicyclic inhibitors, the FRET substrate 
RE(Edans)TKVLVVQPK(Dabcyl)R (Bachem, Germany) was used in a concentration of 
3 µM.  Under these conditions the Ki-values of indinavir (as reference) was determined 
to 2.0 ± 0.3 µM, which is in acceptable agreement to the literature value (3.48 µM).4 
Crystals of the HTLV-1 protease-NK101 complex were obtained by cocrystallization 
from a HTLV-1 PR (1-116) solution at a concentration of 10 mg/ml in presence of 5 mM 
inhibitor (NK101) using 1.5 M ammonium sulfate, 20 % glycerol (v/v), 0.1 M Tris, pH 
7.5 as reservoir solution. 
 
 
 
 
 
 
106                                    5. Pyrrolidine-Based Bicyclic Compounds as HTLV-1 Protease Inhibitors 
 
	  
5.7      References 
(1)   Klee, N. Strukturbasiertes Design, Synthese und Affinitätsbestimmung neuartiger HIV-1-
Protease-Inhibitoren. Dissertation, Philipps-Universität Marburg, 2013. 
(2)   The ligand efficiency was calculated by following equation: LE=-R*T*ln(Ki)/HA. R: ideal gas 
constant, T: temperature [K], Ki: Ki-value, HA: number of non-hydrogen atoms. 
(3)   Hopkins, A. L.; Keserü, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of 
ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discovery 2014, 13, 105–121. 
(4)   Bagossi, P.; Kádas, J.; Miklóssy, G.; Boross, P.; Weber, I. T.; Tözsér, J. Development of a 
microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. J. 
Virol. Methods 2004, 119, 87–93. 
 
 
  107  
 
 
6. Tracing Binding Modes in Hit-to-Lead Optimization: 
Chameleon-Like Poses of Aspartic Protease Inhibitors 
	  
6.1 Introductory Remarks 
The following chapter has been published in Angewandte Chemie Int. Ed. (M. Kuhnert 
et al., 2015, 54, 2849-2853) and Angewandte Chemie (M. Kuhnert et al., 2015, 
127, 2891-2896). 
The respective text is taken from the original publication, figures of the supporting 
information are implemented in the main part of the manuscript. The experimental 
procedures of compounds which were not synthesized within this thesis are not 
included in the experimental section but can be found in the original publication. In 
addition to the published manuscript, a detailed discussion of the synthesis is included 
(chapter 6.4).  
The preliminary work of Dr. Ruben Bartholomäus, Dr. Helene Köster, and Amir Shahim 
related to this project is described in chapter 1.5.2 and its results are incorporated in 
this chapter. The synthesis of the majority of the studied compounds, i.e. 3, 4, 5, 6, 8, 
9, and 10, the determination of all biophysical and affinity data presented in this study 
(TSA and fluorescence based assay), and the crystallization of compounds 5, 6 and 8 
have been performed by the author of this thesis, along with the interpretation of the 
data, as well as drafting of the manuscript. The X-ray structures of 5, 6, and 8 were 
refined within a cooperation project by Dr. Holger Steuber (LOEWE-Zentrum für 
Synthetische Mikrobiologie SYNMIKRO, Philipps-Universität Marburg). The X-ray 
structures of 3 and 9 were determined in cooperation with the group of Prof. Dr. G. 
Klebe (Philipps-Universität Marburg) by Dr. Ah Young Park and Prof. Dr. Andreas 
Heine. 
 
* Tracing binding modes in hit-to-lead optimization: Chameleon-like poses of aspartic protease inhibitors, 
Kuhnert, M.; Köster, H.; Bartholomäus, R.; Park, A.Y.; Shahim, A.; Heine, A.; Steuber, H.; Klebe, G.; 
Diederich, W. E., Angew. Chem., Int. Ed. 2015, 54, 2849–2853. Copyright © 2015 WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim. 
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6.2 Abstract 
Successful lead optimization in structure-based drug discovery depends on the correct 
deduction and interpretation of the underlying structure-activity relationships (SAR) to 
facilitate efficient decision-making on the next candidates to be synthesized. 
Consequently, the question arises, how frequently a binding mode (re)-validation is 
required, to ensure not to be misled by invalid assumptions on the binding geometry. 
We present an example in which minor chemical modifications within one inhibitor 
series lead to surprisingly different binding modes. X-ray structure determination of 
eight inhibitors derived from one core scaffold resulted in four different binding modes 
in the aspartic protease endothiapepsin, a well-established surrogate for e.g. renin and 
β-secretase. In addition, we suggest an empirical metrics that might serve as an 
indicator during lead optimization to qualify compounds as candidates for structural 
revalidation. 
 
6.3 Introduction, Results and Discussion, Conclusion 
In the field of drug discovery and medicinal chemistry, the concept of target-structure-
based design considerations in the optimization process from hit-to-lead and (pre-) 
clinical candidate to an eventually approved drug has been well established over the 
last three decades.1,2 Success stories of this structure-guided design approach range 
from the discovery of various HIV-1 protease inhibitors via the design of the 
neuraminidase inhibitor oseltamivir, the BCR-Abl kinase inhibitor imatinib, and various 
HCV protease inhibitors to a virtually unlimited number of current design campaigns 
that make use of structure-educated decision-making in prioritizing medicinal chemistry 
activities.3–6 
This optimization typically starts with one or more identified hits sharing a common 
basic scaffold. The binding mode of one representative with this scaffold and the target 
protein is determined by crystallography, and subsequently a series of derivatives is 
synthesized and their activity is monitored by appropriate assays. Typically, structural 
modifications are realized assuming that an identified binding mode of a given parent 
scaffold is maintained during structure-activity relationship (SAR) exploration and 
optimization. However, despite the meanwhile long history of structure-guided lead 
discovery there is an ongoing debate on how frequently structural support is required to 
establish a reliable SAR by monitoring putative changes of ligand binding geometry. 
Moreover, what criteria can be applied to indicate the requirement to assess putative 
conservation or changes in the binding mode throughout the optimization campaign? 
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Herein, we follow these questions by utilizing a well-suited model system and suggest 
advice that may support the decision as to whether the (re)-validation of a binding 
mode is required.  
In lead discovery, the aspartic protease endothiapepsin (EP) commonly serves as a 
model enzyme and has successfully been exploited as a surrogate for renin and β-
secretase in structure-based inhibitor design.7,8 Based on the Gewald reaction 
(Scheme 6.1),9 we have synthesized a series of substituted 2-aminothiophene-type EP 
inhibitors that cover a broad range of affinities from two-digit µm up to submicromolar 
potency.	  
 
Scheme 6.1. General synthetic route to the 2-aminothiophene core through the Gewald reaction. 
 
Starting from the two-digit micromolar inhibitors 1 and 2 (Figure 6.1) we embarked on a 
structure-guided SAR exploration of this ligand series.  
 
 
Figure 6.1. Chemical structures of 1 and 2 and their affinity data against EP. 
 
 
The crystal structure of EP in complex with 1, determined at 1.30 Å resolution, 
unambiguously shows the ligand’s tryptamine moiety bound into the S1 pocket, while 
the thiophene core resides between the S1’ and S2 pockets (Figure 6.2a). Key 
hydrogen bonds are formed between the ligand’s sp3-hybridized nitrogen and the two 
aspartates of the catalytic dyad (Asp35 and Asp219), mediated by the lytic water 
molecule. Likely, this amine is protonated and serves as hydrogen-bond donor to the 
carbonyl group of Gly221. The indole NH contributes a charge-assisted H-bond to 
Asp81 located at the tip of the hairpin-type flap region. Noteworthy, for the 4-phenyl 
substituent of the ligand, no properly defined difference electron density could be 
observed, suggesting a distribution over multiple conformational states in the binding 
site, and therefore it was omitted from the structural model. Interestingly, the amide NH 
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and the ester carbonyl oxygen of the ligand establish an intramolecular H-bond, 
keeping the ester and the thiophene plane approximately coplanar (dihedral angle ca. 
18°) and the spatially demanding substituents (ethyl ester and phenyl ring) in an 
eclipsed-type conformation.  
 
Figure 6.2. a) Observed binding mode of 1 in complex with EP. Amino acids involved in key hydrogen 
bonds (dashed lines) are shown as rods. For the detailed interaction pattern, see Figure 6.12 (appendix). 
b) Sites for structural variations derived from compound 1. 
 
Based on the observed binding mode we designed and synthesized a series of 
compounds with different structural variations to explore the underlying SAR of this 
inhibitor scaffold (Figure 6.2b). Via extension of the ethyl ester with larger hydrophobic 
substituents aimed to address the hydrophobic S2/S4 pocket, a gain in affinity was 
anticipated. In addition, to modulate the electronic properties of the intramolecular H-
bond, the influence of an exchange of the ester for an amide moiety was investigated. 
A thereby induced change in the rotameric state of the carbonyl group might 
additionally enable a polar contact to Tyr226 (Figure 6.3). Further sites for variation 
consisted in changing the length of the tryptamine side chain as well as the positioning 
of the basic nitrogen. The replacement of the indole by morpholine was considered to 
enhance solubility. Finally, the observation that the 4-phenyl substituent is disordered 
prompted us to evaluate a more rigid scaffold such as a tetrahydrobenzothiophene. 
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Figure 6.3. The exchange of the ester moiety to an amide in 1 (yellow, stick representation) might enable 
a polar contact to Tyr226. 
 
The synthesized compounds and their inhibitory activities are shown in Figure 6.4, with 
4 and 9 being the most potent representatives (460 and 545 nM, respectively). 
However, the interpretation of the underlying SAR turned out to be challenging based 
on the initially determined binding geometry of 1. Surprisingly, the simple ester-to-
amide exchange resulted in an affinity improvement by a factor of five (3, 4.0 µM). Is 
this gain solely attributed to the changed interaction of the introduced amide function, 
and how does this relate to the intramolecular H-bond observed in 1? The replacement 
of the ethyl moiety in 3 by a benzyl substituent leads to the most potent compound of 
our series, 4, with a Ki value of 460 nM and thus an improvement in the inhibitory 
activity of one order of magnitude. Removal of the 4-phenyl substituent and annulation 
 
 
 
Figure 6.4. Chemical structures of the synthesized compounds 3-10 and their corresponding Ki values 
against EP. 
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of a tetrahydrobenzene moiety at the [b] site of the thiophene ring (6) reduces affinity 
by about fourfold, although in 1 this substituent appeared disordered and was not 
expected to contribute significantly to the establishment of a directional interaction to 
EP. The replacement of the indole moiety (4) by a benzyl group (5), presumably 
accompanied by the loss of the charge-assisted H-bond to Asp81, reduces the affinity 
by approximately twofold (1.1 µM). A positional shift of the aliphatic nitrogen that was 
involved as a donor in an H-bond to the lytic water resulted in 8 (1.5 µM) and 
additionally a one-carbon insertion rendered 9, which, with an activity of 545 nM, was 
unexpectedly found to be nearly as potent as 4. 
Overall, this rather incongruent SAR prompted us to perform a comprehensive 
structural analysis of the underlying binding modes by crystal structure analysis. To our 
surprise, the binding modes of the synthesized ligands successfully determined for 1 
and 3-9, split into four clusters of binding poses, and our starting compound 1 turned 
out to represent a structural singleton, in other words, the sole representative of this 
binding mode. Figure 6.5a shows the crystal structures determined in this study and 
the affiliation for each inhibitor to the corresponding cluster, as well as the 
superposition of one cluster representative with the binding pose of our initial lead 1. 
Among the eight crystal structures, all adopting the same crystal packing, the protein 
itself manifests nearly identical conformation: rmsd values for the all-atom fitting are 
below 0.5 Å, backbone fitting yielded rmsd values below 0.3 Å.10,11 Hence, the 
deviating binding modes are neither caused by significant rearrangements of the 
protein environment, nor are they induced by different crystal forms that might create a 
different packing environment. Surprisingly, the two most potent compounds belong to 
different binding mode clusters. The largest cluster (green) comprises four derivatives 
(3, 4, 5, and 6), followed by a two-membered cluster (8 and 9) and two structural 
singletons (1 and 7). 
 
 
 
6. Chameleon-Like Poses of Aspartic Protease Inhibitors  113 
 
 
 
Figure 6.5. a) Left: Binding modes and assignment to binding mode clusters. Green, purple, yellow, and 
orange frames indicate the four different binding modes. Resolutions of the X-ray structures are shown in 
Å. The 2Fo-Fc electron densities are depicted for the ligands as a blue mesh at 1σ. Right: Superposition of 
1 (yellow) with one representative of each binding mode cluster in the active site. b) H-bond of the amide 
NH of 3 to Thr222 Oγ. Likely Thr222 forms an H-bond as an H-bond donor to Asp219 and therefore can 
only act as an H-bond acceptor to the ligand. Distances in Å. c) H-bond of the indole NH of 3, 4, and 6 to 
Asp81 and Ser83. This interaction is not possible for 5 due to the replacement of the indole by benzyl. d) 
The charge-assisted H-bond interaction to Asp81, which in the green cluster (here shown for 4) is formed 
with the indole NH, is established in 8 and 9 by means of the 2-amino function of the thiophene. e) H-bond 
network of 8 and 9 formed with the ligands’ aniline NH or benzyl NH, respectively. Involved water 
molecules are shown in spheres. 
 
Noteworthy, in between the four clusters, the binding modes of the inhibitors with 
respect to the two catalytic aspartates and the occupancy of the remaining binding 
pockets differ substantially. The lytic water molecule adopts a versatile role: it acts 
either as an H-bond donor or an H-bond acceptor or is released from the complex. 
Inhibitor 1 addresses the Asp35/219 with its sp3-hybridized nitrogen via the lytic water 
molecule, the latter acting as an H-bond acceptor (Figure 6.5a). In the structures of 8 
and 9 (purple cluster) the benzyl-substituted amide nitrogen forms a polar contact to 
the lytic water molecule, even though the interaction geometry appears rather 
unfavorable for a typical H-bond. Inhibitor 7 interacts through its morpholinomethylene-
substituted carbonyl oxygen mediated by the lytic water molecule with the catalytic 
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aspartates; in this case, however, the water molecule acts as an H-bond donor. All 
representatives of the green cluster directly address the catalytic dyad, while the lytic 
water molecule is released upon binding of the inhibitors. The significantly different 
binding modes provoke substantially deviating H-bond networks between the inhibitors 
and the protein, which are shown in Figures 6.10-6.13 (appendix).  
The binding mode of 1 apparently relies on the presence of the ester moiety, whereas 
the amide derivative (3) adopts an altered binding mode. Interestingly, the intra-
molecular H-bond observed in 1 (Figure 6.2a) breaks up in favor of the establishment 
of an H-bond to Thr222 Oγ through the ethyl-substituted amide nitrogen. How does the 
mere replacement of the ester by an amide translate into such a predominant change 
in binding geometry? In all the EP crystal structures determined in our study, the 
interaction pattern between Thr222 Oγ and the Asp219 carboxylate (2.7 Å) is 
conserved. Likely, this Thr side chain donates an H-bond to the carboxylate of Asp219 
keeping the proton of Thr222 Oγ oriented towards the aspartate (Figure 6.5b). This 
observation supports the conclusion that Thr222 Oγ itself can only be involved in 
favorable polar interactions if addressed by appropriate H-bond donors on the ligand 
site. This is impossible for the ester 1 as its oxygen can only serve as an H-bond 
acceptor; hence the ester prefers to saturate its polar contact inventory by an 
intramolecular H-bond. However, when the ester is changed to an amide (3), the 
introduced NH function is able to address Thr222 Oγ as a donor rather than 
maintaining the intramolecular H-bond, while the concomitantly nonsaturated glycine 
amide NH rotates by ≈100° to establish an H-bond to the Asp219 carboxylate (Figure 
6.5a).  
Although the overall SAR interpretation is inconclusive in the absence of structural 
data, the SAR within the clusters reveals a consistent picture, which will be discussed 
only exemplarily. In the green cluster, 3 bearing an ethyl group at P2 has the lowest 
affinity (4.0 µM); this most likely results from the reduced hydrophobic interactions, 
compared to those of the inhibitors equipped with a benzyl group at this position. 
Furthermore, 3 and 6 lack the intramolecular π–π interaction between the two phenyl 
rings observed in 4 and 5, which leads to a loss of preorganization corresponding to 
the bound conformation. In 5, due to the exchange of the indole moiety for the benzyl 
group, the H-bond to Asp81 and the weak polar contact to Ser83 as observed in 3, 4, 
and 6 cannot be established (Figure 6.5c). In 4, the representative with the highest 
affinity (460 nM) of this cluster, the four varied substituents seem to be optimally 
chosen among all investigated variations, as the indole moiety is able to form an H-
bond to Asp81 whereas the benzyl moiety interacts via π–π stacking to Tyr226. 
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Inhibitor 8 (purple cluster) differs from 5 (green cluster) only by the position of the 
secondary amino nitrogen in the P1 substituent of the inhibitor. Based on the X-ray 
structure of 5, a lower affinity caused by a less efficient interaction of the relocated 
nitrogen to the catalytic aspartates would have been expected for 8. Interestingly 
though, its affinity is nearly unchanged. The X-ray structure of 8 provides the 
explanation for this initially surprising observation: the switch in binding geometry 
between 5 and 8 seems to be mainly triggered by the loss of the H-bond to Asp35 that 
would be expected for an unchanged geometry of 5. The thiophene moiety formerly 
located in the S1’ pocket (green cluster) flips by about 180° in order to populate now the 
S2 pocket. Likewise, inhibitor 9, in which the P1 substituent is extended by one carbon 
atom, shows this altered binding geometry, which enables 8 and 9 to maintain the 
charge-assisted H-bond interaction to Asp81, although the indole moiety that 
previously accomplished this task is replaced by the phenyl/benzyl group with the 
amide NH in thiophene 2-position (Figure 6.5d). Even though the aryl- and benzyl-
substituted nitrogens are located at virtually identical positions, the increase in affinity 
by about threefold from 8 to 9 might be explained by the different pKa values of the 
aniline NH compared to the benzyl NH. Thus, the latter, which is being most likely 
protonated to a larger extent, is capable of forming a more efficient charge-assisted H-
bond to the water molecule that mediates the H-bond to Asp33 and Gly221 (Figure 
6.5e).  
In our inhibitor series also less or inactive compounds were synthesized which are 
essential for SAR interpretations as well. However, in the present case the inter-
pretation of these data is almost impossible, as the assignment to one of the binding 
mode clusters remains speculative.  
The current example highlights the complexity of binding events and their strong 
dependence on seemingly minor effects of scaffold decoration and modifications. That 
1, 7, 8, and 9 do not adopt the same binding geometry as observed in the green cluster 
can be rationalized retrospectively, but without the crystal structure determinations the 
adopted binding modes would have been difficult to predict, and, if so, would have 
hardly been believed or attracted sustained attention without our experimental 
evidence. 
Such an unexpected flipping of binding modes after modification of the scaffold 
substitutions has been detected sporadically, however, mostly by serendipity.12–15 As 
the commonly accepted hypothesis that similar ligands bind in a similar fashion16 
apparently does not hold true on a comprehensive basis, the question arises, how 
frequently a (re-)validation of an assumed binding mode is required. Are there any 
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easily available indicative hints to estimate whether a crystallographic (re-)validation of 
the assumed binding mode used as working hypothesis is required throughout the lead 
exploration campaign?  
In addition to the affinity determination via a fluorescence-based assay (Ki values), we 
performed a thermal shift assay (TSA) to investigate the extent to which the studied 
compounds stabilize the protein, especially with respect to the different binding modes. 
TSAs are commonly used for hit identification and affinity ranking of inhibitors.17–21  
The results for our inhibitor series (Table 6.1) clearly suggest that the observed shifts in 
the melting temperature do not generally correlate with the Ki values.  
 
Table 6.1. TSA data ordered by decreasing ΔTm values, as well as assignment to the 
binding mode clusters (color coded) and Ki values. 
 
inhibitor  
[100 µM] 
Tm  
[°C] 
ΔTm 
[°C] 
Ki  
DMSO 58.7 ± 0.2   
4 63.3 ± 0.2 4.6 460 ± 24 nM 
9 62.5 ± 0.0 3.8 545 ± 35 nM 
6 61.9 ± 0.1 3.2 1.8 ± 0.2 µM 
3 61.5 ± 0.2 2.8 4.0 ± 0.7 µM 
5 60.9 ± 0.1 2.2 1.1 ± 0.2 µM 
1 59.4 ± 0.2 0.7 18.2 ± 7.4 µM 
8 59.1 ± 0.1 0.4 1.5 ± 0.5 µM 
7 58.8 ± 0.1 0.1 13.1 ± 3.0 µM 
 
However, within one binding mode cluster, the ΔTm values are ranked correctly, with 5 
being an exception: this might be attributed to the loss of the charge-assisted H-bond 
to Asp81 due to the absence of the indole moiety, while the other members of this 
cluster establish this interaction. This observation is in agreement with the concept that 
TSA measurements require similar binding enthalpies for correct affinity ranking.21 
However, how do TSA data perform for ligands of identical chemotype that fall in the 
same affinity range, but exhibit different binding geometries?  
Only two of our four binding mode clusters qualify for such a comparison, as the 
singletons 1 and 7 are slightly off-range with respect to their affinity. However, the 
affinities of the green and the purple clusters cover a similar affinity range thus 
permitting such a comparison. Interestingly, for these two clusters, ligands of rather 
identical affinity deviate with respect to their associated TSA profile: the two most 
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potent ligands 4 and 9 possess affinities of 460 nM and 545 nM, respectively, but differ 
by 0.8°C in their TSA profiles (4.6 versus 3.8°C) which corresponds to a deviation of 
more than threefold of the standard deviation of the measurement. Analogously, 5 and 
6 inhibit EP with a virtually identical affinity of 1.1 and 1.8 µM, respectively, and 8 is 
equally potent (1.5 µM). However, the latter exhibits a TSA shift of only 0.4°C, while the 
first two ligands significantly enhance the stability of the protein as indicated by a shift 
of ΔTm of 2.2 and 3.2°C, respectively (with 5 being the abovementioned internal outlier 
within the green cluster). These observations suggest that protein stabilization by a 
particular ligand depends not only on affinity, but also on its adopted interaction 
pattern. This is also true for the comparison of 1 and 8, both of which exhibit a similar 
TSA shift (0.7 vs. 0.4°C, respectively) but possess a substantial difference in affinity 
(18 vs. 1.5 µM), thus suggesting that they stabilize the target protein by deviating 
interaction geometries.  
Hence, discrepancies between affinity data based on enzyme kinetics and TSA results 
within one inhibitor series may be exploited as a hint for putative changes in the 
adopted binding geometry, which may qualify the seeked “outlier”-type ligands as 
promising candidates for revalidation of the assumed binding mode.  
The presented example impressively points out that minor structural changes within 
one lead series, such as the replacement of an ester by an amide or the introduction of 
an additional carbon atom, may result in entirely different binding modes. An 
inconsistent affinity-TSA correlation may serve as an easily available indicator to 
qualify candidates for structural revalidation, even if the interaction mode is believed to 
be known. In the absence of such structural data, a reasonable interpretation of 
substituent effects or assumed bioisosteric replacements at a given chemotype will be 
rather meaningless and will likely drive scaffold optimization in the wrong direction. We 
expect that our case study and the application of the suggested validation protocol will 
encourage drug designers to further pursue and study chemically attractive scaffolds 
albeit an at first glance seemingly inconclusive SAR. This is likely to be rewarded with a 
more comprehensive understanding and an increasing number of starting options for 
further lead optimization.  
 
Protein Databank codes for this manuscript: 
1 (3T7Q), 3 (4L6B), 4 (3PSY), 5 (3WZ6), 6 (3WZ7), 7 (3T7X), 8 (3WZ8), 9 (4LAP). 
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6.4 Detailed Discussion of the Synthesis of Gewald Reaction-Based 
Inhibitors 
As the manuscript as published in Angewandte Chemie is mainly related to the lessons 
learned for drug discovery and lead optimization, the synthesis of the compounds is 
described in more detail in this subchapter.  
 
6.4.1 Gewald Reaction  
The Gewald reaction, named after the German chemist Karl Gewald, is an organic 
name reaction in which the treatment of an α-methylen-activated nitrile with an 
α-methylene carbonyl compound and elemental sulfur gives rise to substituted 2-
aminothiophenes.9 In the first step, Knoevenagel condensation of the CH-acidic α-
carbon of nitrile G2 with the carbonyl function of G1 furnishes the acrylonitrile 
intermediate G3. The subsequent mechanism finally leading to the 2-aminothiophene 
scaffold G5 is yet not fully understood, but it most likely proceeds via the thiolated 
intermediate G4, followed by its ring closure and prototropic rearrangement to G5 in the 
last step (Scheme 6.2).22,23  
 
Scheme 6.2. Synthesis of the 2-aminothiophene scaffold by the Gewald reaction. 
The 2-aminothiophene scaffold has also attracted some interest in the field of drug 
discovery: the atypical antipsychotic drug olanzapine (Eli Lilly) represents a well-known 
successful example of a Gewald reaction-derived small molecule being approved to the 
market. In addition, the 2-aminothiophene scaffold can also be found in the non-
steroidal anti-inflammatory drug tinoridine (nonflamin®). Other drug candidates like T-
62, a selective allosteric enhancer of the adenosine A1 receptor (neuropathic pain), or 
AX20017, an inhibitor of the protein kinase G (tuberculosis), also bear this structure 
motif. (Figure 6.6).23,24  
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Figure 6.6. Chemical structures of 2-aminothiophene compounds in drug research. 
 
6.4.2 Previous Work  
The Gewald reaction-based compounds synthesized previously in our research group 
(Dr. Ruben Bartholomäus and Amir Shahim) all show the common basic scaffold 
shown below (Figure 6.7).  
 
Figure 6.7. Basic scaffold of the 2-aminothiophene compounds synthesized as aspartic protease inhibitors 
in our group. 
 
Within the scope of this thesis as well as with respect to the motivation described in 
chapter 1.5 and 6.3, seven Gewald reaction-based inhibitors were synthesized (Figure 
6.8). 
Except for 3, all inhibitors bear a benzylamine moiety in R2-position and are varied in 
their R1- and/or R3-substituents. While the R3-substituent is introduced via the ketone 
component at the beginning of the synthesis, a synthetic route allowing the introduction 
of the variable R1-substituent in a later step was envisioned to be advantageous as it 
would reduce the number of intermediates to be characterized. 
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Figure 6.8. Chemical structures of compounds 3-6 and 8-10, which were synthesized within the scope of 
this thesis. 
 
During his Diploma thesis,25 Dr. Ruben Bartholomäus developed a synthetic strategy 
for the synthesis of inter alia compounds 1, 2 and 4 (Scheme 6.3). This route, leading 
in three consecutive steps to compounds 1 and 2 and in seven steps to compound 4, is 
quite straightforward for synthesizing inhibitors which bear an ethylester function in R2-
position and vary in their R1-substituent, such as in compounds 1 and 2. The synthesis 
of compound 4 being equipped with a benzylamine moiety in R2-position, however, was 
intricate as it included a low-yielding Boc-protection-step of the aromatic amine at the 
beginning of the synthesis (step 2), and hence an additional deprotection step at a later 
stage of the protocol.  
In conclusion, this route is quite feasible for the synthesis of inhibitors featuring an 
ethylester functionality as R2-residue, but for the introduction of other R2-residues, like 
e.g. a benzylamine group or the variation of the R1-substituent, it is less suitable.  
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Scheme 6.3. Synthetic route for compound 4 (a) as well as 1 and 2 (b) developed by Dr. R. 
Bartholomäus.25 Compounds 1 and 2 were synthesized analogously, however, the reaction steps 2, 3, 4, 
and 5 for introducing the R2-substituent were skipped and in step 7 the respective amines were used 
instead of tryptamine. 
 
As shown for compound 7 (Scheme 6.4), Amir Shahim synthesized derivatives with a 
morpholino residue in R1- and varying substituents in R2-position. Therefore, the 
synthesis of these compounds was designed in such a way that enabled the 
introduction of the R1-substituent at first and the variation of the R2-moiety in the last 
step, which also disqualified this route for the efficient synthesis of the inhibitor series 
with modified R1-moieties planned to be synthesized at the onset of this thesis (Figure 
6.8).  
 
 
Scheme 6.4. Synthesis route developed by Amir Shahim for synthesizing compound 7. 
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A previous synthesis project carried out during my practical year prior to the initiation of 
this thesis also comprised Gewald reaction-based inhibitors: a series of inhibitors with 
variation of the R2-moiety was planned to be synthesized as inhibitors for aspartic 
proteases, while the tryptamine moiety as R1-substituent should be present in all 
inhibitors. For synthetic reasons, in this case it was considered to be favorable to 
introduce the common tryptamine R1-substituent at first and the different variable 
R2-residues at a later stage. The proposed route of the synthesis is shown in Scheme 
6.5. 
Interestingly, in practice this synthetic pathway, however, beard unexpected 
challenges: the cleavage of the ester (step 5) for instance resulted in an additional 
cleavage of the amide function (main product) and therefore in the loss of the R1-
substituent. Also different reaction conditions (varying bases and solvents) for the ester 
cleavage did not give rise to the desired product. Pursuit of other protection strategies 
instead of the Boc-protection like usage of the benzyl-, triphenylmethyl- or p-nitrobenzyl 
group did not lead to the final compound due to difficulties in the amine protection (p-
nitrobenzyl protection group), cleavage of the ester after protection (triphenylmethyl 
group) or the final deprotection of the amine function (benzyl protection group). 
From a synthetic point of view, the described challenges were rather unexpected, 
especially when keeping in mind that a similar route (Scheme 6.4) worked well for its 
closely related scaffold. 
 
Scheme 6.5. Proposed synthesis route for the inhibitor series with the tryptamine moiety as R1-substituent 
and variable R2-residues. 
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6.4.3 Synthesis of Compounds 3-6 and 8-10 
Based on the previous results, an appropriate route for synthesizing the above 
mentioned compounds 3-6 and 8-10 had first to be developed in order to efficiently 
enable the incorporation of a broader variety of R1-substituents such as e.g. tryptamine, 
benzylamine and morpholine moieties. 
First of all, the optimization of the Boc-protection (step 2, Scheme 6.3) of the aromatic 
amino functionality of the thiophene was pursued in order to follow up on the synthesis 
via the established route shown in Scheme 6.3. Different bases and catalysts like 
triethylamine (TEA) and 4-dimethylaminopyridine (DMAP) as well as different solvents 
were tested for optimizing the formation of the Boc-protected 2-aminothiophene, but, 
unfortunately, all these attempts did not enhance the yield of this step. Efforts like the 
iodine-catalyzed solvent-free Boc-protection26 or the usage of guanidine-hydrochloride 
as an alternative catalyst27 also did not result in a satisfactory conversion of the 2-
aminothiophene starting material into the desired product. 
Fortunately, the failure of optimizing the initial sequence lead to an elegant and efficient 
route (Scheme 6.6a) designed in the context of this work, which was successfully 
employed for most of the seven compounds to be synthesized.  
 
 
Scheme 6.6. a) Overview of the synthesis of compounds 3-6 and 10. b) The synthesis of 8 is similar, but 
proceeds via the acrylamide derivative 20 as intermediate product of step 3 (dehydrohalogenation). c) 
Synthesis of 9 via the 3-chloro-propanamide derivative 21 as intermediate product. 
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The Gewald reaction (step 2) was directly performed with the final R2-moiety, being 
synthesized from ethylcyanoacetate and the respective amine prior to the Gewald 
reaction (step 1). Thus, the cleavage of the ester moiety and protection/deprotection of 
the reactive amino group was no longer required. The R3-residue was also directly 
introduced via the Gewald reaction. Subsequent reaction of the 2-aminothiophene 
derivative with chloroacetyl chloride/ chloropropionyl chloride (step 3), followed by the 
introduction of various amines by a nucleophilic substitution of the terminal chloro-
substituent (step 4) finally yielded the fully decorated inhibitors. In comparison to the 
initial route, the newly developed sequence significantly reduced the required steps of 
the synthesis of 4 from seven to four and concomitantly resulted in a by a factor of five 
increased overall yield (3 % over 7 steps versus 14 % over 4 steps). Compounds 3, 5, 
and 6 were synthesized analogously to 4, while for compound 6, cyclohexanone 
instead of acetophenone was used as ketone-component in the Gewald reaction. 
The synthesis of compounds 8 and 9 (Scheme 6.6b, c) slightly deviates from the pre-
vious one because the chloropropionyl chloride turned out to be susceptible to terminal 
dehydrohalogenation giving rise to the respective acrylamide derivative 20 (step 3). In 
analogy to the synthesis of 3, 4, 5, and 6, 9 could be obtained via the 3-chloro-
propanamide derivative, while for the generation of 8 the acrylamide intermediate 20 
was subjected to a Michael reaction with aniline (step 4) rendering the final compound. 
The 3-chloro-propanamide- and the acrylamide-intermediates, 21 and 20 respectively, 
were isolated from the reaction mixture obtained under the denoted reaction conditions 
(room temperature and 0°C, respectively), however both reactions were not optimized 
for obtaining the respective intermediate product. 
 
6.4.4 Conclusion 
In summary, an efficient and successful synthetic route has been developed for the 
synthesis of compounds 3-6 and 8-10. In this context it is noteworthy to mention that 
the chemical scaffold of 2-amino-3-carbonyl-thiophenes has recently been assigned to 
belong to the group of pan-assay interference compounds (PAINs)28 and has therefore 
even been retracted from certain chemical libraries. However, as convincingly 
emphasized in our study, this structural motif nevertheless is able to establish specific 
interactions and inhibition mechanisms to enzyme targets thus qualifying a removal of 
such a particular scaffold to be seemingly premature. The utilization of the Gewald 
reaction as pursued in this thesis has successfully been exploited in order to make 
novel derivatives of this chemical compound class available.    
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6.5 Experimental Section 
6.5.1 Synthesis - General Experimental Details 
Unless stated otherwise, reagents and solvents that were purchased were used without 
further purification. Cyclohexane was purchased in p.a. quality (Grüssing, Germany) 
and distilled prior to use. Thin layer chromatography (TLC) was performed on 
precoated TLC plates purchased from Merck (silica gel 60 F254). Purification by flash 
chromatography was either performed manually with glass columns (silica gel 60, 0.04-
0.063mm, Macherey-Nagel) or with a Büchi separation system using prepacked flash 
chromatography columns purchased from Interchim (PuriFlash colums). 1H-NMR and 
13C-NMR spectra were recorded on a JEOL ECX-400 or on a JEOL ECA-500 
spectrometer. Chemical shifts (δ) are given in ppm with the residual solvent signal 
(unless otherwise noted) or TMS (Tetramethylsilane) signal used as reference [1H: 
CDCl3: s, δ=7.26ppm, DMSO-d6: quint, δ=2.50ppm; 13C: CDCl3: t, δ=77.16ppm, 
DMSO-d6: quint, δ=39.52ppm); MeOH-d4: sept, δ=49.00ppm; TMS: s, δ=0.0ppm].29 
Spectra with CDCl3 as solvent were recorded at room temperature (RT) while spectra 
with DMSO-d6 as solvent were recorded at 30.0°C. Coupling constants (J) are reported 
in hertz (Hz). Peak patterns were abbreviated as follows: s (singlet), d (doublet), dd 
(double doublet), ddd (doublet of doublet of doublet), t (triplet), m (multiplet), sm 
(symmetric multiplet), br (broad), ps (pseudo). Elemental combustion analyses were 
performed on a Vario MICRO cube (Elementar Analysensysteme GmbH, Hanau, 
Germany). Mass spectra were recorded on a double-focusing sector field spectrometer 
type 70-70H (VacuumGenerators) or on a double-focusing sector field spectrometer 
type AutoSpec (Micromass) using electron ionization (EI) or electrospray ionization 
(ESI). Melting points were determined using the melting point meter MPM-H2 (Schorpp 
Gerätetechnik, Germany) or FP62 (Mettler Toledo) and are uncorrected. 
 
6.5.2 Synthesis - General Procedures 
Procedure A: Gewald Reaction - Synthesis of the 2-Amino-Thiophene Scaffold 
The Gewald reaction was performed following a slightly modified literature procedure:30  
To an ice-cooled solution of the respective ketone and nitrile dissolved in dry 
tetrahydrofuran (THF) or dichloromethane (DCM) titanium tetrachloride (TiCl4) (2eq) 
was added dropwise. Pyridine (3.4eq) was added stepwise after 10min (1/3) and after 
30min (2/3) and the reaction mixture was stirred at RT until full conversion of the 
ketone was observed, (≈15h), indicated by TLC. The solvent was removed in vacuo, 
the remaining residue was dissolved in ethyl acetate and washed with 2M HCl, water, 
and brine, dried over MgSO4, filtered, concentrated in vacuo and finally redissolved in 
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dry THF. Sulfur (1.17eq) and diethylamine (3.5eq) were added and the reaction mixture 
was stirred at RT until TLC indicated the conversion of the intermediate (≈15h). THF 
was removed in vacuo, the residue was dissolved in DCM and washed with water and 
brine, dried over MgSO4, filtered, and concentrated in vacuo. The remaining oily 
residue was purified by flash chromatography. 
 
Procedure B: Acetylation of the 2-Amino-Thiophene Scaffold 
The acetylation was performed in accordance to a publication from Kobayashi-
Matsunaga et al.:31  
To an ice-cooled solution of the respective thiophene (1eq) in dry DCM, triethylamine 
(1.5eq) and chloroacetyl chloride or chloropropionyl chloride (1.5eq) were added 
dropwise. The reaction mixture was stirred at room temperature until TLC indicated full 
conversion of the starting material (4-14h). The reaction mixture was diluted with DCM, 
washed with an aqueous ammonium chloride solution (sat.) and brine, dried over 
MgSO4, filtered, concentrated in vacuo and the remaining residue was purified by flash 
chromatography. 
 
Procedure C: Nucleophilic Substitution with Primary Amines or Morpholine 
According to a procedure from Jung et al.,32 triethylamine (2eq), the respective amine 
(2-5eq) and tetrabutylammonium iodide (TBAI) (0.1eq) were added to a solution of the 
respective N-chloroacetyl [or N-chloropropionyl]-2-aminothiophene (1eq) in acetonitrile. 
The reaction mixture was stirred for 4-15h at 100°C (reflux) and concentrated in vacuo. 
The residue was dissolved in DCM, washed with water and brine, dried over MgSO4, 
filtered, and concentrated in vacuo. The product was obtained after purification by flash 
chromatography.  
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6.5.3 Synthesis – Reaction Schemes and Characterization of the Synthesized 
Compounds 
 
Synthesis of compounds 1 and 2* 
 
 
Scheme 6.7. Synthesis of compound 1 and 2. 
 
 
*) Compounds 1 and 2 were synthesized by Dr. Ruben Bartholomäus.  
The characterization of 11, 12, 1, and 2 as well as the experimental procedures can be 
found in the diploma thesis of Dr. Ruben Bartholomäus, Philipps-Universität Marburg 
and in the original publication.25,33  
 
Synthesis of Compounds 3, 4, 5, 10 
 
Scheme 6.8. Synthesis of 3, 4, 5, 10.  
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2-Cyano-N-ethyl-acetamide (14)  
 
The compound was synthesized according to a literature procedure34 utilizing 
ethylamine (68% solution in H2O) (5mL, 61.1mmol) and ethyl cyanoacetate (3.25mL, 
30.5mmol). The product was purified by flash chromatography (DCM, 2% MeOH) and 
14 was obtained as colorless solid (2.7g, 24.1mmol, 79%).  
 
1H-NMR (399.78MHz, DMSO-d6):  
δ=8.18 (brs, 1H, H-N(6)), 3.57 (s, 2H, H-C(3)), 3.09 (dq, 3J=7.3Hz, 3J=5.5Hz, 2H, H-
C(7)), 1.03 (t, 3J=7.2Hz, 3H, H-C(8)) 
 
13C-NMR (100.53MHz, DMSO-d6, APT):  
δ=161.7 (C(4)),116.2 (C(1)), 34.0 (C(7)), 25.2 (C(3)), 14.3 (C(8)) 
 
MS (ES+):  
m/z (%): 113 (100) [M+H]+, 130 (34) [M+NH4]+ 
 
CHN: 
Anal. calcd for C5H8N2O (%):   C: 53.56  H: 7.19  N: 24.98  
Found:     C: 54.01  H: 7.26 N: 24.77 
 
 
N-Benzyl-2-cyano-acetamide (15)  
 
 
The compound was synthesized according to a literature procedure35 employing 
benzylamine (10mL, 91.6mmol) and ethyl cyanoacetate (9.8mL, 91.6mmol). The 
product was recrystallized from ethanol. The obtained crystals were washed with 
cooled ethanol, the crystallization procedure was repeated three times from mother 
liquor. 15 was obtained as colorless crystals (12.05g, 69mmol, 76%). 
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1H-NMR (399.79MHz, CDCl3):  
δ=7.40-7.27 (m, 5H, 5 phenyl-H), 6.49 (brs, 1H, H-N(6)), 4.46 (d, 3J=5.5Hz, 2H, H-
C(7)), 3.38 (s, 2H, H-C(3)) 
 
13C-NMR (100.53MHz, DMSO-d6, APT):  
δ=162.1 (C(4)), 138.5 (C(8)), 128.3 (2C, C(10), C(12)), 127.3 (2C, C(9), C(13)), 127.0 
(C(11)), 116.1 (C(1)), 42.7 (C(7)), 25.3 (C(3)) 
 
MS (ES+):  
m/z (%): 192 (100) [M+NH4]+, 366 (89) [2M+NH4]+, 371 (49) [2M+Na]+ 
 
HRMS (EI):  
Calcd for C10H10N2O [M]+:   174.079313  
Found:     174.078649 
 
CHN: 
Anal. calcd for C10H10N2O (%):  C: 68.95  H: 5.79  N: 16.08  
Found:     C: 69.06  H: 5.71  N: 16.24 
 
2-Amino-N-ethyl-4-phenyl-thiophene-3-carboxamide (16) 
 
 
 
Compound 16 was synthesized according to procedure A, however, using dry DCM 
instead of THF in the first step. Utilization of 2-cyano-N-ethyl-acetamide (15) (1.6g, 
14.3mmol), acetophenone (1.53mL, 13.0mmol), TiCl4 (2.86mL, 26.0mmol), sulfur 
(0.49g, 15.2mmol), pyridine (3.6mL, 44.1mmol), and diethylamine (4.75mL, 45.5mmol) 
rendered after two purification steps by flash chromatography (1. cyclohexane:EtOAc 
85:15, 2. DCM:MeOH 99:1) 16 as orange-brown solid (0.98g, 4.0mmol, 31%). 
 
Mp: 135°C 
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1H-NMR (399.79MHz, DMSO-d6):  
δ=7.42-7.30 (m, 5H, 5 phenyl-H), 6.74 (s, 2H, H-N(17)), 6.26 (s, 1H, H-C(5)), 5.98 (brt, 
3J=5.6Hz, 1H, H-N(14)), 3.02 (sm, 2H, H-C(15)), 0.80 (t, 3J=7.2Hz, 3H, H-C(16))  
 
13C-NMR (100.53 Hz, DMSO-d6, APT):  
δ=164.9, 159.7 (C(12), C(2)), 138.8, 136.7 (C(6), C(4)), 128.4 (2C, C(8), C(10)), 128.2 
(2C, C(7), C(11)), 127.3 (C(9)), 108.6 (C(3)), 105.1 (C(5)), 33.2 (C(15)), 14.3 (C(16))  
 
MS (ES+):  
m/z (%): 247 (100) [M+H]+), 202 (86) [M-C2H6N]+ 
 
HRMS (EI): 
Calcd for C13H14N2OS [M]+:   246.082685 
Found:     246.082233  
 
CHN: 
Anal. calcd for C13H14N2OS (%):   C: 63.39  H: 5.73 N: 11.37 
Found:      C: 63.72 H: 5.88  N: 11.47 
 
2-Amino-N-benzyl-4-phenyl-thiophene-3-carboxamide (17)  
 
 
 
According to procedure A, utilization of acetophenone (5.3mL, 45.3mmol), N-benzyl-2-
cyano-acetamide (15) (8.69mg, 49.9mmol), TiCl4 (10mL, 90.7mmol), pyridine (12.5mL, 
154.2mmol), and diethylamine (16.6mL, 159mmol) rendered, after two purification 
steps by flash chromatography (1. DCM:cyclohexane 8:2; 2. cyclohexane:EtOAc 8:2), 
compound 17, as a light yellow solid (4.5g, 14.6mmol, 32%).  
 
Mp: 121°C 
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1H-NMR (500.16MHz, DMSO-d6):  
δ=7.29 (pss, 5H, H-C(6-11)), 7.26-7.23 (m, 2H, H-C(8’), H-C(10’)), 7.21-7.18 (m, 1H, H-
C(9’)), 7.04 (d, 3J=7.2Hz, 2H, H-C(7’), H-C(11’)), 6.82 (s, 2H, H-N(16)), 6.50 (t, 3J=5.4 
Hz, 1H, H-N(14)), 6.25 (s, 1H, H-C(5)), 4.22 (d, 3J=5.7Hz, 2H, H-C(15))  
 
13C-NMR (125.77MHz, DMSO-d6):  
δ=165.2, 160.1 (C(2), C(12)), 139.0, 138.8, 136.7 (C(6’), C(6), C(4)), 128.3 (2C, C(8), 
C(10)), 128.2 (2C, C(7), C(11)), 128.0 (2C, C(8’), C(10’)), 127.23 (C(9)), 127.17 (2C, 
C(7’), C(11’)), 126.6 (C(9’)), 108.3 (C(3)), 105.3 (C(5)), 42.3 (C(15)) 
 
MS (ES+):  
m/z (%): 309 (100) [M+H]+, 331 (36) [M+Na]+, 617 (38) [2M+H]+ 
 
HRMS (EI): 
Calcd for C18H16N2OS [M]+:   308.098335  
Found:     308.099874  
 
CNH: 
Anal. calcd for C18H16N2OS (%):   C: 70.10  H: 5.23 N: 9.08 
Found:      C: 70.19  H: 5.37  N: 9.03 
 
2-[(2-Chloroacetyl)amino]-N-ethyl-4-phenyl-thiophene-3-carboxamide (18)  
 
 
 
According to procedure B, usage of 2-amino-N-ethyl-4-phenyl-thiophene-3-
carboxamide (16) (0.8g, 3.3mmol), chloroacetyl chloride (0.4mL, 4.9mmol), and 
triethylamine (1.1mL, 8.1mmol) yielded after purification by flash chromatography 
(cyclohexane:EtOAc 9:1) 18 as light yellow solid (660mg, 2.0mmol, 63%). 
 
Mp: 145° 
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1H-NMR (399.79MHz, DMSO-d6):  
δ=11.50 (s, 1H, H-N(17)), 7.43-7.33 (m, 5H, 5 phenyl-H), 7.23 (brt, 3J=4.9Hz, 1H, H-
N(14)), 7.01 (s, 1H, H-C(5)), 4.51 (s, 2H, H-C(20)), 3.14 (sm, 2H, H-C(15)), 0.89 (t, 
3J=7.3Hz, 3H, H-C(16)) 
 
13C-NMR (100.53MHz, DMSO-d6, APT):  
δ=164.03, 163.99 (C(12), C(2)), 141.0 (C(18)), 137.4, 135.5 (C(4), C(6)), 128.3 (4C, 
C(7), C(8), C(10), C(11)), 127.5 (C(9)), 119.4 (C(3)), 115.8 (C(5)), 42.4 (C(20)), 33.7 
(C(15)), 13.9 (C(16)) 
 
MS (ES+):  
m/z (%) = 323 (100) [M35Cl+H]+, 325 (43) [M37Cl+H]+ 
 
HRMS (ES+): 
Calcd for C15H16N2O2SCl35 [M+H]+:   323.062102 
Found:      323.060514 
 
CHN: 
Anal. calcd for C15H15N2O2SCl (%):   C: 55.81  H: 4.68 N: 8.68  
Found:      C: 56.22   H: 4.81 N: 8.66 
 
N-Benzyl-2-[(2-chloroacetyl)amino]-4-phenyl-thiophene-3-carboxamide (19)  
 
According to procedure B, utilization of 2-amino-N-benzyl-4-phenyl-thiophene-3-
carboxamide (17) (2.5g, 8.11mmol), chloroacetyl chloride (0.97mL, 12.16mmol), and 
triethylamine (1.69mL, 12.16mmol) rendered, after purification by flash chromato-
graphy (cyclohexane:DCM 7:3), 19 (2.8g, 7.37mmol, 91%) as light yellow solid. 
 
Mp: 123°C 
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1H-NMR (399.79MHz, DMSO-d6):  
δ=11.49 (s, 1H, H-N(16)), 7.82 (t, 3J=5.8Hz, 1H, H-N(14)), 7.36-7-29 (m, 5H, H-C(7-
11)), 7.28-7.20 (m, 3H, H-C(8‘), H-C(9‘), H-C(10‘)), 7.09 (m, 2H, H-C(7‘), H-C(11‘)), 
7.07 (s, 1H, H-C(5)), 4.52 (s, 2H, H-C(19)), 4.33 (d, 3J=6.0Hz, 2H, H-C(15)) 
 
13C-NMR (100.53MHz, DMSO-d6, APT):  
δ=164.4, 164.1 (C(2), C(12)), 141.2 (C(17)), 138.3, 137.4, 135.4 (C(4), C(6), C(6’)), 
128.3 (4C, C(7), C(8), C(10), C(11)), 128.1 (2C, C(8’), C(10’)), 127.5 (3C, C(7’), C(11’), 
C(9)), 126.8 (C(9’)), 119.4 (C(3)), 115.9 (C(5)), 42.7, 42.4 (C(19), C(15)) 
 
MS (ES+):  
m/z (%): 385 (100) [M35Cl+H]+, 387 (44) [M37Cl+H]+, 402 (43) [M35Cl+NH4]+, 407 (52) 
[M35Cl+Na]+), 409 (31) [M37Cl+Na]+ 
 
HRMS (EI): 
Calcd for C20H17N2O2SCl35 [M]+:   384.069928 
Found:      384.070887 
Calcd for C20H17N2O2SCl37 [M]+:  386.066977 
Found:      386.068372 
 
CHN: 
Anal. calcd for C20H17N2O2SCl (%):   C: 62.41  H: 4.45  N: 7.28  
Found:      C: 62.65  H: 4.53  N: 7.21 
 
N-Ethyl-2-[[2-[2-(1H-indol-3-yl)ethylamino]acetyl]amino]-4-phenyl-thiophene-3-
carboxamide (3)  
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According to procedure C, employment of 2-[(2-chloroacetyl)amino]-N-ethyl-4-phenyl-
thiophene-3-carboxamide (18) (0.30g, 0.93mmol), tryptamine (0.45g, 2.79mmol), 
triethylamine (0.26mL, 1.86mmol), and TBAI (34mg, 0.09mmol) furnished 3 after 
purification by flash chromatography (DCM:MeOH:NH3(MeOH) 99:1:0.1) as beige solid 
(310mg, 0.69mmol, 75%). 
 
Mp: 149°C 
  
1H-NMR (399.79MHz, DMSO-d6):  
δ=10.77 (s, 1H, H-N(17)), 7.55 (d, 3J=8.0Hz, 1H, H-C(31)), 7.44-7.35 (m, 6H, 5 phenyl-
H, H-N(26)), 7.32 (d, 3J=8.2Hz, 1H, H-C(28)), 7.16 (sm, 1H, H-C(25)), 7.07-7.03 (m, 
2H, H-C(29), H-N(14)), 6.99 (s, 1H, H-C(5)), 6.95 (sm, 1H, H-C(30)), 3.41 (s, 2H, H-
C(20)), 3.14 (sm, 2H, H-C(15)), 2.94-2.91 (m, 2H, H-C(22)), 2.87-2.82 (m, 2H, H-
C(23)), 0.88 (t, 3J=7.2Hz, 3H, H-C(16)). 
 
13C-NMR (100.53MHz, DMSO-d6, APT):  
δ=169.9, 164.1 (C(2), C(12)), 142.4 (C(18)), 137.3 (C(4) or C(6)), 136.2 (C(27)), 135.6 
(C(4) or C(6)), 128.4 (2C, C(8), C(10)), 128.3 (2C, C(7), C(11)), 127.4 (C(9)), 127.2 
(C(32)), 122.5 (C(25)), 120.8 (C(30)), 118.2, 118.1 (C(29), C(31)), 117.6 (C(3)), 114.7 
(C(5)), 112.1 (C(24)), 111.3 (C(28)), 51.7 (C(20)), 50.5 (C(22)), 33.6 (C(15)), 25.6 
(C(23)), 14.1 (C(16)) 
 
MS (ES+):  
m/z (%): 447 (100) [M+H]+ 
 
HRMS (ES+): 
Calcd for C25H27N4O2S [M+H]+:   447.185473 
Found:      447.182874  
 
CHN: 
Anal. calcd for C25H26N4O2S (%):   C: 67.24  H: 5.87  N: 12.55  
Found:      C: 66.98  H: 5.97  N: 12.50 
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N-Benzyl-2-[[2-[2-(1H-indol-3-yl)ethylamino]acetyl]amino]-4-phenyl-thiophene-3-
carboxamide (4)  
 
 
 
According to procedure C, employment of N-benzyl-2-[(2-chloroacetyl)amino]-4-phenyl-
thiophene-3-carboxamide (19) (0.45g, 1.17mmol), tryptamine (0.56g, 3.5mmol), 
triethylamine (0.33mL, 2.34mmol), and TBAI (43mg, 0.12mmol) yielded, after 
purification by flash chromatography (gradient cyclohexane:EtOAc 8:2 – 6:4), 4 as 
orange-brown solid (385mg, 0.76mmol, 65%). 
 
Mp: 71°C 
 
1H-NMR (399.79MHz, DMSO-d6):  
δ=10.78 (s, 1H, H-N(16)), 7.57-7.52 (m, 2H, H-C(30), H-N(14)), 7.35-7.29 (m, 7H, H-
C(7-11), H-C(27), H-N(25)), 7.24-7.16 (m, 3H, H-C(8‘), H-C(9‘), H-C(10‘)), 7.16 (sm, 
1H, H-C(24)), 7.07-7.03 (m, 3H, H-C(28), H-C(7‘), H-C(11‘)), 6.98-6.93 (m, 2H, H-C(5), 
H-C(29)), 4.32 (d, 3J=6.0Hz, 2H, H-C(15)), 3.42 (s, 2H, H-C(19)), 2.95-2.91 (m, 2H, H-
C(21)), 2.86-2.83 (m, 2H, H-C(22)) 
 
13C-NMR (100.53MHz, DMSO-d6, APT):  
δ=170.0, 164.5 (C(2), C(12)), 142.8 (C(17)), 138.4, 137.3 (2C, C(4) and/or C(6) and/or 
C(6‘)), 136.2 (C(26)), 135.7 (2C, C(4) or C(6) or C(6‘)), 128.5 (2C, C(8), C(10)), 128.3 
(2C, C(7), C(11)), 128.1 (2C, C(8‘), C(10‘)), 127.4, 127.3 (3C, C(9), C(7‘), C(11‘)), 
127.2 (C(31)), 126.7 (C(9‘)), 122.6 (C(24)), 120.8 (C(29)), 118.3, 118.1 (C(28), C(30)), 
117.3 (C(3)), 114.9 (C(5)), 112.1 (C(23)), 111.3 (C(27)), 51.7 (C(19)), 50.4 (C(21)), 
42.6 (C(15)), 25.5 (C(22)) 
 
MS (ES+): 
 m/z (%): 509 (100) [M+H]+ 
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HRMS (EI): 
Calcd for C30H28N4O2S [M]+:    508.193298 
Found:      508.192909  
 
CHN: 
Anal. calcd for C30H28N4O2S (%):   C: 70.84  H: 5.55 N: 11.01 
Found:      C: 70.64  H: 5.7 3 N: 11.00 
 
N-Benzyl-2-[[2-(benzylamino)acetyl]amino]-4-phenyl-thiophene-3-carboxamide 
hydrochloride (5)  
 
 
According to procedure C, usage of N-benzyl-2-[(2-chloroacetyl)amino]-4-phenyl-
thiophene-3-carboxamide (19) (0.50g, 1.30mmol), benzylamine (0.43mL, 3.9mmol), 
triethylamine (0.36mL, 2.59mmol), and TBAI (0.05g, 0.13mmol) furnished, after 
purification by flash chromatography (cylcohexane:EtOAc 9:1-1:1) and precipitation as 
HCl salt with hydrogen chloride solution 2M in diethyl ether, 5 as colorless solid 
(340mg, 0.69mmol, 53%). 
 
Mp: 188°C 
 
1H-NMR (500.16MHz, DMSO-d6):  
δ=11.23 (bs, 1H, H-N(16)), 9.84 (bs, 2H, H-N(20)), 8.45 (t, 3J=5.9Hz, 1H, H-N(14)), 
7.62-7.57 (m, 2H, H-C(7’’), H-C(11’’)), 7.48-7.42 (m, 3H, H-C(8’’), H-C(9’’), H-C(10’’)), 
7.34-7.20 (m, 8H, H-C(7-11), H-C(8’), H-C(9’), H-C(10’)), 7.13 (s, 1H, H-C(5)), 7.12-
7.10 (m, 2H, H-C(7’), H-C(11’)), 4.35 (d, 3J=6.0Hz, 2H, H-C(15)), 4.24 (s, 2H, H-C(21)), 
4.03 (s, 2H, H-C(19)) 
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13C-NMR (125.77MHz, DMSO-d6):  
δ=164.0, 163.5 (C(2), C(12)), 138.6, 138.1, 137.6, 135.5, 131.6 (C(17), C(4), C(6), 
C(6’), C(6’’)), 130.2 (2C, C(8’’), C(10’’)), 129.0 (C(9’’)), 128.6, 128.2, 128.1, 127.8 (8C, 
C(7), C(8), C(10), C(11), C(8’), C(10’), C(7’’), C(11’’)), 127.5 (2C, C(7’), C(11’)), 127.2 
(C(9)), 126.7 (C(9’)), 122.3 (C(3)), 115.9 (C(5)), 49.9 (C(21)), 47.0 (C(19)), 42.8 (C(15)) 
 
MS (ES+):  
m/z (%): 456 (100) [M+H]+ 
 
HRMS (EI):  
Calcd for C27H25N3O2S [M]+:    455.166749 
Found:      455.165004 
 
CHN: 
Anal. calcd for C27H25N3O2S*HCl (%):  C: 65.91 H: 5.33 N: 8.54 
Found:      C: 65.95 H: 5.48  N: 8.47 
 
N-Benzyl-2-[(2-morpholinoacetyl)amino]-4-phenyl-thiophene-3-carboxamide (10)  
 
 
 
According to procedure C, usage of N-benzyl-2-[(2-chloroacetyl)amino]-4-phenyl-
thiophene-3-carboxamide (19) (0.76g, 1.97mmol), morpholine (0.52mL, 5.92mmol), 
triethylamine (0.55mL, 3.95mmol), and TBAI (0.07g, 0.20mmol) yielded, after 
purification by flash chromatography (cyclohexane:EtOAc 8:2) and recrystallization 
from methanol, 10 as colorless needles (403mg, 0.94mmol, 46%). 
 
Mp: 123°C 
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1H-NMR (399.79MHz, DMSO-d6):  
δ=11.74 (s, 1H, H-N(16)), 7.45 (t, 3J=5.8Hz, 1H, H-N(14)), 7.37-7.31 (m, 5H, H-C(7-
11)), 7.28-7.19 (m, 3H, H-C(8’), H-C(9’), H-C(10’)), 7.10-7.08 (m, 2H, H-C(7’), H-
C(11’)), 6.99 (s, 1H, H-C(5)), 4.31 (d, 3J=5.95Hz, 2H, H-C(15)), 3.65 (sm, 4H, H-C(22), 
H-C(24)), 3.24 (s, 2H, H-C(19)), 2.53* (sm, 4H, H-C(21), H-C(25)). *overlaid with the 
DMSO signal  
 
13C-NMR (100.53MHz, DMSO-d6, APT):  
δ=167.7, 164.6 (C(2), C(12)), 142.9 (C(17)), 138.5, 137.3, 135.5 (C(4), C(6), C(6’)), 
128.5 (2C, C(8), C(10)), 128.3 (2C, C(7), C(11)), 128.1 (2C, C(8’), C(10’)), 127.4 (C(9)), 
127.3 (2C, C(7’), C(11’)), 126.7 (C(9’)), 117.2 (C(3)), 115.1 (C(5)), 66.1 (C(22), C(24)), 
60.4 (C(19)), 53.2 (C(21), C(25)), 42.6 (C(15)) 
 
MS (ES+):  
m/z (%): 436 (75) [M+H]+, 458 (45) [M+Na]+, 871 (100) [2M+H]+, 893 (23) [2M+Na]+ 
 
HRMS (EI+): 
Calcd for C24H25N3O3S [M]+:   435.161664 
Found:     435.160123 
 
CHN: 
Anal. calcd for C24H25N3O3S (%):   C: 66.18 H: 5.79  N: 9.65 
Found:      C: 66.04 H: 5.87  N: 9.63 
 
 
Synthesis of Compound 8 
 
 
 
Scheme 6.9. Synthesis of 8. 
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2-Acrylamido-N-benzyl-4-phenylthiophene-3-carboxamide (20)  
 
 
 
Following procedure B, employment of 2-amino-N-benzyl-4-phenyl-thiophene-3-
carboxamide (17) (1.5g, 4.86mmol), chloropropionyl chloride (0.7mL, 7.30mmol), and 
triethylamine (1.0mL, 7.30mmol) furnished, after two purification steps by flash 
chromatography (cyclohexane:tert-butyl methyl ether 8:2), 8 as light yellow solid 
(850mg, 2.3mmol, 49%). 
 
Mp: 79°C 
 
1H-NMR (500.16MHz, DMSO-d6):  
δ=11.04 (s, 1H, H-N(16)), 8.15 (t, 3J=5.7Hz, 1H, H-N(14)), 7.38-7.32 (m, 2H, H-C(7), H-
C(11)), 7.31-7.21 (m, 6H, H-C(8-10), H-C(8’), H-C(9’), H-C(10’)), 7.13 (m, 2H, H-C(7’), 
H-C(11’)), 7.06 (s, 1H, H-C(5)), 6.69 (dd, 3J=10.2Hz, 3J=17.0Hz, 1H, H-C(19)), 6.32 
(dd, 2J=1.7Hz, 3J=16.9Hz, 1H, Htrans-C(20)), 5.86 (dd, 2J=1.7Hz, 3J=10.3Hz, 1H, Hcis-
C(20)), 4.36 (d, 3J= 6.0Hz, 2H, C(15)) 
 
13C-NMR (125.77MHz, DMSO-d6):  
δ=164.4, 162.3 (C(12), C(2)), 140.2, 138.6, 137.4, 135.6 (C(17), C(6), C(6’), C(4)), 
130.2 (C(19)), 128.2, 128.1 (6C, C(7), C(8), C(10), C(11), C(8’), C(10’)), 127.5, 127.2 
(4C, C(7’), C(11’), C(9), C(20)), 126.7 (C(9’)), 120.4 (C(3)), 115.9 (C(5)), 42.8 (C(15)) 
 
MS (ES+):  
m/z (%): 108 (50) [C7H9N+H]+, 256 (24) [M-C7H8N]+, 363 (100) [M+H]+ 
 
HRMS (EI): 
Calcd for C21H18N2O2S [M]+:    362.108900 
Found:      362.113617 
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CHN: 
Anal. calcd for C21H18N2O2S*0.25 H2O (%):  C: 68.74  H: 5.08  N: 7.63  
Found:      C: 68.94  H: 5.14  N: 7.70  
 
2-(3-Anilinopropanoylamino)-N-benzyl-4-phenyl-thiophene-3-carboxamide 
hydrochloride (8) 
 
To a solution of 2-acrylamido-N-benzyl-4-phenylthiophene-3-carboxamide (20) 
(0.45mg, 1.24mmol) in trifluoroethanol (0.2mL, 2.48mmol) and water (1.5mL), aniline 
(1.1mL, 1.24mmol) was added. The reaction mixture was heated at 100°C until 
complete conversion of the starting material, detected by TLC. The reaction was 
allowed to reach RT and was diluted with ethyl acetate, washed with water and brine, 
dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash 
chromatography [cyclohexane:EtOAc 9:1 (10min), gradient to 8:2 (7min), 8:2 (5min)], 
followed by precipitation of the reaction product as its HCl salt with hydrogen chloride 
solution 2M in diethyl ether gave rise to 8 as beige solid (279mg, 0.57mmol, 46%). 
 
Mp: 140°C 
 
1H-NMR (399.79MHz, DMSO-d6):  
δ=10.94 (s, 1H, H-N(16)), 8.04 (t, 3J=5.8Hz, 1H, H-N(14)), 7.33-7.19 (m, 11H, H-C(7-
11), H-C(8’, 9’,10‘), H-C(8‘‘,9‘‘,10‘‘)), 7.12-7.10 (m, 2H, H-C(7‘), H-C(11‘)), 7.01 (s, 1H, 
H-C(5)), 6.91-6.77 (m, 2H, H-C(7‘‘), H-C(11‘‘)), 4.31 (d, 3J=6.0Hz, 2H, H-C(15)), 4.12 
(brs, 2H, H-N(21)), 3.43 (t, 3J=6.9Hz, 2H, H-C(20)), 2.80 (t, 3J=6.9Hz, 2H, H-C(19)) 
 
13C-NMR (125.77MHz, MeOH-d4):  
δ=168.9, 167.0 (C(2), C(12)), 145.0 (C(6’’)), 139.2, 138.9, 137.5, 137.1 (C(17), C(6), 
C(6’), C(4)), 131.5, 130.1, 130.0, 129.8, 129.5, 129.1, 128.8, 128.3, 123.2 (15C, C(7-
11), C(7’-11’), C(7’’-11’’)), 118.6 (C(3)), 117.0 (C(5)), 48.3 (C(15)), 44.4 (C(20)), 32.6 
(C(19)) 
 
6. Chameleon-Like Poses of Aspartic Protease Inhibitors  141 
 
 
MS (ES+): 
 m/z (%): 456 (100) [M+H]+, 478 (39) [M+Na]+ 
 
HRMS (EI): 
Calcd for C27H25N3O2S [M]+:     455.166749 
Found:       455.166775 
 
CHN: 
Anal. calcd for C27H25N3O2S*HCl (%):  C: 65.91  H: 5.33  N: 8.54 
Found:       C: 65.92 H: 5.75   N: 8.12 
 
Synthesis of Compound 9 
	  
Scheme 6.10. Synthesis of 9. 
 
N-Benzyl-2-(3-chloropropanamido)-4-phenylthiophene-3-carboxamide (21)  
	  
To a solution of 2-amino-N-benzyl-4-phenyl-thiophene-3-carboxamide (17) (4.5g, 
14.59mmol) in dry DCM (70mL), 3-chloropropionyl chloride (2.1mL, 21.89mmol) was 
added dropwise, followed by the addition of triethylamine (3.05mL, 21.89mmol). The 
reaction mixture was stirred at RT, until complete consumption of the 2-amino-
thiophene (≈15h), detected by TLC. The reaction mixture was diluted with DCM, 
washed with an aqueous ammonium chloride solution (sat.), brine, dried over MgSO4, 
filtered, and concentrated in vacuo. Purification by flash chromatography (twice, 
cyclohexane:tert-butyl methyl ether 8:2), yielded 21, as colorless solid (1.3g, 3.3mmol, 
22%). 
Mp: 102°C 
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1H-NMR (399.79MHz, DMSO-d6):  
δ=10.93 (s, 1H, H-N(16)), 8.14 (t, 3J=5.6Hz, 1H, H-N(14)), 7.34-7.20 (m, 8H, H-C(7-11), 
H-C(8’), H-C(9’), H-C(10’)), 7.13-7.11 (m, 2H, H-C(7’), H-C(11’)), 7.03 (s, 1H, H-C(5)), 
4.35 (d, 3J=6.0Hz, 2H, H-C(15)), 3.89 (t, 3J=6.3Hz, 2H, H-C(20)), 3.00 (t, 3J=6.2Hz, 2H, 
H-C(19)) 
 
13C-NMR (100.53MHz, DMSO-d6, APT):  
δ=167.3, 164.4 (C(2), C(12)), 140.1, 138.6, 137.3, 135.7 (C(17), C(6), C(6’), C(4)), 
128.2, 128.1, 128.0 (6C, C(8), C(10), C(8’), C(10’), C(7), C(11)), 127.5, 127.2 (3C, 
C(7’), C(11’), C(9)), 126.7 (C(9’)), 120.1 (C(3)), 115.3 (C(5)), 42.8 (C(15)), 40.4 (C(20)), 
38.2 (C(19)) 
 
MS (ES+):  
m/z (%): 108 (60) [C7H9N+H]+, 292 (18) [M35Cl-C7H8N]+, 399 (100) [M35Cl+H]+, 401 (39) 
[M37Cl+H]+  
 
HRMS (EI): 
Calcd for C21H19N2O2SCl35 [M]+:   398.085578 
Found:      398.086965  
Calcd for C21H19N2O2SCl37 [M]+:   400.082627 
Found:      400.081696  
 
CHN: 
Anal. calcd for C21H19N2O2SCl (%):   C: 63.23  H: 4.80  N: 7.02  
Found:      C: 63.65 H: 5.02  N: 7.20  
 
N-Benzyl-2-[3-(benzylamino)propanoylamino]-4-phenyl-thiophene-3-carboxamide 
(9)  
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Following procedure C, utilization of N-benzyl-2-(3-chloropropanamido)-4-
phenylthiophene-3-carboxamide (21) (0.40g, 1.00mmol), benzylamine (0.33mL, 
3.02mmol), triethylamine (0.28mL, 2.01mmol), and TBAI (37mg, 0.10mmol), furnished, 
after two purification steps (1. gradient cyclohexane:tert-butyl methyl ether 7:3 - 0:100, 
2. cyclohexane:tert-butyl methyl ether 4:6), 9 as colorless solid (310mg, 0.7mmol, 
66%). 
 
Mp: 120°C 
 
1H-NMR (399.79MHz, DMSO-d6):  
δ=8.05 (bs, 1H, H-N(16)), 7.38-7.19 (m, 14H, H-C(7-11), H-C(8‘,9‘,10‘), H-(7‘‘-11‘‘), H-
N(14)), 7.10-7.07 (m, 2H, H-C(7‘), H-C(11‘)), 6.97 (s, 1H, H-C(5)), 4.28 (d, 3J=6.0Hz, 
2H, H-C(15)), 3.73 (s, 2H, H-C(22)), 2.78 (t, 3J=6.3Hz, 2H, H-C(20)), 2.57 (t, 3J=6.2Hz, 
2H, H-C(19)) 
 
13C-NMR (100.53MHz, DMSO-d6, APT):  
δ=169.8, 164.5 (C(2), C(12)), 141.0, 140.2, 138.7, 137.2, 135.8 (C(17), C(6’’), C(6’), 
C(6), C(4)), 128.2 (2C, C(8), C(10)), 128.1 (5C, C(7), C(11), C(8’), C(10’), C(8’’), 
C(10’’)), 127.4 (2C, C(7’), C(11’)), 127.1 (C(9)), 126.7, 126.6 (4C, C(9’), C(7’’), C(11’’), 
C(9’’)), 119.1 (C(3)), 114.9 (C(5)), 52.5 (C(22)), 44.1 (C(20)), 42.6 (C(15)), 35.2 (C(19)) 
 
MS (ES+):  
m/z (%): 470 (100) [M+H]+  
 
HRMS (EI): 
Calcd for C28H27N3O2S [M]+:    469.182399  
Found:      469.181301 
 
CHN: 
Anal. calcd for C28H27N3O2S (%):   C: 71.61 H: 5.80  N: 8.95  
Found:      C: 71.57 H: 5.97  N: 8.99 
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Synthesis of Compound 6 
 
Scheme 6.11. Synthesis of 6. 
 
 
N-Benzyl-2-[(2-chloroacetyl)amino]-4,5,6,7-tetrahydrobenzothiophene-3-
carboxamide (23) 
 
According to procedure A, usage of 15 (1.5g, 8.6mmol), cyclohexanone (0.74mL, 
7.2mmol), TiCl4 (1.59mL, 14.4mmol), pyridine (1.98mL, 24.5mmol), sulfur (0.27g, 
8.4mmol), and diethylamine (2.63mL, 25.2mmol) yielded after two purification steps by 
flash chromatography (cyclohexane:EtOAc 85:15) 22 as crude product which was used 
without further purification (710mg, not pure). According to procedure B, employment of 
crude 22 (130mg), chloroacetyl chloride (0.05mL, 0.63mmol), and triethylamine 
(0.09mL, 0.65mmol) rendered 23 as colorless solid (58mg, 0.16mmol, 12% over to 
steps) after purification by flash chromatography (cyclohexane:EtOAc 8:2). 
 
Mass spectra data for 22: 
 
HRMS (EI): 
Calcd for C16H18N2OS [M+]:    286.113985 
Found:      286.116558 
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Analytical data for 23: 
 
Mp: 188°C 
 
1H-NMR (500.16MHz, DMSO-d6):  
δ=11.84 (s, 1H, H-N(16)), 8.03 (t, 3J=5.7Hz, 1H, H-N(14)), 7.36-7.31 (m, 4H, 4 phenyl-
H), 7.27-7.22 (m, 1H, 1 phenyl-H), 4.49 (d, 3J=6.0Hz, 2H, H-C(15)), 4.48 (s, 2H, H-
C(19)), 2.72 (sm, 2H, H-C(21)), 2.64 (sm, 2H, H-C(24)), 1.74 (sm, 4H, H-C(22), H-
C(23)) 
 
13C-NMR (125.77MHz, DMSO-d6):  
δ=164.9, 163.4 (C(2), C(12)), 140.0 (C(17)), 139.2 (C(6)), 128.9 (C(4)), 128.2 (2C, 
C(8), (10)), 127.1 (2C, C(7), C(11)), 127.0 (C(5)), 126.7 (C(9)), 117.9 (C(3)), 42.5, 42.4 
(C(15), C(19)), 25.0 (C(21)), 23.8 (C(24)), 22.4, 22.3 (C(22), C(23)) 
 
MS (ES+):  
m/z (%): 119 (100), 363 (77) [M35Cl+H]+, 365 (47) [M37Cl+H]+, 380 (45) [M35Cl+NH4]+, 382 
(17) [M37Cl+NH4]+, 385 (63) [M35Cl+Na]+, 387 (24) [M37Cl+Na]+ 
 
HRMS (EI): 
Calcd for C18H19N2O2SCl35 [M+]:   362.085578 
Found:      362.085863  
Calcd for C18H19N2O2SCl37 [M+]:   364.082627 
Found:      364.081173 
CHN: 
Anal. calcd for C18H19N2O2SCl (%):   C: 59.58  H: 5.28  N: 7.72  
Found:      C: 59.29 H: 5.37 N: 7.44 
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N-Benzyl-2-[[2-[2-(1H-indol-3-yl)ethylamino]acetyl]amino]-4,5,6,7-tetrahydro-
benzothiophene-3-carboxamide (6)  
 
According to procedure C, utilization of N-benzyl-2-[(2-chloroacetyl)amino]-4,5,6,7-
tetrahydrobenzothiophene-3-carboxamide (23) (90mg, 0.25mmol), tryptamine (0.12g, 
0.75mmol), triethylamine (69µL, 0.50mmol), and TBAI (9mg, 0.02mmol) furnished after 
purification by flash chromatography (DCM:MeOH 99:1), 6 as light orange solid (74mg, 
0.15mmol, 61%). 
 
Mp: 113°C 
 
1H-NMR (500.16MHz, DMSO-d6):  
δ=10.76 (s, 1H, H-N(16)), 8.00 (t, 3J=5.7Hz, 1H, H-N(14)), 7.54 (d, 3J=7.7Hz, 1H, H-
C(34)), 7.38-7.31 (m, 4H, phenyl-H), 7.29 (d, 3J=7.5Hz, 1H, H-C(31)), 7.27 (s, 1H, H-
N(29)), 7.23-7.17 (m, 1H, phenyl-H), 7.13 (sm, 1H, H-C(28)), 7.05 (dd, 3J=7.7Hz, 
3J=7.2Hz, 1H, H-C(32)), 6.95 (dd, 3J=7.7Hz, 3J=7.2Hz, 1H, H-C(33)), 4.50 (d, 3J=6.0Hz, 
2H, H-C(15)), 3.38 (s, 2H, H-C(19)), 2.90 (t, 3J=7.5Hz, 2H, H-C(25)), 2.81(t, 3J=7.3Hz, 
2H, H-C(26)), 2.73 (sm, 2H, H-C(21)), 2.63 (sm, 2H, H-C(24)), 1.74 (sm, 4H, H-C(22), 
H-C(23)) 
 
13C-NMR (125.77MHz, DMSO-d6, APT):  
δ=169.3, 164.9 (C(2), C(12)), 140.9 (C(17)), 139.5 (C(6)), 136.2 (C(30)), 128.6 (C(4)), 
128.2 (2C, C(8), C(10)), 127.21 (C(5)), 127.17 (2C, C(7), C(11)), 126.6 (C(9)), 125.8 
(C(35)), 122.5 (C(28)), 120.8 (C(33)), 118.2, 118.1 (C(32), C(34)), 116.8 (C(3)), 112.0 
(C(27)), 111.2 (C(31)), 51.7 (C(19)), 50.3 (C(25)), 42.4 (C(15)), 25.3 (C(26)), 25.1 
(C(21)), 23.8 (C(24)), 22.5, 22.4 (C(22), C(23)) 
 
MS (ES+):  
m/z (%): 487 (100) [M+H]+ 
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HRMS (EI):  
Calcd for C28H30N4O2S [M]+:    486.208948  
Found:      486.207907 
 
CHN: 
Anal. calcd for C28H30N4O2S (%):   C: 69.11  H: 6.21  N: 11.51  
Found:      C: 68.72 H: 6.17  N: 11.30 
 
 
Synthesis of Compound 7 
 
 
Scheme 6.12. Synthesis of 7.* 
 
*) Compound 7 was synthesized by Amir Shahim (AK Diederich, Philipps-Universität Marburg).  
The experimental procedures and characterization of 24-27 and 7 can be found in the 
original publication.33   
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6.5.4 Protein Purification 
Endothiapepsin was purified as published previously.36 The protein (5mg/mL) was 
stored at -20°C until use. 
 
 
6.5.5 Fluorescence Assay  
Ki-values were determined in a fluorescence based assay. To detect the activity of the 
enzyme, the FRET substrate Abz-Thr-Ile-Nle-p-nitro-Phe-Gln-Arg-NH2 (Bachem) was 
used. The assay was performed in the assay buffer containing 0.1M sodium acetate, 
pH 4.6 and 0.01% Tween20. Each well contained a reaction mixture of 178µL assay 
buffer or assay buffer-substrate-mix and 2µL DMSO or 2µL inhibitor (DMSO) or 2µL 
substrate (DMSO). Immediately before the measurements, 20µL endothiapepsin 
[≈ 2nM] were added to start the reaction. The increase of fluorescence was detected at 
414nm after excitation at 337nm using a Tecan Safire II plate reader. For Km-
determination the assay was run with 12 different substrate concentrations (100µM-
49nM). IC50 values were determined at a substrate concentration of 1.78µM, for each 
inhibitor 23 different inhibitor concentrations (1mM-238pM) were used. From the 
increase in fluorescence the IC50-values were calculated with the program GraFit 4.09 
(Erithacus Software). The corresponding Ki-values were calculated by means of the 
Cheng-Prusoff-equation37 under inclusion of the determined Km-value and substrate 
concentration. Each Km- and Ki-values were determined at least in duplicate. 
 
 
6.5.6 Thermal Shift Assay (TSA) 
TSA measurements were performed in the iCycler IQ5 Real Time Detection System 
(Bio-Rad). For the assay, 96-well plates (MultiplateTM Low-Profile 96-well unskirted 
PCR Plates, BioRad) were used with a total volume of 40µL. The reaction mixture 
contains 36µL assay buffer-SyproOrange-mix, 3µL endothiapepsin (70µM) and 1µL 
DMSO/inhibitor. The assay buffer-SyproOrange-mix consists of the endothiapepsin-
assay buffer (0.1M sodium acetate, pH 4.6, 0.01% Tween20) and 0.2% (V/V) 
SyproOrange (protein gel stain 5000x concentration in DMSO, Invitrogen). The plate 
was heated from 20°C to 80°C with a heating rate of 0.5°C/min. The final inhibitor 
concentration was 100µM. Tm values were manually determined from the first 
derivative of the resulting data (fluorescence intensity vs temperature). The unfolding 
temperature of endothiapepsin without a ligand (Tm(DMSO)) was subtracted from the 
unfolding temperature with ligand (Tm(lig)) to obtain the thermal shifts ΔTm. Each Tm-
value was at least measured in triplicate. 
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6.5.7 Crystallization 
Crystals of endothiapepsin were obtained using the vapor diffusion method in drops 
containing 2µL protein solution (endothiapepsin 5mg/mL, 0.1M sodium acetate, pH 4.6) 
and 2µL reservoir solution (0.1M ammonium acetate, 24-30% PEG4000 (w/w) and 
0.1M acetate buffer, pH 4.6). Crystals appeared after several days of incubation at 
291K. The complex formation for compounds 5, 6 and 8 was performed by soaking the 
obtained ligand-free endothiapepsin crystals for an appropriate time in reservoir 
solutions saturated with the respective ligand. For the other ligands the crystals were 
soaked for 1-2d in a mixture of 25% glycerol, 75% mother liquor and the ligand at a 
final concentration of 10mM.  
 
 
6.5.8 Data Collection, Structure Determination and Refinement  
Crystals were frozen in liquid nitrogen after prior cryo-protection treatment using 25% 
glycerol in reservoir solution. Data were collected at 100K at the synchrotron beamline 
as indicated in Table 6.2. 
Data processing and scaling was performed using the programs HKL200038 (EP in 
complex with 1, 3, 4, 7, and 9) or XDS (EP in complex with 5, 6, and 8).39 The 
coordinates of EP as deposited under PDB access code 1OEW40 were used as search 
models after removal of ligands, ions and water molecules. Molecular replacement was 
carried out via Phaser41 as implemented in Phenix.42 Refinement was performed under 
repeated cycles of manual model building using Coot43 and crystallographic refinement 
with the program phenix.refine or SHELXL44 as indicated in Table 6.2. The final models 
were validated using PROCHECK.45 Data collection and refinement statistics are 
shown in Table 6.2. The coordinates of the EP complexes determined in this study 
have been deposited in the Protein Data Bank under the PDB accession codes listed in 
Table 6.2. 
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Table 6.2. Data collection and refinement statistics. 
Inhibitor 1 3 4 5 
PDB Entry 3T7Q 4L6B 3PSY 3WZ6 
Data collection and 
Processing 
    
Beamline Location SLS  
(X06DA) 
BESSY 
(BL14.2) 
SLS  
(X06DA) 
PETRA III 
(P14/MX 2) 
Wavelength [Å] 1.000 0.91841 1.000 0.826606 
Space group P21 P21 P21 P21 
Unit cell parameters     
a, b, c [Å] 45.4; 73.1; 
52.8 
45.4; 73.5; 
53.0 
45.5; 73.1; 
52.8 
45.4; 73.0; 
53.2 
β [°] 109.7 109.8 109.5 110.1 
Matthews coefficient 
[Å3/Da] 
2.4 2.5 2.4 2.4 
Solvent content  [%] 49.6 50.0 49.6 48.9 
Diffraction data     
Resolution range [Å] 40-1.30  
(1.32-1.30)* 
30-1.37 
(1.39-1.37)* 
40-1.43  
(1.45-1.43)* 
50-1.40 
(1.60-1.40)* 
Unique reflections 78609 (3339) 68886 (3442) 55570 (2578) 62145 
(19124) 
R(I)sym [%] 6.3 (41.6) 9.2 (48.6) 3.4 (28.5) 10.6 (64.6) 
Completeness [%] 98.6 (83.6) 99.9 (100.0) 92.8 (87.3) 97.7 (93.2) 
Redundancy 3.3 (2.4) 3.9 (3.9) 3.5 (3.3) 8.2 (7.6) 
I/σ(I) 20.1 (2.2) 15.6 (2.7) 34.2 (4.2) 15.3 (3.0) 
Refinement     
Program PHENIX PHENIX SHELXL PHENIX 
Resolutions range [Å] 29.4-1.3 29.6-1.37 10.0-1.43 42.7-1.40 
Reflections used in 
refinement (work/free) 
71189/3845 65410/3452  51397/2741       60894/1242 
 
Final R values for all 
reflections (work/free) [%] 
16.2/17.5 16.6/19.7 12.8/16.7 14.3/16.3 
Protein residues 330 330 330 330 
Inhibitor atoms 32 32 37 33 
Water molecules 420 324 235 614 
RMSDs     
Bonds [Å] 0.005 0.009 0.010 0.005 
Angles [°] 1.1 1.2 2.7 1.1 
Ramachandran plot     
Residues in most favored 
regions [%] 
94.2 94.2 93.9 93.9 
Residues in additional 
allowed regions [%] 
5.8 5.8 6.1 6.1 
Residues in generously 
allowed regions [%] 
- - - - 
Mean B factors [Å2]     
Protein 11.1 10.9 14.3 9.5 
Inhibitor 21.4 11.5 16.3 23.8 
Water 24.5 22.8 26.9 26.0 
Other ligands 
(DMSO,PEG, ...) 
19.3 15.4 35.2 35.3 
     
* Number in parentheses characterize the highest resolution shell 
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Inhibitor 6 7 8 9 
PDB Entry 3WZ7 3T7X 3WZ8 4LAP 
Data collection and 
Processing 
    
Beamline Location BESSY 
(BL14.1) 
BESSY 
(BL14.2) 
BESSY 
(BL14.1) 
BESSY 
(BL14.2) 
Wavelength [Å] 0.91841 0.91841 0.91841 0.91841 
Space group P21 P21 P21 P21 
Unit cell parameters     
a, b, c [Å] 45.2; 73.6; 
53.2 
45.4; 73.2; 
53.0 
45.6; 73.9; 
54.2 
45.4; 73.1; 
52.8 
β [°] 110.2 109.8 110.7 109.7 
Matthews coefficient 
[Å3/Da] 
2.4 2.5 2.5 2.4 
Solvent content  [%] 49.1 49.9 50.5 49.5 
Diffraction data     
Resolution range [Å] 50-1.90  
(2.05-1.90)* 
25-1.27  
(1.29-1.27)* 
50-1.45 
(1.60-1.45)* 
30-1.12  
(1.14-1.12)* 
Unique reflections 23054 (3959) 84384 (3480) 59674 
(15187) 
119175 (5702) 
R(I)sym [%] 7.3 (35.2) 4.0 (16.1) 8.1 (56.7) 4.5 (42.1) 
Completeness [%] 89.1 (75.6) 98.0 (81.1) 99.2 (99.3) 95.9 (92.1) 
Redundancy 3.2 (3.0)  3.1 (2.5) 3.7 (3.7) 3.9 (3.8) 
I/σ(I) 17.2 (3.5) 23.8 (6.1) 12.9 (2.6) 30.2 (3.3) 
Refinement     
Program PHENIX PHENIX PHENIX PHENIX 
Resolutions range [Å] 42.4-1.90 21.6-1.27 40.5-1.45 17.6-1.12 
Reflections used in 
refinement (work/free) 
22030/920 78767/4206 57296/1770 113197/5978 
Final R values for all 
reflections (work/free) [%] 
24.0/28.0 15.4/16.9 18.9/22.4 12.9/14.4 
Protein residues 330 330 330 330 
Inhibitor atoms 35 29 33 34 
Water molecules 196 409 566 321 
RMSDs     
Bonds [Å] 0.007 0.005 0.004 0.012 
Angles [°] 2.0 1.1 0.97 1.5 
Ramachandran plot     
Residues in most favored 
regions [%] 
90.6 93.5 93.9 93.9 
Residues in additional 
allowed regions [%] 
9.4 6.5 6.1 6.1 
Residues in generously 
allowed regions [%] 
- - - - 
Mean B factors [Å2]     
Protein 15.7 9.2 8.4 11.3 
Inhibitor 22.5 17.2 18.2 19.8 
Water 17.6 21.9 21.0 25.0 
Other ligands 
(DMSO,PEG, …) 
18.5 21.9 26.6 19.2 
 
* Numbers in parentheses characterize the highest resolution shell 
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6.6 Appendix  
 
 
 
Figure 6.9. Schematic overview of the binding modes of 1 (yellow), 4 (green), 7 (orange) and 9 (purple) in 
the active site of endothiapepsin (wheat, surface representation, PDB code: 3T7Q). Ligands are shown in 
stick representation. The flap amino acids 77-83 are excluded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10. a) The schematic overview of the binding mode of the green cluster is exemplarily shown for 
4 (stick representation). Endothiapepsin is shown as surface, the flap amino acids 77-83 are excluded. b) 
Detailed H-bond network of 4. Ligands and amino acids are shown in stick representation, color coded by 
atom type, distances in Å.  
 
	  
4 
a) b) 
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Figure 6.11. a) The schematic overview of the purple binding mode cluster is exemplarily shown for 9 
(stick representation). Endothiapepsin is shown as surface, the flap amino acids 77-83 are excluded. b) 
Detailed H-bond network of compound 9. Ligands and amino acids are shown in stick representation, color 
coded by atom type, distances in Å.  
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Figure 6.12. a) Schematic overview of 1 (stick representation). Endothiapepsin is shown as surface, the 
flap amino acids 77-83 are excluded. b) H-bond network of compound 1. Ligands and amino acids are 
shown in stick representation, color coded by atom type, distances in Å.  
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Figure 6.13. a) Schematic representation of the binding mode of 7 (orange cluster) in endothiapepsin 
(shown as surface), the flap amino acids 77-83 are excluded. b) H-bond network for 7. Ligands and amino 
acids are shown in stick representation, color coded by atom type, distances in Å. 
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7. Fragment Screening by Thermal Shift Assay 
 
7.1 Introduction  
The concept of fragment-based drug discovery (FBDD) has successfully been 
exploited within the last 15 years and has led with vemurafenib (Zelboraf®) to one 
approved drug and more than 30 candidates that entered clinical trials so far.1–3 Thus, 
FBDD has proven to be a valuable alternative method for hit identification. It is based 
on the idea that the chemical space is more efficiently probed with fragments than e.g. 
by screening a large HTS library.2  
For successful FBDD the library composition plays an important role. In analogy to the 
Lipinki’s “rule of five” which describes properties for a druglike and orally bioavailable 
molecule, the “rule of three” was defined as similar rule for fragments by researchers at 
Astex.4,5 According to this rule, fragments should have a molecular weight below 
300 Da, a ClogP ≤ 3 and three or less H-bond donors as well as H-bond acceptors. 
However, as the experience with the FBDD approach is continuously growing, also 
other library design strategies emerged in literature.6 
As a consequence of their reduced size and complexity, fragments usually exhibit 
lower affinities (mM-30 µM) in comparison to HTS hits.7 Thus, for the detection of these 
rather weakly interacting molecules, robust screening assays or sensitive biophysical 
techniques such as e.g. high-concentration screening, fragment screening by X-ray 
crystallography, STD-NMR experiments, or the thermal shift assay (TSA) among others 
are frequently applied.8 However, little is known in literature about the hit-overlap 
utilizing different fragment screening methods. Are screening methods or rather the 
combination of different prescreening methods able to detect the hits to comparable 
extent as the time-consuming X-ray crystallography-based screening approach in 
which all fragments of interest are subjected to crystallization trials in absence of other 
prescreening options?  
In a cooperation project with the research group of Prof. Klebe (Philipps-Universität 
Marburg), the in-house fragment library comprising 364 fragments6 was evaluated 
against endothiapepsin, which represents a robust and well accessible protein to 
compare and analyze the hit-overlap of different fragment screening methods. In the 
context of this thesis, the TSA-based fragment screen was established and the results 
are discussed in the following.  
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7.2 Concept of the Thermal Shift Assay – an Overview  
In drug discovery, the thermal shift assay is commonly used as screening method for 
hit identification, for affinity ranking of inhibitors as well as for protein stability studies to 
e.g. identify suitable buffer conditions for protein crystallization or assay conditions.9–12 
Recently, TSA was also used to evaluate drug candidates in a cellular context, e.g. to 
monitor the transport of drug molecules through cellular barriers to their targets, target 
specificity as well as dose-dependent target engagement in animals i.e. the analysis of 
ligand target interactions within cells from appropriate cell cultures or animal tissues.13 
Additionally, TSA has also been applied to obtain information about the binding mode 
of compounds utilizing wild-type and mutant enzymes.14  
In a thermal shift assay, the thermal stability of a protein is determined. The thermal 
unfolding of the protein can be detected in the presence of an appropriate fluorescence 
dye leading to an increase in the fluorescence, which is measured in dependence of 
the temperature (Figure 7.1). The fluorescence dye used for TSA is quenched in 
aqueous solution like the assay buffer, but shows fluorescence in a hydrophobic 
environment such as the hydrophobic surface of an unfolded protein. Therefore, the 
increase in fluorescence indicates the unfolding of the protein and the beginning 
thermal denaturation. In general, binding of ligands to the target protein can either 
induce a stabilizing effect, or a destabilizing effect, or result in neutral behavior towards 
the protein of interest being subjected to a heating experiment. 
Different dyes have been developed for the TSA measurements, with SYPRO Orange 
being the most famous one. Its excitation and emission wavelengths are 492 nm and 
610 nm, respectively. Thus, it is well suited for the identification of small molecules as 
this high excitation wavelength generally decreases the likeliness for interfering with 
these. However, the quenching of the fluorescence of the dye by the respective ligand 
or other components might falsify the results, as all fluorescence-based assays can be 
affected by this effect if absorption and emission wavelength are in inappropriate 
proximity. Besides SYPRO Orange, 1.8-ANS (1-anilino-8-naphthalene sulfonate), bis-
ANS, nile red, or dapoxyl sulfonic acid are used and represent an alternative if the 
measurements do not succeed with SYPRO Orange, or if another wavelength area is 
desired.12  
The thermal unfolding of the protein is dependent on the protein stability and can be 
related to the temperature-dependent Gibbs free energy of unfolding (ΔGu). The 
melting temperature (Tm) is the point where ΔGu is zero and the concentrations of 
folded and unfolded protein are equal.  
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Figure 7.1. a) Typical TSA-curve (example: HIV-1 PR, determined for validation purpose in the context of 
this thesis). The increase in fluorescence indicates the protein unfolding. LL and UL are the lower and 
upper level in the fluorescence intensity; Tm is the melting temperature of the protein. b) Derivative of the 
HIV-1 PR TSA-curves with DMSO (red) and with two HIV-1 PR inhibitors (blue, green). The minimal 
turning point reflects the Tm-value. Clearly shifts of the melting temperature due to protein stabilization by 
the ligands are observed. 
 
The melting temperature can be calculated from the first derivative (derivative method) 
or from the inflection point of the melting curve using the Boltzmann equation.12,15,16 
In general, the thermal shift assay is easy to handle, rapid, label-free, inexpensive, and 
only requires the target protein in low concentration, a fluorescence dye (commercially 
available), an assay buffer, and in case of an inhibitor screening also the respective 
inhibitors.10,12  As no or only little prior knowledge of the protein or the protein function 
is required and no specific substrate or labeling is needed, the TSA is well-suited as 
incipient assay setup for the identification of inhibitors, especially for a new therapeutic 
target.9  
A drawback of TSA is that this assay, using only native proteins, does not provide 
information about the way the ligand stabilized the protein: one cannot easily 
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discriminate whether a ligand stabilized a protein by addressing the active site or by 
binding to an allosteric site, which both could result in similar ΔTm-values. Also a ligand 
can bind to more than one site of the protein simultaneously. The affinity ranking of 
inhibitors, not only if they comprise different scaffolds, should be interpreted with care 
as the Tm-shift is dependent on the enthalpy and entropy of binding.10,12 An intriguing 
example is given in chapter 6 of this thesis. 
 
7.3 Experimental Setup 
Fragments in general exhibit a comparably low affinity to the target protein, which 
makes it challenging to develop an experimental setup being suitable to detect little 
changes in the protein stability, which, consequently, results in low Tm-shifts. Therefore, 
the TSA in this thesis was performed with a high fragment concentration of 2.5 mM to 
facilitate the detection of binding events. The in-house fragment library was screened 
according to the following procedure (the step size of the temperature increment per 
minute is given in the lower line): 
  
 
 
 
 
 
7.4 Results, Discussion and Conclusion 
In general, the thermal shift assay allows to distinguish between compounds which 
show a significant shift of the melting temperature in comparison to the DMSO-Tm-
value (“hits”), compounds which do not provoke a Tm-shift, and compounds which 
destabilize the target protein (negative Tm-shift). Typically, for this classification the 
intervals of 2-3 fold the standard deviation above and below the mean of the recorded 
melting points are used as cutoff values. 
Out of the 364 fragments of the in-house library, 16 fragments could not be measured 
due to insufficient solubility. Out of the remaining 348 fragments tested in total, the 
initial screening of the fragment library (Table 7.2, appendix) yielded 52 fragments 
which showed a shift of Tm higher than the 2-fold standard deviation, 260 fragments 
which had no significant influence on stabilization of the protein and 21 fragments 
which destabilized the protein. The data obtained from 15 fragments could not be 
analyzed accurately. 
1. Screening 
 
all fragments (364) 
 
0.5°C/min 
	  
2. Screening 
all promising 
fragments 
0.2°C/min 
	  
	  	  
3. Screening  
 
    fragment hits 
 
0.2°C/min 
	  
4. Screening  
revision, if variation 
between 2. and 3.  
0.2°C/min	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The fragments which destabilized the protein were not investigated in more detail as 
they were not considered as putative hits within the scope of this project. 
Therefore, in a second screening the 52 fragment hits as well as some fragments 
which had shown a ΔTm-value slightly under the 2-fold standard deviation cutoff were 
measured again, however, this time with a heating rate of 0.2°C/min (Table 7.4, 
appendix). The hits obtained by this second screening were evaluated again utilizing 
the same conditions (3. screening) and in case of discrepancies between these two 
screening results (2. and 3. screening), the fragment was evaluated a third time 
applying the above mentioned conditions. 
Overall, 17 fragment hits which showed a shift of the melting temperature greater or 
equal than the 3-fold standard deviation (3σ) were identified (Table 7.1). The chemical 
structures of the ten screening hits with the highest shift of the melting temperature are 
shown in Figure 7.2. 
 
Table 7.1. ΔTm-values (mean of the 2.-4. screening) with respective standard deviation 
of the fragment hits. Fragments possessing a ΔTm-value of ≥ 3σ (≥ 1.2°C) were defined 
as “hits”. 
 
Nr. ΔTm [°C] Nr. ΔTm [°C] 
177* 3.4 ± 0.3 216 1.8 ± 0.1 
149 2.8 ± 0.4 335 1.8 ± 0.0 
284 2.0 ± 0.1 306 1.7 ± 0.2 
017 1.9 ± 0.1 041 1.6 ±0.3 
064 1.9 ± 0.1 236 1.5 ± 0.2 
159 1.9 ± 0.1 127 1.3 ± 0.2 
255 1.9 ± 0.1 337 1.3 ± 0.3 
008 1.8 ± 0.2 290 1.2 ± 0.1 
178 1.8 ± 0.1   
*fragment measured at 1.25 mM 
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Figure 7.2. Chemical structures of the 10 TSA fragment hits with highest ΔTm-value. 
 
The screening of the fragment library by a fluorescence-based assay prior to that 
thesis,6 performed by Dr. Helene Köster, yielded 55 Hits (> 40 % inhibition at 100 µM). 
These 55 hits were additionally subjected to a crystallographic screening by soaking of 
fragment mixtures (2 fragments), which resulted in 11 X-ray structures.6  
The comparison of the TSA results with those obtained from the fluorescence-based 
assay and crystallographic screening reveals that most of the hits obtained by TSA 
could also be found by the fluorescence-based assay: out of the 17 TSA hits, 14 were 
also identified by the fluorescence assay and for 6 of them an X-ray structure could be 
determined (Figure 7.3). Considering also the TSA fragments which show a shift of the 
melting temperature ≥ the 2-fold standard deviation, the hit rate increases from 17 to 31 
hits, however, the hit overlap in comparison to the fluorescence assay is only increased 
by 4 fragments (14 vs 18).  
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Figure 7.3. Hit overlap of the fragment hits found in the thermal shift assay and in the fluorescence assay. 
Hits of the TSA are defined as fragments which yield ΔTm-value of ≥ the 3-fold standard deviation. In 
brackets the amount of TSA hits with ΔTm-values ≥ 2σ are shown. 
 
In summary, the TSA screening of the in-house library with in total 348 accessible 
fragments yielded 17 fragment hits, 14 of which were also identified in the 
fluorescence-based assay; additional 41 hits could only be detected in the fluorescence 
assay. 
Depending on the outcome of a screen, in a typical setup the cutoff value is adapted to 
obtain a reasonable amount of hits, which are then evaluated by further screening 
methods or directly subjected to crystallization trials. By applying less stringent cutoff 
limits (ΔTm-shift ≥ the 2-fold of the standard deviation instead of the previous analysis 
with a threshold of ≥ 3σ), the hit-rate increases in our case from 17 to 31 fragment hits, 
noteworthy, the hit overlap between both methods remaining nearly unchanged (14 vs 
18).  
In this part of the collaborative study, the suitability of the TSA-method in general and 
the established setup used for the identification of stabilizing fragments binding to 
endothiapepsin was confirmed. A final analysis, however, is not possible until the data 
of other screening methods as well as the X-ray screening results of the whole 
fragment library are available. 
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7.5 Experimental Section 
7.5.1 Thermal Shift Assay 
TSA measurements were performed in the iCycler IQ5 Real Time Detection System 
(Bio-Rad). For the assay, 96-well plates (MultiplateTM Low-Profile 96-well unskirted 
PCR Plates, BioRad) were used with a total volume of 40 µL. The reaction mixture 
contained 36 µL assay buffer-SYPRO Orange-mix, 3 µL endothiapepsin (29 µM) and 
1 µL DMSO/fragment. The assay buffer-SYPRO Orange-mix consisted of the 
endothiapepsin-assay buffer (0.1 M sodium acetate, pH 4.6, 0.01 % Tween20) and 
0.2 % (V/V) SYPRO Orange (protein gel stain 5000x concentration in DMSO, 
Invitrogen).  
The plate was heated from 20°C to 80°C applying a heating rate of 0.5°C/min (1. 
screening) or 0.2°C/min (2.-4. screening) to allow a more precise determination of the 
shift of the melting temperature. Unless specified otherwise, the final inhibitor 
concentration was 2.5 mM. 
Tm-values were manually determined from the derivation of the resulting data 
(-d(RFU)/dT). A least three DMSO reference values (Tm(DMSO)) were determined per 
plate. The respective standard deviations of Tm(DMSO) were used for defining the cutoff 
(2-fold or 3-fold of the standard deviation). To obtain the Tm-shifts of the fragments 
(ΔTm), the unfolding temperature of endothiapepsin without a ligand (Tm(DMSO)) was 
subtracted from the unfolding temperature with ligand (Tm(lig)). Each Tm-value was at 
least measured in duplicat. 
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7.6 Appendix  
Table 7.2. Results of the first screening run of all 364 fragments. Unless specified 
otherwise (column “conc.”), the fragments were measured at 2.5 mM. 
 
x: fragment shows no significant shift of Tm (>2-fold standard deviation).  
H: fragment shows a shift of Tm >2-fold standard deviation 
d: fragment destabilizes the protein: –ΔTm >2-fold standard deviation 
n.a.: data could not be analyzed accurately 
uk: concentration of the fragment unknown 
-: fragment could not be measured (due to low solubility) 
 
Nr. conc. [mM] shift Nr. 
conc. 
[mM] shift Nr. 
conc. 
[mM] shift Nr. 
conc. 
[mM] shift 
001  x 029  H 057  n.a. 085  x 
002  x 030  x 058  x 086  x 
003  x 031  d 059  n.a. 087  n.a. 
004  x 032  d 060  x 088  n.a. 
005  x 033  x 061  x 089  x 
006  x 034 - - 062  x 090  x 
007  x 035  x 063  H 091  x 
008  H 036 0.75 x 064  H 092  x 
009  x 037  x 065  x 093  x 
010 1.25 x 038 1.25 x 066  H 094  x 
011  x 039  H 067  x 095  x 
012  x 040  H 068  H 096  x 
013  x 041  H 069  x 097  - - 
014  x 042  x 070  d 098  x 
015  x 043 uk n.a. 071  x 099  H 
016  x 044  x 072  d 100  x 
017  H 045  x 073  x 101 1.25 H 
018  x 046  d 074  x 102  x 
019 uk x 047 1.25 H 075 - - 103  x 
020  x 048  x 076  n.a. 104  x 
021  H 049  x 077  x 105  x 
022  H 050 1.25 H 078  n.a. 106  x 
023  d 051  x 079 uk x 107 1.25 x 
024  x 052  x 080  x 108 - - 
025  x 053  n.a. 081  x 109  x 
026  d 054  x 082  x 110  H 
027  x 055  d 083  x 111  x 
028  x 056  H 084  d 112  x 
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Nr. conc. [mM] shift Nr. 
conc. 
[mM] shift Nr. 
conc. 
[mM] shift Nr. 
conc. 
[mM] shift 
113  x 153  x 193  d 233  x 
114  x 154  x 194  x 234  x 
115  x 155  x 195  x 235 1.25 x 
116  x 156 - - 196  x 236  H 
117  x 157  x 197  d 237  x 
118  x 158  H 198  x 238  x 
119  n.a. 159  H 199  x 239  x 
120  x 160  x 200  x 240  x 
121  x 161  H 201  x 241  x 
122  x 162  H 202  x 242  x 
123  x 163  x 203  x 243  x 
124  x 164  x 204  x 244 1.25 x 
125 - - 165  x 205  H 245  x 
126  x 166  x 206  x 246  x 
127  H 167  x 207  H 247  x 
128  x 168  x 208  x 248  x 
129 1.25 x 169  x 209  x 249  x 
130  H 170  x 210 - - 250  x 
131  x 171  x 211  x 251  x 
132  H 172  x 212  x 252  x 
133  x 173  x 213  x 253  x 
134  x 174  x 214  x 254  x 
135  x 175  H 215  x 255  H 
136  x 176  x 216  H 256  x 
137  x 177 1.25 H 217  x 257  x 
138  x 178  H 218 - - 258 1.25 x 
139  x 179  x 219  x 259 1.25 x 
140  x 180  x 220  x 260  x 
141  x 181 - - 221  x 261  H 
142  x 182 - - 222  x 262  x 
143  x 183  x 223  x 263  x 
144  x 184  x 224  H 264  x 
145  n.a. 185  H 225  x 265 - - 
146  x 186  x 226  x 266 1.25 x 
147  x 187  x 227  H 267  x 
148  x 188  x 228  x 268  x 
149  H 189  x 229 - - 269  x 
150  x 190  x 230  x 270  x 
151  x 191  d 231 1.25 x 271 - - 
152  x 192  x 232  x 272  x 
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Nr. conc. [mM] shift Nr. 
conc. 
[mM] shift Nr. 
conc. 
[mM] shift Nr. 
conc. 
[mM] shift 
273  x 296  x 319 0.83 x 342  d 
274  x 297  x 320  x 343  x 
275  x 298  x 321  H 344  H 
276  x 299  x 322  x 345  d 
277  x 300 uk x 323  n.a. 346  x 
278  x 301  x 324  x 347  x 
279  x 302  x 325  x 348  x 
280  x 303  x 326  n.a. 349  d 
281  x 304  x 327  x 350  x 
282  x 305  d 328  x 351  x 
283  x 306  H 329  x 352  d 
284  H 307  x 330  x 353  H 
285  x 308  x 331  x 354  H 
286  x 309  x 332  x 355  x 
287  x 310 - - 333  d 356 uk x 
288  x 311  n.a. 334  H 357  n.a. 
289  x 312 - - 335  H 358  d 
290  H 313  d 336  x 359  n.a. 
291  x 314  x 337  H 360  x 
292  H 315  x 338  x 361  H 
293  H 316  x 339  H 362  x 
294  x 317  d 340  x 363  x 
295  x 318 - - 341  x 364  x 
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Table 7.3. Results of the 2.-4. screening: mean ΔTm-values (at least in duplicate) of all 
fragment hits of the 1. screening, ordered by fragment numbers. Fragments with ΔTm- 
values ≤ 0.4°C (standard deviation) are indicated with “x”.  
 
Nr. ΔTm Nr. ΔTm Nr. ΔTm 
008 1.8 ± 0.2 127 1.3 ± 0.2 255 1.9 ± 0.1 
017 1.9 ± 0.1 130 0.9 ± 0.2 261 0.7 ± 0.1 
021 x 132 1.0 ± 0.1 284 2.0 ± 0.1 
022 1.0 ± 0.4 149 2.8 ± 0.4 290 1.2 ± 0.1 
029 0.8 ± 0.1 158 0.8 ± 0.4 292 0.6 ± 0.1 
039 0.7 ± 0.3 159 1.9 ± 0.1 293 0.9 ± 0.1 
040 0.9 ± 0.2 161 1.1 ± 0.1 306 1.7 ± 0.2 
041 1.6 ± 0.3 162 0.7 ± 0.2 321 x 
 047* x 175 1.0 ± 0.1 334 1.1 ± 0.2 
 050* x  177* 3.4 ± 0.3 335 1.8 ±0.0 
056 0.5 ± 0.3 178 1.8 ± 0.1 337 1.3 ± 0.3 
063 0.6 ± 0.1 185 x 339 x 
064 1.9 ± 0.1 205 0.8 ± 0.2 344 1.0 ± 0.1 
066 1.0 ± 0.1 207 0.6 ± 0.0 353 x 
068 x 216 1.8 ± 0.1 354 x 
099 x 224 1.1 ± 0.1 361 0.6 ± 0.1 
 101* 0.7 ± 0.1 227 0.7 ± 0.1   
110 x 236 1.5 ± 0.2   
*) fragments were measured at 1.25 mM 
 
Table 7.4. Fragments which yielded ΔTm-values slightly under the 2-fold standard 
deviation in the first screening and were measured again, but did not show any 
significant shift of Tm in the second screening. 
 
094 131 173 217 304 328 
098 134 174 267 309 
 111 138 176 272 316 
 112 140 190 277 322 
 121 142 196 289 327 
 
 
7. Fragment Screening by Thermal Shift Assay  171 
 
	  
7.7  References 
(1)     Baker, M. Fragment-based lead discovery grows up. Nat. Rev. Drug Discovery 2013, 12, 
5–7. 
(2)   Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-
based drug discovery. J. Med. Chem. 2008, 51, 3661–3680. 
(3)   Fragments in the clinic: 2015 edition. Avaiable from: 
http://practicalfragments.blogspot.de/2015/01/fragments-in-clinic-2015-edition.html. [access: 
16.04.2015]. 
(4)   Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Adv. Drug Delivery Rev. 2001, 46, 3–26. 
(5)   Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead 
discovery? Drug discovery today 2003, 8, 876–877. 
(6)   Köster, H.; Craan, T.; Brass, S.; Herhaus, C.; Zentgraf, M.; Neumann, L.; Heine, A.; Klebe, 
G. A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin 
crystal structures with various fragment chemotypes. J. Med. Chem. 2011, 54, 7784–7796. 
(7)   Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. 
Rev. Drug Discovery 2004, 3, 660–672. 
(8)   Scott, D. E.; Coyne, A. G.; Hudson, S. A.; Abell, C. Fragment-based approaches in drug 
discovery and chemical biology. Biochemistry 2012, 51, 4990–5003. 
(9)   Pantoliano, M. W.; Petrella, E. C.; Kwasnoski, J. D.; Lobanov, V. S.; Myslik, J.; Graf, E.; 
Carver, T.; Asel, E.; Springer, B. A.; Lane, P.; Salemme, F. R. High-density miniaturized thermal 
shift assays as a general strategy for drug discovery. J. Biomol. Screening 2001, 6, 429–440. 
(10)   Lo, M.-C.; Aulabaugh, A.; Jin, G.; Cowling, R.; Bard, J.; Malamas, M.; Ellestad, G. 
Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. 
Anal. Biochem. 2004, 332, 153–159. 
(11)   Ericsson, U. B.; Hallberg, B. M.; Detitta, G. T.; Dekker, N.; Nordlund, P. Thermofluor-
based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 
2006, 357, 289–298. 
(12)   Niesen, F. H.; Berglund, H.; Vedadi, M. The use of differential scanning fluorimetry to 
detect ligand interactions that promote protein stability. Nat. Protoc. 2007, 2, 2212–2221. 
(13)   Martinez Molina, D.; Jafari, R.; Ignatushchenko, M.; Seki, T.; Larsson, E. A.; Dan, C.; 
Sreekumar, L.; Cao, Y.; Nordlund, P. Monitoring drug target engagement in cells and tissues 
using the cellular thermal shift assay. Science 2013, 341, 84–87. 
(14)   Śledź, P.; Lang, S.; Stubbs, C. J.; Abell, C. High-throughput interrogation of ligand binding 
mode using a fluorescence-based assay. Angew. Chem., Int. Ed. 2012, 51, 7680–7683. 
(15)   APPLICATION NOTE Protein Thermal Shift™ technology (Life technologies™). Available 
from: 
 
172                                                                               7. Fragment Screening by Thermal Shift Assay   
 
www3.appliedbiosystems.com/cms/groups/mcb_marketing/documents/generaldocuments/cms_
095306.pdf. [access: 26.02.2015]. 
(16)   Vivoli, M.; Novak, H. R.; Littlechild, J. A.; Harmer, N. J. Determination of protein-ligand 
interactions using differential scanning fluorimetry. J. Visualized Exp. 2014, 51809. 
 
  
  173    
 
 
8. Summary 
Aspartic proteases are involved in various physiological and pathophysiological 
processes. Famous examples highlighting the success of inhibition of aspartic 
proteases in drug discovery include, among others, e.g. aliskiren which represents a 
non-peptidic inhibitor of renin, and ten HIV-1 protease (HIV-1 PR) inhibitors which are 
or have been clinically used in the therapy of AIDS.  
This thesis focuses on the identification and synthesis as well as kinetic and structural 
characterization of non-peptidic small molecule inhibitors of the two aspartic proteases 
HTLV-1 protease (HTLV-1 PR) and endothiapepsin.  
The HTLV-1 PR, a promising target for the treatment of viral infections caused by the 
human T-cell leukemia virus type-1, is related to the well-known HIV-1 PR, however, it 
exhibits a substantially different substrate specificity and inhibition profile than the 
latter. However, due to the similarity in the active site, HIV-1 PR inhibitors provide a 
promising starting point for the identification and further optimization of novel small 
molecule inhibitors against HTLV-1 PR.  
First, after successful establishment of an in-house HTLV-1 protease technology 
platform, the well-known HIV-1 PR inhibitor indinavir, which displays a Ki-value in the 
one-digit micromolar range (3.5 µM) against the HTLV-1 PR, was chosen as auspicious 
starting point although in comparison to the HIV-1 PR (540 pM) its affinity is strongly 
reduced. However, other highly potent HIV-1 protease inhibitors (saquinavir, ritonavir, 
nelfinavir, and amprenavir) do not show any relevant affinity against the HTLV-1 
protease (Ki > 20 µM).  
Within this thesis the X-ray structure of indinavir in complex with the HTLV-1 PR was 
determined at 2.40 Å resolution, representing, to the best of our knowledge, the first 
HTLV-1 PR crystal structure with a non-peptidic inhibitor. This structural information 
laid the foundation for rationalizing the rather moderate affinity of indinavir against the 
HTLV-1 PR and thus provided the basis for further structure-guided optimization 
strategies. Interestingly, indinavir binds at first glance similar to both enzymes. As the 
H-bond inventory between both proteases is quite conserved, one would not directly 
expect such a drastic difference in affinity. However, particularly the van der Waals 
contact inventory established by hydrophobic residues of indinavir seems to be less 
favorable in the HTLV-1 PR compared to the original HIV-1 PR complex thus 
presumably accounting for the observed affinity difference. 
As a second approach for lead identification, the privileged structure concept was 
exploited as tool to identify novel small molecule scaffolds for HTLV-1 PR inhibition. A 
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screening of our in-house aspartic protease inhibitor library was performed and 
resulted in the identification of C2-symmetric 3,4-bis-N-alkylsulfonamido-pyrrolidines 
and pyrrolidine-based bicyclic HIV-1 PR inhibitors as promising candidates for HTLV-1 
PR inhibition. Both inhibitor classes were characterized in more detail regarding their 
kinetic as well as structural properties. 
Out of a series of ten 3,4-bis-N-alkylsulfonamido-pyrrolidine inhibitors, AB84 exhibits an 
affinity of 15 nM (Ki-value) and represents, to the best of our knowledge, the most 
potent non-peptidic inhibitor of HTLV-1 PR described so far. The successfully deter-
mined crystal structures of AB84 and AB83, the latter being another representative of 
this inhibitor series, enabled structure-guided SAR interpretations thus laying the 
foundation for the deduction of design ideas for the further optimization of this inhibitor 
scaffold. In addition, with the determined crystal structures in hand the observed affinity 
differences within the members of this compound class towards HTLV-1 PR and HIV-1 
PR could convincingly be rationalized.  
The pyrrolidine-based bicyclic compounds exhibit affinities from the three-digit up to the 
one-digit micromolar range, with NK232, decorated with two benzhydryl moieties, being 
the most potent inhibitor of this series (Ki-value: 1.4 µM). The crystal structure of 
NK101 was determined at moderate resolution, nevertheless, this structure provides 
valuable information about the binding mode of this inhibitor scaffold. 
Based on these fundamental insights and the deduced SAR described in this thesis, 
both scaffolds represent promising starting points for the further inhibitor optimization 
utilizing structure-based drug design. 
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Figure 8.1. Novel scaffolds for HTLV-1 protease inhibition as promising starting points for structure-based 
lead optimization identified within this thesis. 
 
The second part of this thesis deals with the aspartic protease endothiapepsin that 
serves as a model system for aspartic proteases in general. Various 2-aminothiophene 
compounds were synthesized as inhibitors of endothiapepsin utilizing the Gewald 
reaction. Surprisingly, the binding mode analysis of eight similar 2-aminothiophene 
inhibitors resulted in four completely different binding modes, hence, explaining 
retrospectively, why the initial deduction of the SAR based on the obtained affinity data 
had failed. The presented example highlights the complexity of binding events and their 
strong dependence on seemingly minor effects of the scaffold decoration. As structure-
based drug discovery indispensably relies on the correct deduction and interpretation 
series of ten inhibitors:  
   Ki: >250µM – 15nM  
two X-ray structures in  
complex with the HTLV-1 PR 
X-ray structure of NK101 in  
complex with the HTLV-1 PR 
series of ten inhibitors:  
 Ki: 215µM – 1.4µM  
NK232 Ki: 1.4µM AB84 Ki: 15nM 
    AB83                                     AB84                 NK101 
         indinavir C2-symmetric 3,4-bis-N-
alkylsulfonamido-pyrrolidines  
pyrrolidine-based  
bicyclic inhibitors 
Ki: 3.5µM 
X-ray structure (2.4Å)   
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of the underlying SAR, not only the incipient determination of the binding mode of 
solely a single lead representative or a set of identified hits at the beginning, but also 
the re-validation of the initially determined binding mode during the optimization 
process is of utmost importance. Moreover, we could demonstrate that any inconsistent 
affinity-thermal shift assay (TSA) correlation may serve as an easily available indicator 
to qualify candidates for structural revalidation, even if an interaction mode is believed 
to be known.  
The detailed analysis presented herein highlights the necessity to continuously monitor 
binding modes during the hit-to-lead optimization process and questions the commonly 
accepted hypothesis that similar ligands usually bind in a similar fashion.  
 
 
Figure 8.2. Multiple binding modes of Gewald reaction-based aspartic protease inhibitors: a representative 
case study for structure-based lead optimization projects challenging typical design paradigms in medicinal 
chemistry.  
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9. Zusammenfassung 
Aspartylproteasen spielen in vielen physiologischen aber auch pathophysiologischen 
Abläufen eine bedeutende Rolle. Zahlreiche Beispiele belegen die erfolgreiche 
Wirkstoffentwicklung auf dem Gebiet der Aspartylprotease-Inhibitoren: z.B. ist der zur 
Behandlung von Bluthochdruck eingesetzte Wirkstoff Aliskiren ein nicht-peptidischer 
Inhibitor des Renin. Des Weiteren werden bzw. wurden zehn HIV-1-Protease-
Inhibitoren erfolgreich in der Therapie der Immunschwächekrankheit AIDS eingesetzt. 
Diese Arbeit umfasst die Identifizierung und Synthese sowie kinetische und strukturelle 
Charakterisierung von nicht-peptidischen Kleinmolekülen als Inhibitoren der beiden 
Aspartylproteasen HTLV-1 Protease und Endothiapepsin.  
 
Die HTLV-1-Protease stellt ein vielversprechendes Zielenzym für die Behandlung von 
viralen Infektionen mit dem Humanen T-Zell-Leukämie-Virus dar und ist eng verwandt 
mit der bekannteren HIV-1-Protease. Trotz struktureller Ähnlichkeit beider Proteasen 
unterscheiden sich diese jedoch deutlich voneinander hinsichtlich ihrer Substrat-
spezifität und dem Inhibitionsprofil gegenüber bekannten Inhibitoren. Jedoch stellen auf 
Grund der Ähnlichkeiten im aktiven Zentrum einige der bereits bekannten HIV-1-
Protease-Inhibitoren einen geeigneten und vielversprechenden Startpunkt für die 
Identifizierung und Optimierung von neuartigen Kleinmolekülen zur Inhibition der 
HTLV-1-Protease dar, über deren Bindungsmodus vor Aufnahme dieser Arbeiten 
allerdings noch nichts bekannt war.  
Nach erfolgreicher in-house-Etablierung der Expression, der Proteinreinigung, eines 
Affinitätsassays sowie geeigneter Kristallisationsbedingungen für die HTLV-1-Protease 
wurde zunächst der bekannte HIV-1-Protease-Inhibitor Indinavir, der gegenüber der 
HTLV-1-PR eine Affinität im einstellig mikromolaren Bereich aufweist, näher 
untersucht. Die Affinität (Ki-Wert: 3,5 µM) gegenüber der HTLV-1-Protease ist im 
Vergleich zur HIV-1-Protease (540 pM) zwar deutlich geringer, jedoch weisen andere 
hoch-affine HIV-1 PR-Inhibitoren (Saquinavir, Ritonavir, Nelfinavir und Amprenavir) 
keine nennenswerte Affinität gegenüber der HTLV-1-Protease auf (Ki > 20 µM). Im 
Rahmen dieser Arbeit konnte mit der Kristallstruktur von Indinavir im Komplex mit der 
HTLV-1-Protease, die nach unserem Wissen erste HTLV-1-Protease-Kristallstruktur 
mit einem nicht-peptidischen Inhibitor beschrieben werden. Die so erhaltenen struktu-
rellen Informationen trugen maßgeblich zum Verständnis der moderaten Affinität von 
Indinavir gegenüber der HTLV-1-Protease bei und legten darüber hinaus den 
Grundstein für weitere strukturbasierte Optimierungsansätze. Interessanterweise 
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bindet Indinavir auf den ersten Blick sehr ähnlich im aktiven Zentrum beider Proteasen 
(HTLV-1- und HIV-1-Protease): das ausgebildete Wasserstoffbrücken-Netzwerk 
zwischen beiden Proteasen ist annähernd gleich und liefert zunächst keine direkte 
Erklärung für den so deutlichen Affinitätsunterschied. Dahingegen scheinen 
insbesondere die van der Waals-Interaktionen, die von den hydrophoben Gruppen des 
Indinavirs ausgebildet werden, im Fall der HTLV-1-PR weniger vorteilhaft im Vergleich 
zur HIV-1-Protease zu sein.  
In einem zweiten Ansatz zur Leitstrukturidentifizierung wurde das Konzept der 
„privilegierten Strukturen“ zur Identifizierung neuartiger niedermolekularer Grund-
gerüste für die HTLV-1 PR-Inhibition verfolgt. Durch Screening der Arbeitskreis-
internen Substanzbibliothek verschiedener Aspartylproteaseinhibitoren konnten C2-
symmetrische 3,4-bis-N-alkylsulfonamid-substituierte Pyrrolidine sowie bizyklische 
Pyrrolidine als vielversprechende Kandidaten zur Inhibition der HTLV-1-Protease 
identifiziert werden. Beide Inhibitorklassen wurden ursprünglich als HIV-1-Protease-
Inhibitoren entwickelt und im Rahmen dieser Arbeit bezüglich ihrer enzymkinetischen 
und strukturellen Eigenschaften gegenüber der HTLV-1-Protease genauer untersucht.  
Aus einer Serie mit zehn C2-symmetrischen 3,4-bis-N-alkylsulfonamid-substituierten 
Pyrrolidinen stellt die Verbindung AB84 mit einer Affinität von 15 nM nicht nur den 
affinsten Vertreter dieser Serie, sondern, nach bestem Wissen, auch den bislang 
affinsten nicht-peptidischen HTLV-1-Protease-Inhibitor dar. Die erfolgreiche Bestim-
mung der Kristallstrukturen von AB84 sowie AB83, einem weiteren Vertreter dieser 
Inhibitorklasse, ermöglichte ebenfalls die strukturbasierte Interpretation der Struktur-
Wirkungs-Beziehungen (SAR) und legt somit den Grundstein für die weitere 
strukturbasierte Leitstrukturoptimierung. Die Kristallstrukturen ermöglichten ebenfalls 
die Interpretation der Affinitätsunterschiede nicht nur innerhalb der Inhibitorserie, 
sondern darüber hinaus auch im Vergleich zur HIV-1-Protease.  
Die bizyklischen Pyrrolidin-basierten Inhibitoren weisen Affinitäten im drei- bis einstellig 
micromolaren Bereich auf, wobei die mit zwei Benzhydrylgruppen substituierte 
Verbindung NK232 der bisher aktivste Vertreter dieser Inhibitorserie (Ki: 1,4 µM) ist. 
Eine Kristallstruktur dieser Verbindungsklasse wurde mit NK101 erfolgreich bestimmt. 
Obwohl der HTLV-1-Protease-NK101-Komplex nur eine moderate Auflösung aufwies, 
lieferte er dennoch erste wertvolle Informationen über den Bindungsmodus dieser 
Substanzklasse in der HTLV-1-Protease. 
Basierend auf den erhaltenen, grundlegenden Erkenntnissen über den Bindungsmodus 
sowie der abgeleiteten SAR bieten beide Grundgerüste vielversprechende Optionen für 
die weitere strukturbasierte Leitstrukturoptimierung.  
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Abbildung 9.1. Neuartige Grundgerüste zur HTLV-1-Protease-Inhibition: aus dieser Arbeit hervorge-
gangene vielversprechende Startpunkte für eine strukturbasierte Leitstrukturoptimierung. 
 
Der zweite Teil dieser Arbeit beschäftigt sich mit der Aspartylprotease Endothiapepsin, 
einem bekannten Modellenzym für Aspartylproteasen. Verschiedene Verbindungen mit 
einem 2-Amino-Thiophen Grundgerüst wurden basierend auf der Gewald-Reaktion 
synthetisiert. Überraschenderweise wurden innerhalb einer Serie von acht strukturell 
sehr ähnlichen Liganden vier verschiedene Bindungsmodi gefunden, was im 
Nachhinein erklärt, warum die auf den Affinitätsdaten und der Kristallstruktur der 
Leitstruktur basierte SAR nicht schlüssig interpretiert werden konnte. Dieses Beispiel 
unterstreicht eindrucksvoll die Komplexität des Bindungsgeschehens von Liganden und 
Serie von zehn Inhibitoren:  
   Ki: >250µM – 15nM  
zwei Kristallstrukturen im 
Komplex mit der HTLV-1-PR 
Kristallstruktur von NK101 im 
 Komplex mit der HTLV-1-PR 
Serie von zehn Inhibitoren:  
 Ki: 215µM – 1.4µM  
NK232 Ki: 1.4µM AB84 Ki: 15nM 
  AB83                                   AB84                 NK101 
         Indinavir C2-symmetrische 3,4-bis-N-
alkylsulfonamid-Pyrrolidine 
Pyrrolidin-basierte  
Bizyklen 
Ki: 3.5µM 
Kristallstruktur (2.4Å)   
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dessen Abhängigkeit von kleinsten chemischen Veränderungen am Substitutions-
muster einer Leitstruktur. Strukturbasiertes Wirkstoffdesign beruht auf der korrekten 
Interpretation der zugrundeliegenden SAR, und somit ist nicht nur die anfängliche 
Bestimmung der Kristallstruktur(en) im Komplex mit einer/mehreren Leitstruktur(en) 
von größter Bedeutung, sondern ebenfalls die Überprüfung des angenommenen 
Bindungsmodus während des Leitstrukturoptimierungsprozesses. Darüber hinaus 
konnte gezeigt werden, dass Unstimmigkeiten bei der Korrelation von klassischen 
Affinitäts- mit TSA-Daten als Hinweis auf Kandidaten dienen können, für die eine 
Überprüfung des Bindungsmodus lohnenswert sein könnte, auch wenn ein vermeintlich 
zugrundeliegender Bindungsmodus bekannt zu sein scheint. Die hier präsentierte 
Fallstudie unterstreicht die Notwendigkeit der kontinuierlichen Überwachung der 
Bindungsmodi während eines Leitstrukturoptimierungsprozesses und stellt die im 
Allgemeinen angenommene Hypothese, dass strukturell ähnliche Liganden in ähnlicher 
Weise binden, in Frage. 
 
 
Abbildung 9.2. Wechselnde Bindungsmodi von Gewald-Reaktions-basierten Aspartylprotease-Inhibitoren: 
eine beeindruckende Fallstudie für die strukturbasierte Leitstrukturoptimierung stellt gängige Design-
Paradigmen in der Medizinischen Chemie in Frage. 
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